Oral glucose lowering agents and cancer in type 2 diabetes mellitus: focus on sulphonylurea derivatives by Schrijnders, Dennis
  
 University of Groningen





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Schrijnders, D. (2019). Oral glucose lowering agents and cancer in type 2 diabetes mellitus: focus on
sulphonylurea derivatives. [Groningen]: Rijksuniversiteit Groningen.
https://doi.org/10.33612/diss.103517830
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 11-12-2019
ORAL GLUCOSE LOWERING AGENTS AND CANCER IN TYPE 2 
DIABETES MELLITUS: FOCUS ON SULPHONYLUREA DERIVATIVES  
D. Schrijnders
D. Schrijnders
Oral glucose lowering agents and cancer in type 2 diabetes mellitus: 




Cover: Nathan Anderson, Dennis Schrijnders and Gildeprint, Enschede
Printing: Gildeprint, Enschede
The research in this thesis was financially supported by a research grant (grant number 
836041017) of the research programme Good Use of Medication from the Netherlands 
Organization for Health Research and Development (ZonMw). Printing of this thesis was 
financially supported by University of Groningen, University Medical Center Groningen 
and Isala Diabetes Centre.
© 2019 D. Schrijnders
All rights reserved. No part of this publication may be reproduced, stored in a retrieval 








Oral glucose lowering agents and 
cancer in type 2 diabetes mellitus: 













ter verkrijging van de graad van doctor aan de  
Rijksuniversiteit Groningen 
op gezag van de 
rector magnificus prof. dr. C. Wijmenga 
en volgens besluit van het College voor Promoties. 
 
De openbare verdediging zal plaatsvinden op 
 














Prof. dr. H.J.G. Bilo  
Prof. dr. G.H. de Bock  
 
Copromotores 
Dr. G.W.D. Landman  
Dr. N. Kleefstra  
 
Beoordelingscommissie 
Prof. dr.  P. Denig  
Prof. dr.  B.H.R. Wolffenbuttel  




  Dhr. M. Schrijnders 
  Mw. M. Pfeufer

TABLE OF CONTENTS
Chapter 1 Introduction 9
Chapter 2 Sulphonylurea derivatives and cancer, friend or foe? 31
Chapter 3 Within-Sulfonylurea-Class Evaluation of Time to Intensification 
with Insulin (ZODIAC-43)
63
Chapter 4 Addition of sulphonylurea to metformin does not relevantly 
change body weight: a prospective observational cohort study 
(ZODIAC-39)
75
Chapter 5 Body mass index and obesity-related cancer risk in men and 
women with type 2 diabetes: a cohort study (ZODIAC-56)
99
Chapter 6 Sex differences in obesity related cancer incidence in relation 
to type 2 diabetes diagnosis (ZODIAC-49)
115
Chapter 7 Within-class differences in cancer risk for sulfonylurea 
treatments in patients with type 2 diabetes (ZODIAC-55) – 
a study protocol
135
Chapter 8 Summarizing Discussion 147













1Introduction  |  11
DIABETES WORLDWIDE
An increasing group of people worldwide is known with diabetes mellitus. According to 
the World Health Organization (WHO), the number of people with diabetes has risen from 
108 million in 1980 to 422 million in 2014 (1). The global prevalence of diabetes based 
on this figure among adults over 18 years of age has risen from 4.7% in 1980 to 8.5% in 
2014, a rise with immense consequences (1). The International Diabetes Federation (IDF) 
estimated that the worldwide prevalence of diabetes will be somewhere between 521 
and 829 million in 2040 (2). 
Over 90% of the people who are known with diabetes are diagnosed with type 2 
diabetes (T2D), and the prevalence of T2D is expected to double in the next decades, far 
outpacing both the relative and absolute growth of people known with type 1 diabetes 
mellitus (T1D) (3–6). 
The majority of cases of T2D are characterised by insulin resistance in peripheral 
tissues often followed by a relative insulin insufficiency, since β-cells cannot keep up with 
the increased demand for insulin (7). Risk of developing T2D increases with age, obesity 
and lack of physical activity (7). 
Diabetes is a failure of maintaining a normal glucose metabolism and is together with 
other risk factors an important cause of micro- and macrovascular complications. These 
risk factors together can eventually lead to vision impairment, decline in kidney function 
and eventually kidney failure, myocardial infarction, stroke and lower limb amputation (8).
INCIDENCE AND PREVALENCE OF DIABETES IN THE NETHERLANDS
In the Netherlands 1,084,100 people (men: 66.9/1,000, women: 60.5/1,000) were known 
with diabetes mellitus (both T1D and T2D) in 2016 (9). More than 90% of these patients 
were diagnosed with T2D (4,10). According to the RIVM estimates, in 2016, 73,900 
(men: 4.8/1000, women: 3.9/1000) were newly diagnosed with diabetes mellitus (9). It 
is estimated that in 2025 more than 1.3 million people in the Netherlands will be known 
with diabetes (4,5). The prevalence and incidence of T2D are age-dependent (Fig 1-2) (9). 
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Figure 1: One-year prevalence of diabetes mellitus (type 1 and type 2) in 2016 in the Netherlands. 



















Incidence diabetes mellitus, 2016
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Figure 2: Incidence of diabetes mellitus (type 1 and type 2) in 2016 in the Netherlands. Source: 
Nivel Zorgregistraties eerste lijn (9).
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DIABETES TREATMENT
About 90% of the patients diagnosed with T2D in the Netherlands are treated in primary 
care (11). The first step in the 2013 Dutch primary care diabetes guideline is education 
concerning lifestyle and diet (12). When treatment goals are not met, pharmacological 
treatment is initiated, starting with metformin. A preferred second step is addition of a 
sulfonylurea (preferably gliclazide). A third step is the addition of NPH-insulin. In addition 
to the already mentioned biguanides (metformin), sulfonylureas and insulin, there are 
more treatment classes available including meglitinides, thiazolidinediones, α-glucosidase 
inhibitors, DPP-IV inhibitors, incretin mimetics and SGLT-2 inhibitors (12). Most of these 
classes consist of more than one individual drug. Differences in safety in renal impairment, 
cardiovascular event risk and cancer exist between these classes (13–16). 
CANCER WORLDWIDE AND IN THE NETHERLANDS
The International Agency for Research on Cancer (IARC) estimated that in 2012 14.1 million 
people worldwide were diagnosed with cancer and 8.2 million people died as a result of 
cancer (17). The most common cancer types worldwide were cancer of the lung, breast, 
colorectal, prostate and stomach (17). In the Netherlands 102,744 people were diagnosed 
with cancer in 2012 (Fig 3, men: 5.1/1000 patient years, women: 4.3/1000 patient years) 
(18). In 2012, 43,660 patients died as the result of cancer (men: 1.5/1000 patient years, 
women: 1.9/1000 patient years) (18). The most common cancers in the Netherlands were 
skin cancer, colorectal cancer, breast cancer, lung cancer and prostate cancer. 
CANCER RISK AND DIABETES 
In recent years, it has been suggested that patients known with T2D are threatened 
not only by microvascular and macrovascular complications, but that their chances of 
developing malignancies are also higher, at least for some specific forms of cancer (19–21).
Studies have reported that patients with T2D are more frequently diagnosed with 
cancer than people without T2D (19). Cancer and T2D occur concomitantly and have 
also been associated with each other (19–21). A study has shown that T2D patients have 
an excess cancer risk (Standardized Incidence Rate (SIR) in men 1.08 (95%CI 1.07-1.09), 
women 1.22 (95%CI 1.20-1.23)) (22). The different phenomena explaining and linking 
diabetes to cancer are discussed elaborately in next two paragraphs. 
















Incidence all cancer, 2012
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Figure 3: Number of newly diagnosed cancer in 2012 (Source: Nederlandse Kanker Registratie, IKNL).
The strongest associations between specific cancer types and T2D have been reported 
for liver and pancreas cancer (relative risk (RR) ~ 2) (20,21,23). Endometrial, colorectal, 
breast and bladder cancer also have been associated with an increased incidence in T2D 
patients (RR of 1.2 – 1.5) (20,21,23). Recent studies have suggested that at least part of 
the association might be explained by reverse causality (in case of liver and pancreas 
cancer) or ascertainment bias (23,24). In reverse causality it seems that an association is in 
one direction, but in the true association is in reverse. Ascertainment bias is a systematic 
difference in how an outcome is determined. 
OBESITY: MEDIATOR TOWARDS INCREASED CANCER RISK?
Obesity is a major health problem in the world. Obesity is defined by the World Health 
Organization (WHO) as a BMI ≥ 30 kg/m2 (25). The WHO estimates that 1.9 billion 
adults (39%) were overweight and 650 million adults (13%) were obese in 2016 (26). 
In the Netherlands 49.2% of the adults aged 18 and older were overweight, and 14.2% 
were obese in 2016 (27). The prevalence of obesity increases with age (27). A higher 
than normal BMI has been associated with increased risk of cardiovascular diseases, 
T2D, osteoarthritis and some specific cancers (26). To further evaluate and differentiate 
between effects of T2D and obesity is of importance. 
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DIABETES, OBESITY AND CANCER RISK IN DETAIL
The relationships between hyperglycaemia in T2D, obesity and cancer are complicated 
(figure 4). In addition to T2D being associated with obesity and cancer, obesity itself is 
also associated with cancer (and T2D) (28,29). The cancers associated with T2D overlap 
to a large extend with the cancers associated with obesity. The continuous update project 
of the World Cancer Research Fund associates 11 cancers with obesity (28). These 
include liver, advanced prostate, ovarian, gallbladder, kidney, colorectal, oesophageal, 
postmenopausal breast, pancreatic, endometrial, and stomach (cardia) cancer (28). A 
viewpoint published by the International Agency for Research on Cancer (IARC) associates 
some additional cancer types with obesity. In this viewpoint, the IARC recognizes cancers 
of the gastric cardia, colorectal, liver, gallbladder, pancreas, corpus uteri, ovary, thyroid, 
breast (postmenopausal only), kidney (renal-cell), meningioma, multiple myeloma and 
adenocarcinoma of the oesophagus to be associated with obesity (29). According to the 





Figure 4: Relationship between T2D, Obesity and Cancer
There remains discussion whether the increased occurrence of cancer in persons with T2D 
is mediated through diabetes per se, or whether an increased BMI is a more predominant 
factor for the relationship found (30). A recent study showed that 5.6% of all incident 
cancers worldwide in 2012 could be attributed to a combination of diabetes (both T1D 
and T2D) and high BMI (30). Of all liver cancer and endometrial cancer cases, 24.5% and 
38.4% could be attributed to this combination of risk factors, respectively (30). 
If a causal relation between T2D, BMI and cancer risk exists, then weight loss could 
lead better glycaemic control and both to a lower cancer risk. Indeed, studies have shown 
that interventions leading to lower bodyweight are an effective treatment option to treat 
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T2D (31–34). However, whether weight loss in subjects with T2D not only provides a 
better glycaemic control, but also leads to a lower cancer risk remains to be seen. One 
meta-analysis of prospective and retrospective studies involving 236,955 cases and 
3,963,367 controls showed that weight loss results in a lower breast cancer risk (35). A 
meta-analysis of 54 RCTs involving 30.206 patients failed to show an effect of weight loss 
on cancer risk (36).
PATHOPHYSIOLOGY OF INSULIN RESISTANCE 
The pathophysiological process underlying insulin resistance and T2D is not entirely 
clear. Inflammation, mitochondrial dysfunction and lipotoxicity are frequently discussed 
hypotheses (37,38). Inflammation as a result of obesity has been shown to inhibit insulin 
signalling pathways in adipocytes and hepatocytes through several mechanisms (37). 
However, muscle insulin action is not sensitive to inflammation and thus not impaired 
(37). Mitochondria are responsible for oxidation and metabolism of free fatty acids and 
glucose. Mitochondrial dysfunction could lead to free fatty acid and lipid accumulation. 
Some recent evidence, however, showed that mitochondrial dysfunction is not the cause 
of insulin resistance but the result of insulin resistance (37). There is no consensus for a 
unifying explanation of insulin resistance (37,38). 
It has also been shown that insulin resistance is associated with both low and high 
levels of IGF-1 in a U-shaped manner (39). IGF-1 is has been identified as a growth 
factor for cancer and high IGF-1 levels in insulin resistance could therefor contribute 
to cancer risk and growth (40). Both high insulin levels and abnormally high glucose 
concentrations are potent growth factors for cancer. It has been shown in animal 
models that hyperinsulinemia stimulates the PI3K pathway in cells at risk of malignant 
transformation resulting in increased rates of carcinogenesis (41). The PI3K pathway is 
an intracellular signalling pathway that regulates the cell cycle. Continued activation of 
the pathway contributes to cell proliferation, survival, motility and angiogenesis (42). 
However, this effect has not yet been confirmed in clinical studies.
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BIASES, CONFOUNDERS AND EFFECT MODIFIERS 
BETWEEN CANCER AND T2D
There are several factors complicating the evaluation of the relation between cancer and 
T2D and T2D related treatment.
Several risk factors can influence the relation between cancer risk and T2D related 
medication use (23). Poor diet and limited physical activity can influence cancer risk via 
food content but also through obesity and insulin resistance, independent of medication 
use. Also smoking has been associated with numerous cancers (23). It has been shown 
that persons with T2D smoke more often than those who don’t have T2D (43). In addition, 
smoking has been associated with a higher probability of developing insulin resistance 
(44). 
Since a higher body weight is associated with both T2D occurrence and cancer, oral 
glucose lowering agents that modify body weight can confound a presumed relation. 
Another confounding factor in assessing cancer risk of medications could be renal failure, 
which has been reported to be independently associated with increased cancer risk 
(45,46), but also with a higher BMI (47–49). If, for example, a certain medication can’t be 
prescribed to patients with renal failure, but a comparator can, an observed difference in 
cancer risk could in theory also be explained by differences in renal function. 
Several sources of bias can influence the outcome of cancer risk (23). The most 
important sources are as follows. A first type that is often described is detection bias, 
sometimes also referred to as ascertainment bias (50,51). Detection bias is a systematic 
difference in how an outcome is determined (52). It is known that this kind of bias occurs 
frequently in observational studies researching T2D and cancer risk (23,24,53,54). For 
example, a health care provider might be more likely to do more intense surveillance 
or screening in T2D patients. Because these patients have contact with a health care 
provider, is it more likely that they are diagnosed with other diseases in addition to the 
T2D. 
Another important potential source of bias is diagnostic bias. This occurs when 
exposure to something, for example a certain medication, makes it more likely to be 
diagnosed. For example, a study investigating the relationship between endometrial 
cancer and oral contraceptives might suffer from this type of bias. Women who use 
oral contraceptives might be offered screening more often systematically or because of 
breakthrough bleeding. In other words, the use of oral contraceptives might trigger a 
diagnostic process for endometrial cancer (because patients without symptoms bleed), 
rather than causing it. 
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A third source is reverse causality. In this case it seems that factor A, for example 
hyperglycaemia, is associated with factor B, for example pancreatic cancer. However, the 
true association is in reverse, i.e. pancreatic cancer is the cause of the hyperglycaemia by 
a dysfunction in insulin secretion caused by the effect of the tumour on the pancreatic 
endocrine function. Recent studies have suggested that at least part of the association 
between increased cancer risk in case of liver and pancreas cancer and T2D might be 
explained by reverse causality. 
Other sources of bias include prevalent-user bias and immortal time bias. Prevalent-
users are patients who benefit from the treatment. Patient who do not benefit from, for 
example, SU use, are more likely to stop taking SUs and start something else. This could 
then result in overestimation of benefits of SUs and underestimation of harms of SUs. 
This is especially important when investigating within-class differences. If a patient using 
glibenclamide is more likely to experience side-effects or non-response and subsequently 
switch to another class than a patient using gliclazide, this could then result overestimation 
of the benefits of gliclazide and an underestimation of the harm of glibenclamide. 
Immortal time bias happens when, by design, death or the study outcome cannot 
occur in a certain follow-up period (55). There can be either misclassified immortal time or 
excluded immortal time (56). For example, suppose one would want to investigate cancer 
occurrence before diabetes diagnosis in a diabetes cohort. Patient who were diagnosed 
with cancer, but did not survive could not have been included in the diabetes cohort. In 
other words, the patients included in the cohort are survivors. 
DIABETES TREATMENT AND 
POSSIBLE MODIFICATION OF CANCER RISK
Since increased body weight is associated with both T2D occurrence and cancer, oral 
glucose lowering agents that potentially modify body weight and or glycaemic control 
could theoretically confound a presumed relationship between diabetes and cancer 
risk. There are glucose lowering agents that have been associated with weight changes. 
Metformin and GLP-1 agonists have been associated with weight loss, while insulin, TZDs 
and SUs have been associated with weight gain (38–41). It is unclear whether this increase 
is a class effect or can be attributed to specific drugs. Metformin is the only biguanide 
available and has been associated with a lower cancer mortality compared with non-
use of metformin (57). Recent meta-analyses show that metformin is associated with 
improved survival (HR 0.78, 95% CI 0.66-0.92 (58) and HR 0.86, 95% CI 0.76-0.97 (59)) 
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in pancreatic cancer, a reduction of overall mortality in women with endometrial cancer 
(adjusted HR [aHR] 0.64, 95% CI 0.45-0.89, p=0.009) (60), a reduced risk of colorectal 
adenoma (pooled OR = 0.76, 95%CI 0.63-0.92) (61) and a reduced overall prostate cancer 
risk (HR 0.81, 95% CI 0.69-0.95) (62). Next to metformin, other drugs and drug classes 
have been implicated to influence cancer risk. 
However, within the classes that contain multiple drugs, differences exist in almost 
every class with regard to safety in renal impairment, cardiovascular risk and cancer risk. 
For example, pioglitazone use, not rosiglitazone, is possibly associated with developing 
bladder cancer (63,64) and in some studies insulin glargine has been associated with 
increased risk of breast cancer (65). However, recent studies could not confirm these 
associations (66,67). 
SULFONYLUREAS: CLASS EFFECTS OR WITHIN CLASS DIFFERENCES?
SUs promote insulin release by binding to sulfonylurea receptors on the β-cell in the 
pancreas (68). The sulfonylurea receptors have several isoforms: SUR1 located on the 
pancreatic β-cell, SUR2A located on cardiac myocytes and SUR2B located on vascular 
smooth tissue (69). It has been shown that gliclazide and glipizide bind selectively to 
SUR1, tolbutamide is partially selective and glimepiride and glibenclamide are non-
selective (70). 
Within-class differences have been reported for the sulfonylureas. These within-
class differences are especially important because, at least in the Netherlands, the SUs 
are the preferred oral glucose lowering agent added to metformin, gliclazide is the 
preferred SU within its class (12). Whether the possible influence on other processes 
than glucose lowering should be seen as a class effect, or whether there might be within 
class differences is discussed below.
Glibenclamide is associated with an increased hypoglycaemia risk (1.83, 95%CI 1.35–
2.49), both non-severe and severe, compared to other SUs (71). Compared with glimepiride 
users, glibenclamide users have a higher incidence of hypoglycaemia (0.86/1000 person 
years vs 5.6/1000 person years) (72). A study investigating glibenclamide versus glimepiride 
showed that glibenclamide delays plasma glucose recovery and stimulates insulin 
secretion at low plasma glucose levels in contrast to glimepiride (73). A systematic review 
and network meta-analysis showed that gliclazide has the lowest risk of hypoglycaemia 
compared with glipizide (OR 0.22, 95% Credible Interval (CrI) 0.05-0.96), glimepiride (OR 
0.40, 95%CrI 0.13-1.27) and glibenclamide (OR 0.21, 95%CrI 0.03-1.48) (74).
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Several studies reported that the initiation of individual SUs is accompanied by weight 
increase (75–78). The UKPDS-34 study showed an increase of about 4 kilograms in the first 3 
years after glibenclamide initiation compared to metformin (75). In the ADOPT glibenclamide 
use resulted in a 1.6 kg increase in the first year compared to baseline (78). Glimepiride was 
associated with a mean weight gain of 1.2 kg in 30 weeks compared to baseline (76). However, 
there are no studies directly comparing the different SUs head-to-head. 
Within-class SU differences have also been reported for failure rate (i.e. when HbA1c 
treatment target is no longer met with a certain SU). Glipizide and glibenclamide are 
associated with a higher failure rate compared to other SUs (79,80). This finding suggests 
that the time until the need to start insulin might differ between the individual SUs; 
however, up to now, this has not been investigated. 
Differences in all-cause mortality and cardiovascular mortality have also been 
suggested. Of the non-selective SUs, glibenclamide, but not glimepiride, prevents ischemic 
preconditioning, a cardioprotective phenomenon (81). Compared to glibenclamide, both 
gliclazide (Relative Risk (RR) 0.65, Credible Interval (CrI) 0.53-0.79) and glimepiride (RR 
0.83, CrI 0.68-1.00) were associated with a lower risk of all-cause mortality, whilst glipizide 
(RR 0.98, 0.80-1.19), tolbutamide (RR 1.13, 0.72-1.43) and chlorpropamide (1.34, 0.98-
1.86) were not (82). For cardiovascular mortality similar associations were found (82,83).
SULFONYLUREAS AND CANCER RISK
A meta-analyses of cohort studies has shown that use of SUs (as a group) is associated with 
an increased risk of developing cancer compared to non-SU use (n= 278,291, relative risk 
(RR) 1.55 (95%CI 1.48-1.63) (84). Unfortunately, most of the included studies have serious 
methodological shortcomings. The included studies showed substantial heterogeneity, 
and were limited by lack of details such as cancer type and stage, and whether cumulative 
dose was taken into account. (84,85). The previously mentioned study also performed a 
meta-analysis of RCTs, which failed to show a significant change in cancer risk. However, 
only two RCTs were available for inclusion, and cancer risk was not the primary endpoint 
of these RCTs (84). Whereas SUs as a group might thus be associated with an increased 
risk of developing cancer, gliclazide use compared to other SUs appears to be associated 
with a decreased cancer risk in several small cohort studies (86–89). However, also these 
studies have methodological limitations; cancer types were grouped together, and the 
authors did not perform head-to-head comparisons and only adjusted for potential 
confounders to a varying degree. 
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Combining this information leads to the tentative conclusion that gliclazide could be 
the most selective SU, associated with the lowest mortality risk in observational studies; 
furthermore, gliclazide has the lowest hypoglycaemia risk and might also have a superior 
safety with regards to cancer risk. 
GENERAL AIMS AND OUTLINE
This thesis aims to investigate the within-class SU differences that can act as confounders 
in the relationship between T2D and specifically SUs used for treating T2D and cancer 
risk in the Dutch primary care diabetes population. The presence of within-class SU 
differences in cancer risk could influence SU preference and prescription behaviour 
as a consequence. This thesis is part of a larger scale ZonMW project which aims 
to investigate within-class SU differences in cancer risk in a Dutch T2D primary care 
population.
In chapter 2 a systematic review is presented, in which the available literature on 
within-class SU differences is discussed and summarized. In this review, observational and 
pre-clinical studies are assessed and further potential mechanisms explored. The study in 
chapter 3 investigates whether within-class differences in weight gain exist. In chapter 4 
the relationship between BMI and obesity-related cancers in men and women with T2D 
is investigated.In chapter 5 within-class SU differences with regard to time to insulin 
initiation are investigated. Diagnostic bias and detection bias are two important sources of 
bias. The aim of chapter 6 was to investigate cancer incidence for obesity-related cancer 
and all-cancer in a 10-year time period around diabetes diagnosis.In chapter 7 a study 
protocol incorporating aspects of this thesis for further research is presented.
DATA SOURCES
ZODIAC
The Zwolle Outpatient Diabetes Integrating Available Care project was initiated in 1998 
in the Zwolle region as an observational cohort study to investigate the effects of shared 
care for patients treated in primary care (90). 
Analysis of longitudinal data showed improved clinical variables and quality of 
life, and shared care became the standard care in the Zwolle region. The project was 
expanded to other regions in the Netherlands in 2006, 2009 and 2012. Patients included 
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in the ZODIAC cohort are diagnosed with T2D and are treated in primary care. Patients 
with a short life expectancy or insufficient cognitive capabilities are excluded. Data 
on age, sex, date of T2D diagnosis, HbA1c, length, weight, estimated GFR, creatinine, 
urinary albumin-creatinine ratio (ACR), total cholesterol, HDL-cholesterol, total/HDL 
cholesterol ratio, triglycerides, blood pressure, macrovascular complications (myocardial 
infarction, transient ischemic attack, stroke), medication use (both diabetes-specific and 
other medication), smoking (yes/no) and alcohol use (yes/no) are recorded annually 
and collected by the Isala Diabetes Centre for benchmarking and research purposes. 
Especially the yearly recorded weight and HbA1c data are unique to this cohort. All 
patients participating in ZODIAC consented with the anonymous use of their data for 
research purposes. Informed consent was obtained by the general practitioner and 
noted in the ZODIAC database system. 
National Cancer Registry
The National Cancer Registry (NCR) was founded in 1989 and records all cancer events 
based on notification by the National Pathology Archive (PALGA) and hospital discharge 
registries. Specially trained registration employees collect data on every cancer event 
recorded in hospital information systems in the Netherlands. The base dataset includes 
cancer type, diagnosis date, stage and primary treatment. Depending on the cancer type 
additional data may be recorded (91).
Combined ZODIAC-NCR
The ZODIAC dataset was linked to the NCR by a trusted third party using postal code, full 
name, date of birth and sex by the end of 2014. The first linkage resulted in a combined 
ZODIAC-NCR cohort containing of 71.648 patients, of which 10.717 were diagnosed with 
12.617 cancer events between January 1st 1989 and December 31st 2012. The linkage 
was updated in April 2017 to include all cancer events between January 1st 1989 and May 
31st 2017. The updated linkage includes 71.648 patients of which 14.144 were diagnosed 
with 17.404 cancer events. Seven thousand sixty-three all-cancer events and 3678 
obesity-related cancer events occurred after patients started participating in ZODIAC. 
The NCR expects that the number of false-positive and the number false-negative for the 
ZODIAC-NCR linkage is both under 1%. 
Municipal Personal Records Database
In order to obtain date of death the ZODIAC-NCR dataset was linked with the Municipal 
Personal Records Database (GBA) by the Isala Hospital using a combination of the 
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personal identification number and full name, postal code, date of birth and sex. The 
GBA is a system used by Dutch governmental organizations to record personal data of 
all inhabitants of the Netherlands, including date of death. Of the 71.648 patients in 
the ZODIAC-NCR dataset 68.910 could be linked; 14.045 patients were deceased and 
54.865 patients were alive at the moment of linkage (16 December 2016). A total of 2.738 
patients 3.8% could not be linked. 
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ABSTRACT
Introduction:
Type 2 diabetes mellitus (T2DM) is associated with a higher risk of cancer and cancer-
related mortality. Increased blood glucose and insulin levels in T2DM patients may 
be, at least in part, responsible for this effect. Indeed, lowering glucose and/or insulin 
levels pharmacologically appears to reduce cancer risk and progression, as has been 
demonstrated for the biguanide metformin in observational studies. Studies investigating 
the influence of sulfonylurea derivatives (SUs) on cancer risk have provided conflicting 
results, partly due to comparisons with metformin. Furthermore, little attention has been 
paid to within-class differences in systemic and off-target effects of the SUs. The aim of 
this systematic review is to discuss the available pre-clinical and clinical evidence on how 
the different SUs influence cancer development and risk. 
Methods:
Databases including PubMed, Cochrane, Database of Abstracts on Reviews and 
Effectiveness and trial registers were systematically searched for available clinical and 
pre-clinical evidence on within-class differences of SUs and cancer risk.
Results:
The overall pre-clinical and clinical evidence suggest that the influence of SUs on cancer 
risk in T2DM patients differs between the various SUs. Potential mechanisms include 
differing affinities for the sulfonylurea receptor and thus differential systemic insulin 
exposure and off-target anti-cancer effects mediated for example through potassium 
transporters and drug export pumps. 
Conclusion:
Pre-clinical evidence supports potential anti-cancer effects of SUs, which are of interest 
for further studies and potentially repurposing of SUs. At this time, the evidence on 
differences in cancer risk between SUs is not strong enough to guide clinical decision 
making. 
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CHEMICAL COMPOUNDS STUDIED IN THIS ARTICLE
Acetohexamide (PubChem ID: 1989); Chlorpropamide (PubChem ID: 2727); Tolazamide 
(PubChem ID: 5503); Tolbutamide (PubChem ID: 5505); Glyburide / Glibenclamide 
(PubChem ID: 3488); Glipizide (PubChem ID: 3478); Gliclazide (PubChem ID: 3475); 
Glimepiride (PubChem ID: 3476).
ABBREVIATIONS
Akt: protein kinase B; ALDH-3: aldehyde dehydrogenase 3; BMI: body-mass index; CI: 
confidence interval; HbA1c: glycated haemoglobin; HDL: high-density lipoprotein; HR: 
hazard ratio; IGF: insulin-like growth factor; K+ATP channel: ATP-sensitive potassium 
channel; LDL: low-density lipoprotein; MRP: multidrug-resistance protein; OR: odds ratio; 
RR: relative risk; SU: sulfonylurea derivative; T2DM: type 2 diabetes mellitus; TNF: tumour 
necrosis factor.
1. INTRODUCTION
Patients diagnosed with type 2 diabetes mellitus (T2DM) have an increased risk of 
cancer and cancer-related mortality (1,2). This increased risk is already present before 
diagnosis of T2DM (3–6). T2DM is characterized by insulin resistance, hyperglycaemia and 
hyperinsulinemia, which have all been associated with cancer development (7,8). Cancer 
cells have an altered energy metabolism characterized by high glucose consumption 
and high glycolysis rates. This provides energy to generate ATP as well as metabolic 
intermediates for production of biomass required for cellular proliferation (9). This so-
called metabolic reprogramming is one of the hallmarks of cancer (10). The metabolic 
characteristics of tumours and their microenvironment are increasingly important for 
understanding cancer development, treatment resistance and for the identification of 
novel treatment targets (11). Therefore, investigation of factors associated with cancer 
development in T2DM patients is of particular interest.
Increased plasma glucose and insulin levels are, at least in part, responsible for 
the increased risk of cancer and cancer related mortality of T2DM patients (12). The 
various classes of glucose-lowering agents have different mechanisms of action, and thus 
differential effects on plasma glucose and insulin levels and different off-target effects. 
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Therefore, these classes of drugs may also differ in their influence on cancer risk and 
development. Pre-clinical studies in cancer models and observational clinical evidence 
indicate anti-cancer effects of the biguanide metformin and clinical trials testing effectivity 
of metformin in cancer patients are ongoing (8,13). For the other important class of oral 
glucose lowering drugs, the sulfonylurea derivatives (SUs), available data is conflicting 
(14–19). Several studies have reported an association between increased cancer risk 
and use of SUs in T2DM patients, in some cases potentially confounded by the use of 
metformin as a comparator (7,14,20). Other studies have shown that SU use did not 
increase cancer risk in T2DM patients (20,21) or even decreased cancer risk (22) compared 
to T2DM patients not using SUs. The conflicting data regarding the effects of SUs on cancer 
risk and development may be the result of differential effects of the individual SUs in 
terms of systemic or off-target effects.
The aim of this systematic review is to discuss the available pre-clinical and clinical 
evidence on differences in cancer risk and development between patients treated with 
different SU drugs. Understanding these so-called within-SU class differences is important 
to understand the conflicting data regarding cancer risk of SUs and to determine whether 
sufficient data is available to guide clinical selection of SUs for glycaemic control. In 
addition, the accumulated pre-clinical and clinical evidence of the differential effects of 
SUs on cancer risk in T2DM patients may help to identify novel cancer treatment targets.
2. SEARCH STRATEGY 
For clinical studies, databases including Medline (using PubMed), Cochrane, Database of 
Abstracts on Reviews and Effectiveness and several trial registers (last search update March 
21st, 2019, see supplementary file S1 for the complete search strategy) were searched for 
relevant meta-analyses, randomized trials, case-control studies and observational studies 
by two authors. Acetohexamide and tolazamide were excluded from the search, since 
these SUs are currently not registered in Europe or the United States of America. Studies 
that investigated cancer incidence in T2DM patients and compared individual SUs to each 
other were eligible for selection. Title and abstract were screened by two authors and full 
text articles were selected. See supplementary file S1 for detailed information on search 
strategy for clinical data and Fig. S1 for the flow chart of data extraction. 
For pre-clinical data, separate searches were performed for the eight different SUs 
in Medline (using PubMed) combined with the terms “cancer OR tumor* OR tumour*”. 
Based on the abstracts, relevant articles on the effects of SUs on cancer cell growth 
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and intracellular mechanisms in pre-clinical models of cancer were selected by two 
authors. Relevant references of the selected articles were also searched. Articles written 
in languages other than English were excluded. Only original papers were included.
3. DIFFERENCES BETWEEN SUS IN GLUCOSE LOWERING CAPACITY 
Increased glucose and insulin levels have cancer initiating and growth stimulatory effects 
in pre-clinical cancer models (12). Therefore, SUs that consistently normalize blood 
glucose levels with minimal systemic insulin exposure, e.g. by a specific meal dependent 
insulin release, are most likely to show benefit in terms of reducing relative cancer risk. 
SUs are grouped into three generations (Table 1), which differ with respect to strength 
of glucose-lowering capacity, side-effects and the presence of active metabolites. Target 
molecules for SUs are the sulfonylurea receptors, which are subunits of ATP-sensitive 
potassium channels (K+ATP channel) (Fig. 1) (23). The different SUs have varying affinities for 
the sulfonylurea receptor isoforms and differ in hypoglycaemia risk (Table 1). No severe 
hypoglycaemia cases have been reported for gliclazide users, in contrast to the other 
SUs (24–26). 
Extra-pancreatic blood glucose lowering effects of SUs in humans have also been 
described (27–29), however the available studies are small and not all SUs have 
been investigated, nor were different SUs compared within clinical studies. In dogs, 
glibenclamide was shown to have a lower extra-pancreatic blood glucose-lowering capacity 
than glimepiride (30). Postulated mechanisms for the extra-pancreatic effects include 
effects on hepatic glycogen metabolism, gluconeogenesis and lipogenesis. However, 
these mechanisms have mostly been studied at varying, often supra-physiological, drug 
concentrations and have not been studied in humans (27,30,31).
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Table 1: Mechanism of actions of SUs.
Sulfonylurea 
derivative
Generation Mechanism of action (32–34) Point of action Hypoglycemia risk §
Acetohexamide 1 - Increases pancreatic insulin secretion. 
- Closes K+ATP channels located on β-cells.
SUR1 (34) No reliable data
Chlorpropamide 1 - Increases pancreatic insulin secretion.
- Closes K+ATP channels located on β-cells.
SUR1 (35) Only as comparator group
Tolazamide 1 - Increases pancreatic insulin secretion.
- Closes K+ATP channels located on β-cells.
- Increases peripheral insulin sensitivity.
SUR1 (34) Versus chlorpropamide: RR 0.6 (0.4-1.0)* (36)
Tolbutamide 1 - Increases pancreatic insulin secretion.
- Closes K+ATP channels located on β-cells.
SUR1 (33) Versus chlorpropamide: RR 0.2 (0.1-0.4)* (36)
Glibenclamide 2 - Increases pancreatic insulin secretion.




Versus other SUs: HR 1.83 (1.35–2.49) (37)
Versus metformin: HR 3.95 (3.66-4.26) (38)
Versus glipizide: HR 1.04 (0.18-6.85) (39)
Versus chlorpropamide: RR 1.0 (0.8-1.3)* (36)
Incidence: 5.6/1000 (25)
Glipizide 2 - Increases pancreatic insulin secretion.
- Closes K+ATP channels located on β-cells.
SUR1 (33) Versus metformin: HR 2.57 (2.38-2.78) (38)
Versus chlorpropamide RR 0.6 (0.4-0.9)* (36)
Gliclazide 2 - Increases pancreatic insulin secretion.
- Closes K+ATP channels located on β-cells.
SUR1 (33) Versus other SUs: RR 0.47 (0.27-0.79) (26)
Versus glipizide: OR 0.22 (0.05 to 0.96) (39)
Versus glimepiride OR 0.40 (0.13 to 1.27) (39)
Versus glibenclamide: OR 0.21 (0.03 to 1.48) (39)
Glimepiride 3 - Increases pancreatic insulin secretion. 
- Closes K+ATP channels located on β-cells.
SUR1 (33)
SUR2 (33)
Versus metformin: 3.28 (2.98-3.62) (38)
Versus glibenclamide: OR 0.51 (0.09-2.83) (39)
Versus glipizide: OR 0.54 (0.18-1.64) (39)
Incidence: 0.86/1000 (25)
HR: hazard ratio; K+ATP channels: ATP-sensitive potassium channels; OR: odds ratio; RR: relative 
risk; SUR: sulfonylurea receptor. *: study in patients aged 65 years or older; this is relevant 
because this patient group has a higher hypoglycemia risk than younger patients. §: HR, OR, and 
RR were all adjusted.
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RR were all adjusted.
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Fig 1 - Schematic representation of the mechanism of action of sulfonylurea derivatives (SUs) 
on a β-cell of the pancreas. ADP: adenosine diphosphate; ATP: adenosine triphosphate; Ca2+: 
calcium; GLUT-2: glucose transporter 2; K+: potassium; SUR-1: sulfonylurea receptor 1. The 
numbered boxes describe the mechanism of action of SUs in sequential order. 
Table 2: Overview of selected clinical studies.
Author Design Mean 
follow-up* 











HR 0.30 (0.16-0.55) (Mortality)
HR 0.48 (0.29-0.79) (Mortality)
Monami, 
2007 (41)




Glibenclamide Gliclazide OR 3.6 (1.1-11.9) (Mortality)
Tuccori, 
2015 (42)






Other 2nd generation SU
Other 2nd generation SU
HR 1.09 (0.98-1.22) (Cancer risk)
HR 1.27 (1.06-1.51) (Cancer risk)
Chang, 
2012 (43)




OR 1.08 (1.01-1.15) (Cancer risk)
OR 1.00 (0.93-1.08) (Cancer risk)
Yang, 
2010 (7)








HR 0.67 (0.51-0.89) (Cancer risk)
HR 0.65 (0.49-0.83) (Cancer risk)
Monami, 
2009 (44)












OR 2.24 (1.21-4.14) (Cancer risk)
OR 2.62 (1.26-5.42) (Cancer risk)
OR 0.39 (0.21-0.74) (Cancer risk)
OR 0.40 (0.23-0.69) (Cancer risk)
DDD: daily defined dose; HbA1c: glycated hemoglobin; HR: hazard ratio; NR: not reported; OR: 
odds ratio. a: median (interquartile range), b: mean (standard deviation), *: in years. All outcome 
measures presented in the table are adjusted values if provided. All studies presented in the table 
investigated any site of cancer. 
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4. DIFFERENCES BETWEEN SUS IN CANCER RISK: CLINICAL EVIDENCE 
The search strategy for the clinical studies yielded six eligible studies (Fig. S1) (7,40–44), of 
which three retrospective (40–42) and three prospective (7,43,44) (). All studies included 
patients with varying durations of diabetes and the mean follow-up periods ranged from 
4.8 to 14 years. Five of the six studies focused on all-cancer incidence (7,40–43) and one 
reported both all-cancer and site-specific cancer incidence (44). Two of the six studies had 
all-cancer mortality as primary outcome (40,41) and the other four had cancer incidence 
as primary outcome. Three of the six studies investigated dose-response relationships 
for individual SUs (7,42,43) and one of the six studies investigated treatment duration-
response differences for individual SUs (44). One study incorporated a time-varying design, 
taking changes in covariates during follow-up into account (42). In these six studies, data 
on cancer risk was found for gliclazide, glimepiride, glibenclamide and tolbutamide use; 
no data was found for the other SUs of interest (chlorpropamide and glipizide). 
4.1 Gliclazide
Clinical evidence regarding effects of gliclazide use on cancer risk and development 
was described in three studies. In a retrospective observational study (n=1,277) with a 
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mean follow-up of 14 years, T2DM patients treated with gliclazide had a lower cancer 
mortality risk (hazard ratio (HR) 0.30, 95% confidence interval (CI) 0.16-0.55) compared to 
glibenclamide treated patients (40). The analyses were adjusted for metformin and insulin 
use, age, sex, body-mass index (BMI), smoking, diabetes duration, anti-hypertensive 
therapy, glycated haemoglobin (HbA1c), presence of retinopathy, neuropathy and 
cardiovascular diseases. 
The second study had a prospective design including 6,103 patients and showed that 
ever use compared to never use of gliclazide was associated with a lower cancer risk (HR 
0.65, 95%CI 0.49-0.83) in a dose dependent matter in the ever group (7). Ever use was 
defined as use of gliclazide at, or within 2.5 years before, enrolment or during follow-up 
period. Outcomes were adjusted for age, sex, BMI, smoking, alcohol use, baseline HbA1c, 
systolic blood pressure, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglyceride, and ever use of statins, renin-angiotensin system inhibitor, 
metformin and insulin. This study did not correct for HbA1c levels of patients during 
follow-up. 
The third study was a prospective, case-control study including 195 cases with cancer 
and 195 cases without cancer matched for age, sex, duration of diabetes, BMI, HbA1c, 
comorbidity, smoking and alcohol use (44). This study showed that T2DM patients using 
gliclazide for at least 12 months (odds ratio (OR) 0.39, 95%CI 0.21-0.74) and for at least 36 
months (OR 0.40, 95%CI 0.23-0.69) had a lower cancer risk compared to patients who had 
never used gliclazide. The analyses were adjusted for other glucose lowering treatments. 
Due to the limit cohort sizes, no separate HRs for specific cancer types were calculated. 
4.2 Glibenclamide
Clinical evidence regarding effects of glibenclamide use on cancer risk and development 
was described in four studies. The first study had a prospective design including 6,103 
patients and showed that ever compared to never use was associated with a lower cancer 
risk (HR 0.67, 95%CI 0.51-0.89) in a dose-dependent manner in the ever group (7). Ever 
use was defined as use of glibenclamide at, or within 2.5 years before, enrolment or during 
the follow-up period. Outcomes were adjusted for age, sex, BMI, smoking, alcohol use, 
baseline HbA1c, systolic blood pressure, LDL-cholesterol related risks, HDL-cholesterol, 
triglyceride, and ever use of statins, renin-angiotensin system inhibitor, metformin and 
insulin. This study did not correct for HbA1c levels of patients during follow-up. 
In contrast, the second study described a retrospective analysis involving 52,600 SU-
naïve T2DM patients starting SU use between 1 January 1988 and 31 July 2013 with a 
mean follow-up was 5.3 years (42). Glibenclamide use was not associated with a change 
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in risk of developing cancer compared to other second-generation SUs (HR 1.09, 95%CI 
0.98-1.22) (42). However, for a high cumulative dose (>1,096 drug consumptions of the 
daily defined dose of glibenclamide, a dose-dependent higher cancer risk was found 
compared to other second-generation SUs (HR 1.27, 95%CI 1.06-1.51) (42). Results were 
adjusted for year of cohort entry, age, sex, BMI, smoking, alcohol use, HbA1c before 
study cohort entry, duration of treated diabetes before study cohort entry, ever use of 
other anti-diabetic drugs before study cohort entry (including first-generation SUs), and 
ever use of aspirin, statins and non-steroidal anti-inflammatory drugs. Strong points of 
this study were that both duration of SU use and the dose were taken into account, and 
a time-dependent analysis of exposure to SUs were incorporated.
Similarly, another study also described an association between glibenclamide use and 
higher cancer risk. This study was a prospective, case-control study including 195 cases 
with cancer and 195 cases without cancer matched for age, sex, duration of diabetes, 
BMI, HbA1c, comorbidity, smoking and alcohol use (44). This study showed that the OR 
for malignancies after exposure to glibenclamide for at least 12 and at least 36 months 
was 2.24 (95%CI 1.21-4.14) and 2.62 (95%CI 1.26-5.42), respectively, compared to no 
exposure to glibenclamide (44). The analyses were adjusted for other oral glucose 
lowering treatments. The number of patients in this study is relatively small.
Lastly, a retrospective study (n=568) with a mean follow-up of 5 years, described a 
higher all-cancer mortality in glibenclamide users compared to gliclazide users (OR 3.6, 
95%CI 1.1-11.9) (41). This analysis was corrected for age, sex, BMI, insulin and metformin 
treatment. No dose response or cumulative duration analyses performed and the analysis 
was not adjusted for HbA1c. 
4.3 Glimepiride
In a case-control study, 108,920 newly diagnosed T2DM patients were identified (43). 
From this cohort, 8,194 cancer cases and 32,776 age- and sex-matched diabetic controls 
with a mean diabetes duration of 3.6 years and a median follow-up of 7.4 years were 
included in the analyses (43). Use of glimepiride compared to ‘non-use’ did not increase 
overall cancer risk (OR 1.00, 95%CI 0.93-1.08) in newly-diagnosed diabetes patients (43). 
It is not clear whether the non-use group included patients using no medication at all or 
patients not using glimepiride. The remaining non-glimepiride SUs were grouped together 
as first/second generation SUs and showed an increased cancer risk compared to ‘non-
use’ (OR 1.08, 95%CI 1.01-1.15) (43). No dose-response or duration response relationships 
for any SUs were found (43). The analyses were adjusted for many covariates including 
insulin, SUs, glinides, metformin, thiazolidinediones, α-glucosidase inhibitors, statins, 
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β-blocker, calcium channel blockers, angiotensin-converting enzyme inhibitors, aspirin, 
chronic liver disease, nephropathy, cerebrovascular disease, and chronic kidney disease. 
However, it was not described whether the analysis was also adjusted for other diabetes 
related covariates, for example HbA1c or BMI. 
4.4 Tolbutamide
In a retrospective observational study (n=1,277) with a mean follow-up of 14 patients 
treated with tolbutamide had a lower cancer mortality compared to patients treated with 
glibenclamide (HR 0.48, 95%CI 0.29-0.79) (40). The analyses were adjusted for metformin 
and insulin use, age, sex, BMI, smoking, diabetes duration, anti-hypertensive therapy, 
HbA1c, presence of retinopathy, neuropathy and cardiovascular diseases. 
4.5 Conclusions clinical evidence
In the majority of the studies described, gliclazide use was either associated with a 
lower risk of developing cancer (7,44) or a lower risk of cancer-related mortality (40,41) 
compared to other SUs or never use. Moreover, one study showed that the reduced 
cancer risk in gliclazide users was dose-dependent (7). The majority of studies point to 
a higher cancer risk and all-cancer mortality risk for glibenclamide users compared to 
T2DM patients using other SUs or never use and this effect was also dose-dependent 
(40–42,44). Only two studies directly compared SUs to one another (glibenclamide vs 
tolbutamide and glibenclamide vs gliclazide (40), and glibenclamide vs gliclazide (41)), 
confirming differences in cancer-related mortality of SUs. However, the evidence should 
be interpreted with caution since all studies included were either small and grouped all 
cancers together or did not account for duration or dose-response relationships. Grouping 
cancer types might introduce bias, since certain tissue types and malignancies may be 
more sensitive to effects of increased blood glucose and insulin levels. Furthermore, 
the methodology used in each study differed substantially; different study designs and 
different statistical analyses were used. All studies adjusted for potential confounders but 
to a varying degree. Importantly, all included studies corrected for at least metformin and 
insulin use. In case patients used other glucose lowering agents, the analyses were either 
corrected for or these patients were excluded from the study. It is uncommon to use 
two different SUs at the same time, so it is unlikely that the effect seen is influenced by 
concurrent SU use. Taking these limitations into account, T2DM patients using gliclazide 
may have a lower cancer risk and T2DM patients using glibenclamide may have a higher 
cancer risk than T2DM patients using other SUs. 
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5. PRE-CLINICAL EVIDENCE OF THE EFFECTS 
AND WORKING MECHANISMS OF SUS ON CANCER CELLS 
To gain insight in possible systemic or off-target effects explaining the different clinical 
cancer risks of varying SUs, available evidence of growth inhibitory effects and potential 
anti-cancer mechanisms of SUs in pre-clinical models of cancer is discussed in this section. 
This evidence is summarized in Fig. 2. Most data are available for glibenclamide, which is 
frequently used in cell line models as a pharmacological tool to block transporters such as 
the potassium transporter channel. This provides data on in vitro effects of glibenclamide 
on cancer cell growth from studies not primarily designed to study SUs. 
5.1 Effect of SUs on cancer cell growth
Glibenclamide inhibited growth of human prostate (45), hepatocellular (46–48), breast 
(49,50), gastric (51), bladder (52), glioma (53) and colon (54) cancer cell lines in vitro. 
In human prostate, glioma and colon cancer cells this effect was dose-dependent and 
occurred at doses around 0.1 mM (50 µg/mL) (45,53,54), which is at least 100-fold higher 
than the plasma concentrations achieved clinically in daily practice with doses used in 
T2DM patients (55). In bladder and breast cancer cells, reduced cellular proliferation 
has also been reported to be dose-dependent and was seen at concentrations which did 
not differ greatly from clinically achievable plasma concentrations (50,52). In human ovarian 
cancer cell line models, cell growth was not inhibited by glibenclamide (56,57). Proliferation 
of glioma cells was inhibited by 7 days tolbutamide treatment at 100 µM (58), this is about 
2600 times the clinically achievable range of tolbutamide plasma concentrations (59). 
Glipizide, but not glimepiride, suppressed tumour growth and metastases in vivo in 
breast cancer and melanoma xenografts and in transgenic mouse models of breast cancer 
(60). The doses of glipizide and glimepiride used in the study resulted in concentrations 
consistent with clinically achievable plasma concentrations (61).
In general, it appears that in certain conditions, treatment with glibenclamide can 
reduce growth of cancer cells. However, in the majority of studies only one or two cancer 
cell lines were studied and glucose concentration of cell culture media used varied widely 
or were not mentioned. No studies compared the influence of glibenclamide on cell 
growth in a large range of different cell lines in the same conditions. Furthermore, the 
potential mechanisms of growth inhibition of glibenclamide are not elucidated. Therefore, 
the results should be interpreted with caution and effects and mechanisms may be cell 
line specific. The possible mechanisms by which SUs might influence cancer development 
are discussed in the following paragraphs. 
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Fig 2 - Potential anti-cancer effects of sulfonylurea derivatives (SUs). ABC: adenosine 
triphosphate (ATP) binding cassette transporter; Akt: protein kinase B; Chemo: chemotherapy; 
IGF: insulin-like growth factor; IGFR: insulin-like growth factor receptor; IR: insulin receptor; IKK: 
I-kappaB-kinase; K+
ATP
: ATP-sensitive potassium channel; MMP: matrix metalloproteinase; PI3K: 
phosphoinositide 3-kinase; TNF: tumor necrosis factor; TNFR: tumor necrosis factor receptor; 
VEGF: vascular endothelial growth factor. SUs have been shown to inhibit VEGF in vitro and 
in vivo resulting in impaired vasculoneogenesis and angioneogenesis. Degradation of the 
extracellular matrix is impaired by the SU glibenclamide by inhibitions of MMPs, which results in 
less proliferation and invasiveness of cancer cells. Sensitivity of cancer cells might increase due to 
inhibited cellular export of chemotherapeutics due to inhibitory effects of the SU glibenclamide 
on ABC transporters. The SU chlorpropamide selectively inhibits the Akt pathway activity in 
cancer cells, resulting in cell growth arrest and apoptosis of cancer cells in vitro and in vivo. SUs 
have also been shown to inhibit TNF levels and TNFRs in cancer cell, which might have pro-cell 
death effects. Inhibition of K+
ATP
 by SUs reduces cancer cell growth in vitro and in vivo, possibly 
by inducing apoptosis.
5.2 Effects of SUs on growth factors and growth factor pathways
Insulin and insulin-like growth factor (IGF) have been shown to stimulate cancer cell 
proliferation. Exposing a human neuroblastoma cell line to glibenclamide resulted in an 
increase of mRNA expression of insulin and IGF-1 receptors (62). This resulted in increased 
binding of insulin and IGF-1 to the neuroblastoma cells, but not in increased glucose 
uptake. Only short-term experiments, up to 24 hours duration, were described. Studies 
with longer drug incubation times are required to determine whether this results in 
enhanced cancer cell growth. 
Gliclazide inhibited levels of tumour necrosis factor (TNF) production by human 
peripheral blood mononuclear cells and inhibited TNF bioactivity and immunoreactivity 
in mouse serum (63–65). Chlorpropamide inhibited levels of TNF receptors in peripheral 
blood mononuclear cells (66). TNF is a cytokine, which can have both pro-survival and 
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pro-cell death effects, mediated through the TNF receptors. More detailed mechanistic 
studies are required to determine how different SUs influence this delicate balance in 
cancer cells. 
The protein kinase B (Akt) pathway is a signalling pathway, often activated in cancer 
and downstream of the insulin receptor. This pathway is involved in many cellular 
processes, including cell survival, cell cycle progression and cellular growth (67). A 
chlorpropamide analogue API-2 selectively inhibited the Akt pathway activity in cancer 
cells with elevated Akt expression without influencing other pathways, resulting in cell 
growth arrest and apoptosis of cancer cells in vitro and in vivo (68). This is of interest 
since the Akt pathway is hyperactivated in many cancer types and therefore an attractive 
therapeutic target. However, clinical development of such inhibitors has been hampered 
by drug-toxicity (69).
5.3 Effects of SUs on ATP-binding cassette transporters and solute channels
Sulfonylurea receptors belong to the ATP-binding cassette transporter superfamily, 
which are transmembrane proteins that transport substrates across cellular membranes. 
Multidrug-resistance proteins (MRPs) are ATP-binding cassette transporters involved 
in the cellular export of several drugs, including chemotherapeutic drugs, and can 
therefore protect cancer cells from anti-cancer drugs (70). Glibenclamide is an inhibitor 
of various ATP-binding cassette transporter proteins (71–74). Glibenclamide inhibited 
MRP1 in human lung cancer cells resulting in enhanced sensitivity of these cells to the 
anti-cancer drug and MRP substrate vincristine (75). However, in this study, the dose of 
glibenclamide required for this effect was at least 10-fold higher than the therapeutic 
plasma concentration currently achieved clinically (55). Glibenclamide also inhibited the 
transport of the drug alpha-tocopheryl-phosphate across the cell membrane into cells 
in a leukaemia cell line, thereby reducing the anti-proliferative effect of this drug (76). 
However, the transporter involved was not identified. If this effect is indeed confirmed 
at physiological doses for certain drug transporters then caution may be required when 
glibenclamide use is combined with anti-cancer drugs. However, although the efficacy of 
efflux pump inhibitors to improve the effect of chemotherapeutics has been extensively 
studied clinically, results have so far been disappointing (77). 
Some potassium channels are regulated by sulfonylurea receptors and can be 
(potently) inhibited by, for example, glibenclamide (48,78,79). Deregulated expression 
of all four classes of potassium channels has been demonstrated in human cancers 
and overexpression has been correlated with increased cell proliferation (80–83). 
Pharmacological inhibition of potassium channels has been shown to reduce cancer cell 
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growth in vitro and in vivo in cancers with overexpression of these channels (84). Voltage-
gated potassium channels were blocked by glibenclamide in a hepatocellular carcinoma 
cell line, resulting in reduced proliferation (48). However, in another study, no effect was 
seen in an ovarian cancer cell line (56). Potassium channel blockers mediate depolarization 
of membranes; this can result in programmed cell-death (apoptosis) and therefore this 
may also be expected for SUs. Indeed, induction of apoptosis by glibenclamide was 
described in several human cancer cell line models (45,46,51,53,85,86). In addition, both 
glibenclamide and tolbutamide enhanced apoptosis induced by other drugs (87,88). In 
contrast, gliclazide protected cancer cells from hydrogen peroxide induced apoptosis 
(89–91). In general, it appears that influence of glibenclamide on potassium channels and 
apoptosis is likely to be dose dependent and potentially cell-line dependent.
5.4 Effects of SUs on angiogenesis and metastasis
Angiogenesis plays a major role in cancer progression and metastasis, and is mediated 
by growth factors such as vascular endothelial growth factor (92). Inhibition of 
neovascularization can be useful as anti-cancer therapy by controlling tumour growth 
and metastasis. Bevacizumab, a monoclonal anti-body against vascular endothelial 
growth factor A, and several tyrosine kinase inhibitors with anti-angiogenic properties 
are registered as anti-cancer therapy in selected tumour types. 
Glibenclamide inhibited cellular invasion and migration in a human ovarian cancer 
cell line model through inhibition of components of the angiogenic pathway (93). In 
vivo studies in early chick embryo chorioallantoic membrane and yolk sac membrane 
models and in prostate cancer mouse models showed that glipizide indeed inhibited 
vasculoneogenesis and angioneogenesis (60,92,94). 
Degradation of the extracellular matrix is essential for tumour invasion and 
metastasis. Among the essential proteins for this process of degradation are various types 
of matrix metalloproteinase. Growth, proliferation and invasiveness of breast cancer in 
TA2 mice was inhibited by a combined treatment of glibenclamide and cobalt chloride 
through inhibition of matrix metalloproteinases (95). In contrast, in ovarian cancer cells, 
glibenclamide had no effect on cell adhesion, cell invasion or migration (96). Lymphatic 
spread is frequently a first step in cancer metastasis. Acetohexamide dose-dependently 
inhibited breast cancer intravasation into lymph ducts in a three-dimensional cell co-
culture assay (97). This effect of acetohexamide was identified during a screening 
procedure of hundreds of drugs registered for non-cancer indications. This observation 
is yet to be confirmed in other in vitro and in vivo cancer models and the exact mechanism 
has not been elucidated. 
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5.5 The effects of SUs on anti-cancer treatment
SUs might not only affect cancer initiation and progression but also the efficacy of anti-
cancer treatment. Glibenclamide has been shown to protect human glioblastoma, primary 
astrocytes and normal lung tissue cell lines from radiation-induced cell death (98). Mice 
injected with glibenclamide before total body irradiation lived longer compared to mice 
injected with glibenclamide after radiation therapy or without glibenclamide treatment 
(98). The specific underlying mechanisms of the radio-protective effect of glibenclamide 
pre-administration are unknown (98). Furthermore, in liver and lung cancer cell lines 
glibenclamide has been shown to increase the cytotoxicity of the chemotherapeutic drug 
doxorubicin (99). This study shows altering DNA conformation effects of glibenclamide 
possibly explaining its synergistic effects on doxorubicin treatment (99). 
Analogues of chlorpropamide inhibited human aldehyde dehydrogenase 3 (ALDH-
3) in cancer cells and sensitize breast cancer cells to chemotherapy (100,101). ALDH-3 
can be overexpressed in cancer cells and is involved in detoxification of certain types 
of chemotherapy and may therefore be involved in resistance to these therapies. Thus, 
inhibition of ALDH-3 is of interest to enhance tumour sensitivity to these chemotherapeutic 
drugs, however this has yet to be investigated in in vivo models. 
Cancer cell resistance to chemo- and radiotherapy is, among others, enhanced by 
upregulation of the Akt-pathway (102,103). A chlorpropamide analogue, API-2, inhibited 
this pathway and reduced chemo- and radioresistance (102–104). Furthermore, API-2 
sensitized immune resistant tumours for CD8+ T-cell mediated apoptosis by Akt inhibition 
and might therefore improve immunotherapy (105). API-2 can induce either apoptosis 
or metastasis depending on the nuclear β-catenin expression, which differs between 
cancer cells suggesting pleiotropic effects of API-2 (106). It is unknown whether use of 
chlorpropamide itself results in the same effects. 
The pre-clinical evidence suggests numerous potential anti-cancer mechanisms of 
SUs. However, systemic studies in cancer cell line panels and relevant model systems at 
clinically achievable drug concentrations are lacking.
6. DISCUSSION 
The overall clinical evidence suggests that the influence of SUs on cancer risk in T2DM patients 
differs between the various SUs. Potential mechanisms include differing affinities for the 
sulfonylurea receptor resulting in differential systemic insulin exposure and off-target anti-
cancer effects mediated for example through potassium transporters or drug export pumps. 
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Observational studies demonstrated that the use of the second generation SU 
gliclazide was associated with a lower risk of developing cancer compared to never use 
of gliclazide (7,44). Gliclazide users also had a lower risk of cancer-related mortality 
compared to glibenclamide users (40,41). Glibenclamide use was associated with a 
higher risk of developing cancer compared to other second-generation SUs and to no 
use of glibenclamide (42,44). All studies had important methodological limitations and 
used different study designs and statistical methods. Interpretation of results and direct 
comparisons of the retrospective clinical studies were hampered by low numbers of 
cancer cases, grouping together of different cancer types and lack of data on dose or 
cumulative exposure of SUs. 
Higher insulin levels have tumour promoting effects in vitro in cell line models, 
in vivo in animal models and in human epidemiological studies (12). Metformin 
reduces peripheral insulin resistance resulting in lower blood insulin and glucose 
levels (Fig. 3). This could, at least in part, explain the potential anti-cancer effects of 
this drug (8,13). The different effects of gliclazide and glibenclamide on cancer risk 
and mortality may also be explained by differential influences on blood insulin levels 
of both agents (Fig. 3). Glibenclamide has been associated with an increased and 
pro-longed hypoglycaemia risk compared to other SUs. This can be explained by the 
relatively long half-life time of glibenclamide due to high affinity for the sulfonylurea 
receptor 1 and the slow reversibly of the sulfonylurea receptor 1 binding (107,108). 
The accumulation of active metabolites due to impaired renal function may also 
contribute to the hypoglycaemia risk of glibenclamide (32,37,109). Glibenclamide is 
not selective for just sulfonylurea receptor 1 located on the pancreatic β-cells of the 
pancreas, but also binds sulfonylurea receptor 2A and B which are widely expressed, 
amongst others, on cardiac muscle (107,110). In contrast, gliclazide binds more 
selectively with rapid reversibility to sulfonylurea receptor 1 located on pancreatic 
β-cells (107,110) and is hepatically metabolised into inactive metabolites before renal 
elimination (111). 
SUs with the most selective meal dependent insulin release are expected to be 
associated with the lowest cancer risks due to lower overall insulin exposure and 
this may explain the observed clinical differences. Differential insulin responses of 
glibenclamide and gliclazide have indeed been demonstrated. The physiological 
pancreatic insulin response is biphasic, the first phase concerns rapid insulin exocytosis 
within 5-10 minutes after stimulation whereas the second phase can sustain for hours 
in case of persisting elevated glucose levels (112). In an in vitro model measuring insulin 
release in isolated rat pancreases, a biphasic insulin response to gliclazide treatment 
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was demonstrated which was in contrast to the delayed monophasic insulin response to 
glibenclamide treatment (113). In two small randomized double-blind trials, containing 
24 and 12 patients respectively, glibenclamide was shown to have a stimulatory effect 
on the second but not on the first phase of insulin secretion (114,115). Furthermore, 
inappropriate insulin secretion in case of low blood glucose levels has been shown in 
T2DM patients and healthy volunteers using glibenclamide (116–119). The biphasic 
glucose-dependent insulin response of gliclazide was confirmed in four diabetic patients 
and four healthy controls (120). In conclusion, gliclazide appears to result in a selective 
glucose dependent insulin release which in turn results in a more physiological insulin 
response and a corresponding lower average blood insulin level than for example 
glibenclamide (Fig. 3).
Pre-clinical studies suggest that SUs could have direct inhibitory effects on cancer 
cell growth (45–54). Especially glibenclamide had anti-proliferative effects in some 
pre-clinical cancer models, potentially through blockade of potassium channels thus 
inducing apoptosis (45,46,71–74,47–54). However, glibenclamide is often studied due 
to its pharmacological effect on the potassium channels and not systematically with the 
goal of studying the anti-cancer effects of the drug. No large systematic comparison of 
growth inhibitory effects of the different SUs in panels of cancer cell lines have been 
performed. Furthermore, thorough investigation of effects of SUs on signal-transduction 
routes important to cancer cell growth have not been performed, and no studies on 
cancer cell metabolism were identified. Extra-pancreatic, organ specific effects of 
SUs on glucose metabolism exist and may differ between individual SUs as has been 
described for glibenclamide and glimepiride (27,30,31). The anti-cancer effects of SUs 
may be considered a novel extra-pancreatic effect. There is insufficient data available to 
determine whether the anti-cancer effects of SUs are correlated to their known extra-
pancreatic effects on glucose metabolism. 
The reported concentrations of SUs used in the reviewed in vitro studies appear 
to be high compared to the achievable therapeutic range in patients, which is 
measured as total (free plus protein-bound) plasma concentrations. Several factors 
complicate interpretation of these reported in vitro concentrations. Firstly, SUs 
bind to proteins in the cell culture medium (121–124) and, therefore, the actual 
free drug concentration available at the target may be lower than the reported SU 
concentration. Consequently, it is unknown at which actual drug concentrations the 
described anti-cancer effects of SUs at the cellular levels occurred. Secondly, SU 
binding affinities to albumin used for cell culture versus human albumin differ and 
SUs may bind to other proteins than only albumin (121). Thus translation of the in 
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vitro data is seriously hampered due to the probable differing degrees of protein 
binding between in vitro models and patients. Furthermore, there are multiple factors 
besides protein binding that determine the free drug concentrations surrounding the 
therapeutic target in the tumour in patients (125). 
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◀ Figure 3 – Schematic representation of blood insulin and glucose interactions in relation to 
oral glucose lowering agents.  GLUT-4: glucose transporter 4; IR: insulin receptor; T2DM: type 
2 diabetes mellitus. A) In non-diabetic patients, binding of insulin to peripheral tissues leads to 
translocation of glucose transporter 4 (GLUT-4) to the cell membrane enabling glucose influx. 
Glucose stimulates insulin excretion by β-cells of the pancreas. Insulin inhibits gluconeogenesis by 
the liver. B) In T2DM patients, peripheral tissues and liver tissue are insulin resistant. This results in 
hyperglycemia due to reduced cellular influx of glucose, increased insulin secretion by β-cells of the 
pancreas and stimulation of gluconeogenesis. C1) T2DM patients suffer from hyperglycemia and 
hyperinsulinemia. C2) Gliclazide treatment results in a slightly higher basal blood insulin level than 
in untreated T2DM patients and in a selective glucose-dependent insulin release. C3) Glibenclamide 
results in a less specific glucose-dependent insulin release than gliclazide, resulting in higher basal 
blood insulin levels and prolonged insulin secretion after a meal. C4) Metformin reduces insulin 
resistance of peripheral tissues and liver tissue resulting in less insulin secretion.
Clinical and pre-clinical data are conflicting regarding influence of glibenclamide 
on cancer risk and development. This is likely due to differential systemic versus intra-
cellular effects of SUs. The association of glibenclamide use and increased cancer risk 
may be explained by the relatively high insulin exposure during glibenclamide treatment 
compared to other SUs. This is clearly not compensated by cancer inhibiting effects at 
the cellular level in patients. The pre-clinically described potential anti-cancer effects of 
SUs are of interest from a mechanistic point of view and deserve further investigation. 
This may result in novel anti-cancer drug targets and/or potential repurposing of SUs. 
In conclusion, it appears that T2DM patients using gliclazide may have a lower cancer 
risk than those using glibenclamide. However, the evidence on differences in cancer risk 
between the different SUs and SU classes is, at this time, not strong enough to guide 
clinical decision-making. 
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SUPPLEMENTARY DATA
Search strategy 
•	 PubMed: ((tumor OR tumour OR tumou*) OR (malignancy) OR (malignan*) OR (cancer) 
OR (“neoplasms”[MeSH Terms]) OR (neoplasm) OR (neoplas*)) AND ((sulfonylu*) 
OR (glicl*) OR (tolbut*) OR (glimepir*) OR (glybur*) OR (gliben*) OR (glipiz*) OR 
(Chlorprop*) OR (“Sulfonylurea Compounds”[MeSH Terms]) OR (“gliclazide”[MeSH 
Terms]) OR (“Chlorpropamide”[MeSH Terms]) OR (“Glipizide”[MeSH Terms]) OR 
(“Glyburide”[MeSH Terms]) OR (“Tolbutamide”[MeSH Terms]))
•	 Cochrane, Database of Abstracts on Reviews and Effectiveness, Current Controlled 
Trials (http://controlled-trials.com), ClinicalTrials.gov (http://clinicaltrials.gov/), 
Netherlands Trial Register (http://www.trialregister.nl), NHS Centre for Reviews and 
Dissemination, NHS Economic Evaluation Database, Health Technology Assessment 
Database, Health Economic Evaluation Database (http://www.ohe-heed.com/), 
Emerging Care Research Institute database (http://www.ecri.org/):
- Sulfonylurea
- Gliclazide
















Full-text articles assesed for eligibility
(n = 47)






















Studies included in qualitative synthesis (table 1)
(n = 6)
Records excluded:
No SU in comparator group: 18
Figure S1 - Flow chart showing the selection of clinical studies for review. SU = sulfonylurea 
derivative.
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ABSTRACT
Background: 
Previous studies have shown that many within-class differences exist between 
sulfonylureas (SUs), however, whether differences exist regarding the time it takes 
between initiating an SU and the need to intensify treatment with insulin is unclear. The 
aim of this study was to investigate the relationships between the three frequently used 
sulphonylureas, prescribed as dual therapy next to metformin, and the time needed to 
treatment intensification with either insulin or oral triple therapy in patients with type 
2 diabetes mellitus. 
Methods: 
Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) is a prospective 
observational cohort study set in primary care in the Netherlands. Annually collected 
data on diabetes medication and clinical variables within ZODIAC are used to evaluate 
the primary outcome, time to insulin and secondary outcome, time to either insulin 
or triple oral therapy. For statistical analysis a time-dependent cox proportional hazard 
model was used.
Results: 
3507 patients were included in the analysis, with a mean age of 61 (SD 11.4) and a median 
HbA1c of 6.8% [IQR 6.4-7.4] (50.8 mmol/mol [IQR 46.4-57.4]).The hazard ratio (HR) for 
the primary endpoint was 1.10 (95% CI 0.78-1.54) for metformin/glimepiride and 0.93 
(95% CI 0.67-1.30) for metformin/tolbutamide with metformin/gliclazide as reference 
group. The HR for the secondary outcome was 1.04 (95% CI 0.78-1.40) and 0.85 (95% CI 
0.64-1.13), respectively. 
Conclusion: 
In this large Dutch primary care cohort, new users of neither gliclazide, glimepiride nor 
tolbutamide as dual therapy with metformin, resulted in differences in the time needed 
for further treatment intensification. 
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INTRODUCTION
Many important within-class SU differences have been described, mostly in favour 
of gliclazide. For example; gliclazide is considered the safest SU in patients with renal 
impairment(1). Furthermore, there is also a clear benefit of prescribing gliclazide for 
reasons of hypoglycaemia risk(2) and possibly cardiovascular safety(3). Within-class 
SU differences have also been described for SU failure rate. For example, glipizide and 
glibenclamide are associated with a higher failure rate compared to gliclazide(4). In the 
2013 Dutch type 2 diabetes mellitus (T2DM) guideline, gliclazide specifically became the 
preferred sulphonylurea (SU) and the first intensification step after metformin (5).
When dual oral therapy fails, next to lifestyle interventions, a switch to or addition of, 
once daily insulin or possibly a third oral agent are advised steps for regaining adequate 
glycaemic control. This moment in time could be considered a turning point for patients 
and is regarded as disease progression for patients and therefore is a relevant surrogate 
endpoint.
Whether within-class differences exist for “time needed to intensification” for SUs 
remains unclear. We hypothesized that a difference in time to intensification could 
be present, since the subsequent generations of SUs have become increasingly more 
potent (4, 6). The presence of a within-class difference concerning time to insulin could 
benefit both patient related outcomes as well as aid in controlling health care costs since 
treatment with oral glucose lowering agents is more cost-effective than treatment with 
insulin (7). 
Using a new-user design, the aim of this study was to investigate the relationships 
between the three most frequently prescribed SUs in the Netherlands, prescribed as dual 
therapy next to metformin and the time needed to treatment intensification with either 
insulin or oral triple therapy in patients with T2DM.
METHODS
The study is reported according to the STROBE (Strengthening the reporting of 
observational studies in epidemiology) recommendations (8).
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Study design and data collection
This study is part of the prospective ZODIAC (Zwolle Outpatient Diabetes project 
Integrating Available Care) cohort study. This ongoing study started in 1998 in the Zwolle 
region, and has since expanded to more than 600 general practices in the north-east and 
western part of the Netherlands. Following two major expansions of the cohort in 2006 
and 2009, the majority of patients were included from 2006 onwards. Patients included 
in the study are diagnosed with T2DM and are exclusively treated in primary care. Data 
are collected annually by general practitioners and send to the diabetes centre annually.
Patient selection
A “new-user” design (9) was used. Patients who used metformin monotherapy for at least 
one year and subsequently intensified for the first time with gliclazide, glimepiride or 
tolbutamide were selected. Patients were also required to be included in the ZODIAC study 
between 1998 and 2012. Patients with an eGFR below 30mL/min/1.73m2 or when eGFR 
at baseline was missing were excluded. We hypothesized that including these patients 
could lead to selection bias because gliclazide is the preferred SU in renal impairment (1).
Outcome measures
The primary outcome was the first receipt of insulin and secondary outcome was first 
receipt of either insulin or triple oral therapy. 
Statistical analysis
Quantitative variables are presented as means with standard deviation for normally 
distributed values, and median and interquartile range (IQR) for skewed variables. Time-
dependent cox proportional hazard analyses, adjusted for HbA1c, age, gender, diabetes 
duration, updated mean creatinine and updated mean BMI were used to evaluate the 
primary and secondary outcome. All analyses were performed with IBM SPSS Statistics 
(Version 22.0).
ETHICS STATEMENT
In the ZODIAC study, patients consented to anonymous use of their data for study 
purposes. The medical ethics committee of Isala, Zwolle, The Netherlands approved the 
ZODIAC study (METC reference numbers 03.0316 and 07.0335).
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RESULTS
From the complete cohort (N = 82.167), 25.183 patients used metformin monotherapy. 
From these, 4096 received some form of intensification. Patients receiving insulin 
as second step on top of metformin (n=83) and 506 patients with an eGFR < 30 ml/
min/1.73m2 or missing eGFR were excluded (Fig 1). From the 3507 selected patients, 
47% was female, the mean age was 61 (SD 11.4), median HbA1c 6.8% [IQR 6.4-7.4] (50.8 
mmol/mol [IQR 46.4-57.4]), median BMI 29.7 [IQR 26.8-33.3], median diabetes duration 
6.8 years [IQR 4.5-9.4], mean eGFR 83.2 (SD 20.1) and median creatinine 76.0 [IQR 
65.0-89.0] (Table 1). There were no baseline differences in median HbA1c between the 
different treatment groups; metformin/gliclazide 6.9 [IQR 6.4-7.4], metformin/glimepiride 
6.8 [IQR 6.3-7.4] and metformin/tolbutamide 6.9 [IQR 6.4-7.5]. Two-and-half and 5 years 
after intensification 13.0% and 32.0% of patients were using insulin, respectively. Two-
and-half and 5 years after intensification 17.5% and 39.7% of patients were using either 
insulin or triple oral therapy, respectively.
Table 1: Baseline characteristics. 
Variables n=3507
Gendera Female: 47%, Male: 53%
Age at diagnosis (years)b 57.8 [17.9]
Age (years)b 61.0 [11.4]
eGFRb 83.2 [20.1]
Creatinine (μmol/L)c 76.0 [65.0-89.0]
Diabetes duration (years)c 6.8 [4.5-9.4]
HbA1c (%) / HbA1c (mmol/mol) c 6.8 [6.4-7.4] / 50.8 [46.4-57.4]
BMIc 29.7 [26.8-33.3]
a%, b mean with SD, c median with interquartile range.
PRIMARY ENDPOINT
In the unadjusted model the HR for metformin/glimepiride was 1.15 (95% CI 0.83-1.61) 
and for metformin/tolbutamide 0.97 (95% CI 0.70-1.34), with metformin/gliclazide as a 
reference category. There were no significant differences between the three groups in 
primary outcome (Fig 2). The pairwise HR’s for the primary endpoint in the unadjusted 
model are shown in Table 2.




























- eGFR < 30: n=4
- eGFR missing at
baseline: n=502
Fig 1. Flow of selected patients. 
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Fig 2. Cumulative survival. Panel A shows the cumulative survival for gliclazide, glimepiride 
and tolbutamide and time to insulin using the unadjusted model. Panel B shows the cumulative 
survival for gliclazide, glimepiride and tolbutamide and time to insulin or triple oral therapy using 
the unadjusted model.
Table 2: unadjusted model. *Reference category.
Time to insulin Time to insulin or third oral agent
HR 95% CI p HR 95% CI p
Medication 0.429 0.161
Gliclazide* vs Glimepiride 1.151 0.825-1.605 0.407 1.111 0.834-1.480 0.470
Glicazide* vs Tolbutamide 0.965 0.695-1.340 0.831 0.878 0.660-1.168 0.371
Glimepiride* vs Tolbutamide 0.838 0.637-1.103 0.207 0.790 0.620-1.006 0.056
The HR for time to insulin using a fully corrected model for metformin/glimepiride was 
1.10 (95% CI 0.78-1.54) and for metformin/tolbutamide 0.93 (95% CI 0.67-1.30), with 
metformin/gliclazide as a reference category. The pairwise HR’s for the primary endpoint 
in the fully corrected model are shown in Table 3. There were no significant differences 
between the three groups in primary outcome. HbA1c and age are significantly associated 
with the primary endpoint with HRs of 1.08 (95%CI 1.00-1.15) and 0.99 (95%CI 0.97-
1.00) respectively. Creatinine, BMI, gender, and diabetes duration are not significantly 
associated with the primary endpoint (Table 3).
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 Table 3: Covariates included in Cox proportional hazard model. * reference category
Time to insulin Time to insulin or third oral agent
HR 95% CI p HR 95% CI p
HbA1c 1.077 1.008-1.151 0.028 1.082 1.022-1.145 0.007
Creatinine 0.998 0.990-1.006 0.688 0.992 0.985-1.000 0.410
BMI 1.007 0.983-1.033 0.585 1.021 1.000-1.043 0.510
Gender 1.012 0.768-1.334 0.934 0.896 0.701-1.145 0.380
Diabetes duration 0.988 0.951-1.026 0.545 0.994 0.969-1.020 0.644
Age 0.986 0.974-0.998 0.026 0.984 0.974-0.995 0.003
Medication 0.541 0.234
Gliclazide* vs Glimepiride 1.095 0.780-0.537 0.602 1.044 0.780-1.397 0.772
Glicazide* vs Tolbutamide 0.933 0.668-1.304 0.684 0.848 0.635-1.134 0.266
Glimepiride* vs Tolbutamide 0.852 0.643-1.131 0.268 0.813 0.634-1.041 0.101
 
SECONDARY ENDPOINT
In the unadjusted model the HR for metformin/glimepiride was 1.11 (95% CI 0.83-1.48) 
and for metformin/tolbutamide 0.88 (95% CI 0.66-1.17), with metformin/gliclazide as a 
reference category. There were no significant differences between the three groups in 
primary outcome (Fig 2). The pairwise HR’s for the primary endpoint in the unadjusted 
model are shown in Table 2.
The HRs for time to insulin or triple oral therapy for metformin/glimepiride was 
1.04 (95% CI 0.78-1.40) and for metformin/tolbutamide 0.85 (95% CI 0.64-1.13) with 
metformin/gliclazide as a reference category. The pairwise HR’s for the secondary 
endpoint are shown in Table 3. HbA1c (HR 1.08, 95% CI 1.02-1.15) and age (HR 0.98, 95% 
CI 0.97 – 1.00) were significantly associated with the need for intensification therapy with 
insulin of a third oral agent. Risk for time to insulin or triple oral therapy by increased 
8% per 1% increase in HbA1c and decreased 2% per 1-year increase in age. Creatinine, 
BMI, Gender and diabetes duration were not significantly associated with the secondary 
endpoint (Table 3).
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DISCUSSION
In this primary care cohort of patients who used metformin monotherapy and intensified 
with gliclazide, glimepiride or tolbutamide, the so-called new users, there were no 
statistically significant differences in time to insulin, or time to either insulin or a third 
oral agent. After 2.5 and 5 years respectively 13.0% and 32.0% of patients were using 
insulin and respectively 17.5% and 39.7% of patients were using insulin or triple therapy. 
The numbers are in accordance with the numbers found previous studies (10). 
No studies were found investigating within-class differences in time to insulin in 
patients using metformin and a SU as dual therapy. A retrospective cohort study conducted 
in Colombia showed a higher risk of insulin treatment (OR=3.49, 95%CI 2.61-4.66) in 
patients treated with metformin and glibenclamide (11). In a Swedish retrospective cohort 
study the probability of insulin use was increased (HR = 2.71, 95%CI: 2.15-3.43) in patients 
using more than one oral antidiabetic agent (12). However, the risk of insulin use was not 
evaluated in individual agents within the SU class.
Based on the results of this study, that in daily primary care practice, the time to 
intensification with insulin or a third oral agent is not influenced by the choice of a specific 
SU but rather by specific patient characteristics despite the differences in potency between 
the three SUs (4, 6). In this study, HbA1c and age appeared to be more important factors.
The strengths of this study were the inclusion of patients from a daily care setting and 
the new-user design. The daily care setting increases the generalizability of our results. 
Excluding prevalent users allowed us to avoid under ascertainment of insulin prescription 
that occurs early after the start of SUs and also allowed us to avoid that confounders are 
influenced by previous treatment (9). A limitation was that the data is collected annually; 
changes in medication within this year might not be reflected in our database. A second 
limitation is the possibility that patients who required insulin could have been referred to 
secondary care. Patients within ZODIAC are lost to follow-up when referred to secondary 
care for their diabetes treatment. However, in the Netherlands insulin treatment is usually 
initiated in primary care and thus expect the underestimation of time to insulin to be 
limited. Furthermore, patients could have refused intensification of therapy like the 
addition of insulin, leading to an underestimation of the primary endpoint which was 
the reason for also analysing the time needed to a third oral agent. However, we don’t 
expect a between-group difference in motivation to use insulin.
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CONCLUSION
In conclusion, there were no differences found in this large Dutch primary care cohort 
with respect to the time needed for further treatment intensification with neither insulin 
nor a third oral agent when treated with gliclazide, glimepiride or tolbutamide on top of 
metformin. In this study higher HbA1c and lower age are associated with a shorter time 
needed to insulin and a shorter time to a third oral agent. 
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ABSTRACT
Aim: 
To investigate changes in body weight trajectories after the addition of individual 
sulphonylureas (SUs) to metformin in patients with type 2 diabetes. 
Methods: 
Prospective observational cohort study, set in primary care, the Netherlands. Patients 
with type 2 diabetes, included in the ZODIAC cohort between 1998 and 2012, aged 18 
years and older, and who received metformin monotherapy at inclusion (n=29,195), 
and used metformin as monotherapy for at least one year before receiving dual therapy 
by the addition of a SU for at least one year. Primary outcome was within-drug yearly 
change in body weight after receiving add-on therapy with individual SUs during 5-years of 
follow-up. Secondary outcome was within-drug yearly change in HbA1c. Annual changes 
in weight and HbA1c were estimated with linear mixed models, adjusted for age, gender 
and diabetes duration. 
Results: 
A total of 2,958 patients were included. No significant weight changes were observed 
within and between any of the individual SUs after treatment intensification (p = 0.24). 
In addition, no significant difference in weight between the add-on therapy combinations 
was observed (p = 0.26). The average HbA1c the year before intensification was 7.2% (55 
mmol/mol) and dropped below 7.0% (53 mmol/mol) the year after. 
Conclusions: 
In patients with type 2 diabetes treated in primary care, strict glycaemic control can be 
maintained with SUs used as add-on therapy to metformin, without the offset of relevant 
weight changes.
4Addition of sulphonylurea and weight changes (ZODIAC-39)  |  77
INTRODUCTION
Avoiding relevant increases in body weight, also specifically after starting new glucose 
lowering agents, is an important treatment target in type 2 diabetes (1). Weight increase 
in patients with type 2 diabetes is problematic because it contributes to increased insulin 
resistance and disease progression (1-3). In trials investigating new glucose lowering 
agents, bodyweight is used as a separate end-point in studies investigating new glucose 
lowering agents. Except for lifestyle factors, the different glucose lowering agents have 
been reported to have either decreasing, neutral or increasing effects on bodyweight. 
From the available agents, metformin is reported to have no effect on weight (4-6). Several 
other glucose lowering agents were reported to cause small increases in weight (7-12). 
The UK Prospective Diabetes Study (UKPDS) reported an increase in weight of about 4 kg 
in the first 3 years after initiation of glibenclamide compared to metformin, after which 
weight remains relatively stable (7). The A Diabetes Outcome Progression Trial (ADOPT) 
showed that glibenclamide monotherapy causes a 1.6kg increase in weight in the first 
year compared to baseline, but remains stable after that for the next 5 years (13).
The magnitude of weight changes in daily practice after starting sulphonylureas (SUs) 
is not entirely clear. Only a few studies investigated the effects of initiation of glucose 
lowering agents on weight in observational cohort studies; a meta-analysis of only 2 
prospective studies reported an increase of 2.06 kg (95% CI: 1.15-2.96) for SUs as a group 
compared to placebo (14). A retrospective cohort study showed that monotherapy with 
any SU was associated with a 1.05 kg/m2 (95% CI: 0.90–1.20) higher BMI 12 months after 
initiation compared to metformin use (15).
It is unclear whether this weight increase is a class-effect or should be attributed 
to specific SU drugs. As a consequence, there is a growing interest in within-class SU 
differences. From the SUs, especially gliclazide has a remarkable safety profile: it’s use is 
associated with exceptionally few hypoglycaemic events (16). Furthermore, gliclazide can 
even be used in patients with renal impairment without dose adjustment (17, 18) and it is 
possibly beneficial with respect to cardiovascular outcomes compared to other SUs (19). 
Together, this led to the incorporation of gliclazide as the preferred SU in the Dutch 2013 
diabetes guideline when treatment intensification next to metformin is required (20). 
Evidence for within-class differences in weight change after the start of individual SUs, 
could have consequences regarding the preferred agent when treatment intensification 
is needed. The aim of this study was to investigate within and between SU-group weight 
trajectories, in a prospective primary care cohort of patients with type 2 diabetes, after 
starting add-on therapy with individual SUs, in addition to metformin. 
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METHODS 
The study is reported according to the STROBE (Strengthening the reporting of 
observational studies in epidemiology) recommendations (21).
Study design and data collection
The here presented study (part of Clinicaltrials.gov #NCT02133118) concerns an analysis of 
patients included in the prospective ZODIAC (Zwolle Outpatient Diabetes project Integrating 
Available Care) study (22). The ZODIAC study started in 1998 and included patients diagnosed 
with type 2 diabetes who were treated exclusively in primary care. Since then, the ZODIAC 
study expanded to more than 600 general practices in the north-eastern and western part 
of the Netherlands. In the Netherlands, all inhabitants have a general practitioner and over 
80% of patients with type 2 diabetes are treated exclusively in primary care (23).
In the ZODIAC study, the following data are collected by general practitioners and 
sent to the diabetes centre annually: the presence of macrovascular complications, 
diabetes duration, medication use (diabetes medication, insulin (including type), and all 
other medication), bodyweight, height (only at baseline), blood pressure, HbA1c, serum 
creatinine, urinary albumin-creatinine ratio, and lipid profiles. All values are measured 
once at the yearly check-up with the general practitioner. Any potential changes within the 
year were not recorded. All laboratory measurements were determined using standard 
laboratory procedures. 
Patient selection
Eligible for selection were patients with type 2 diabetes, included in the ZODIAC cohort 
between 1998 and 2012, aged 18 years and older, who received metformin monotherapy 
during participation in the ZODIAC cohort, and who used metformin as monotherapy for at 
least one year before receiving dual therapy by the addition of a SU in the next year (new-
user design) (24). Patients were not excluded on specific patient characteristics other than 
age (< 18 years). Data were censored when follow-up ended or when patients switched 
medication (including other SUs) during follow-up; for example, monotherapy with a SU or 
metformin, or when they subsequently received triple oral therapy or insulin therapy, or at 
the end of follow-up, or death, or after five year of follow-up. For each patient the baseline 
year was defined as the year before treatment intensification with a SU when they were 
using metformin monotherapy. Patients who achieved their HbA1c targets (HbA1c < 7% / 53 
mmol/mol) on metformin monotherapy were not included in the analysis as a comparator 
group, because this comparator group could have been subject to selection bias.
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Outcome measures
Primary outcome was mean yearly change in body weight compared to weight at baseline 
for each add-on group separately for 5 years. Secondary outcome was mean change in 
HbA1c compared to baseline. 
Statistical analysis 
Quantitative variables were presented as means with standard deviation for normally 
distributed values, and median and interquartile range (IQR) for skewed variables. 
Pairwise comparisons with one-way ANOVA or Kruskal-Wallis tests were Bonferroni 
adjusted. Changes in body weight and HbA1c during follow-up were estimated using 
linear mixed models. The use of linear mixed models allowed us to account for missing 
data. Patients with missing data on weight or HbA1c were not excluded; for example, 
if data on weight is missing in year 2 but available at year 1 and in year 3, the patient 
does not participate in the analysis in year 2 but does at year 1 and year 3. The changes 
in weight and HbA1c were modelled with a random intercept and slope, adjusted for 
baseline age, gender and diabetes duration. Age, gender and diabetes duration were 
modelled as fixed effects with age and diabetes duration as continuous variables, while 
patients were modelled as random effect. The model was adjusted for age, gender and 
diabetes duration because we hypothesized that these factors could have influenced both 
body weight and the choice for a specific SU. All analyses were performed with SPSS 20.0 
software (SPSS Inc, Chicago, Illinois, USA). 
Ethics statement
In the ZODIAC study, patients consented to anonymous use of their data for study 
purposes. The medical ethics committee of Isala, Zwolle, the Netherlands approved the 
ZODIAC study (METC reference numbers 03.0316 and 07.0335).
Patient involvement
Patients were not involved in the design of the study, the development of outcome 
measures and in the recruitment of patients. 
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RESULTS
From all metformin monotherapy users at inclusion (n=29,195), 2,958 (10.1%) patients 
were included in the analysis. The number of patients at each selection step are shown 
in supplemental figure S1. Baseline characteristics are shown in table 1. Mean age (years) 
in the 4 treatment groups ranged from 62.1 to 63.5. Median weight was 91.9 kg in the 
gliclazide group, 92.2 kg in the glibenclamide group, 91.3 kg in the glimepiride group and 
89.4 kg in the tolbutamide group.
Panel A Panel B
Fig 1. (A) Estimated mean body weight (kg) during follow-up. Adjusted for age, gender and diabetes 
duration. (B) Estimated mean HbA1c (%) during follow-up. Adjusted for age, gender, diabetes 
duration. Horizontal line indicates the treatment target at the time the study was performed.
Baseline weight and HbA1c were available for 520 (99.6%) and 521 (99.8%) patients in 
the gliclazide add-on group, for 43 (97.7%) and 43 (97.7%) patients in the glibenclamide 
add-on group, for 963 (99.8%) and 964 (99.9%) patients in the glimepiride add-on group 
and for 1415 (99.2%) and 1427 (100.0%) patients in the tolbutamide add-on group, 
respectively.
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Weight changes during follow-up.
The overall results of the linear mixed model analysis showed a non-significant (p=0.24) 
linear change in weight during the follow-up period and a non-significant (p=0.26) 
difference in weight between the add-on therapy combinations. In addition, the change 
in weight did not significantly differ between the add-on therapy combinations (p value 
for interaction=0.67). The regression parameters of the fixed effects of the mixed model 
analysis are presented in supplemental table S1. Estimated weights for the different add-
on therapy combinations at yearly time points are presented in table 2 and figure 1, panel 
A. After 5 years a non-significant increase in weight was observed in the gliclazide and 
glibenclamide groups, in the glimepiride group no change was observed. 
Glucose control—HbA1c
The HbA1c results showed a non-linear trend over time. A quadratic trend was introduced 
in the mixed model analysis for the changes in HbA1c during follow-up. The results 
showed a significant overall quadratic trend (p<0.005) in the HbA1c value during follow-
up. There was no significant (p=0.37) difference between the different add-on therapy 
combinations, and a non-significant interaction effect (p=0.14). In supplemental table S2 
the regression parameters of the fixed effects of the mixed model analysis are presented. 
Estimated HbA1c for the different add-on therapy combinations at different time periods 
are presented in table 3 and figure 1, panel B. In the gliclazide, glimepiride and tolbutamide 
add-on groups the average HbA1c levels steadily decreased from 7.1% (54 mmol/mol) and 
remained below 7.0% (53 mmol/mol) during the first four years following intensification, 
and rose above 7.0% (53 mmol/mol) in the fifth year.
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Table 1: Demographic and clinical characteristics of patients at baseline.
M+Glicazide (n=521) M+Glibenclamide (n=43) M+Glimepiride (n=964) M+Tolbutamide (n=1427)
Age Start (Years) 63.1 (11.7) 63.5 (12.3) 62.1 (11,3) 63.5 (11.5)








HbA1c % (mmol/mol) 7.1 [6.6 - 7.6] 
(54, [49 - 60])
(n=522)
7.0[6.6 - 7.7] 
(53 [54 - 61])
(n=44)
7.0 [6.6 - 7.5] 
(53 [49 – 58])
(n=965)
7.0 [6.6 - 7.5] 
(53, [49 – 58])
(n=1427)








BMI 30.9 (5.7) 31.4 (6.1) 30.7 (5.6) 30.2 (5.0)
Systolic Blood pressure (mmHg) 140 (17) 140 (14) 139 (17) 138 (16)
Diastolic Blood pressure (mmHg) 81(10) 83 (9) 82 (10) 80 (9)
Cholesterol-HDL ratio 3.7 [3.1 - 4.7] 3.9 [2.8 - 4.8] 3.7 [3.1 - 4.6] 3.7 [3.0 - 4.6]
Creatinine (µmol/L) 78 [66 - 90] 70 [57 - 83] 76 [65 - 88] 76 [64 - 88]
Albumin Creatinine Ratio 1.0 [0.5 - 2.9] 0.8 [0.5 - 1.0] 1.0 [0.4 - 2.1] 0.8 [0.5 - 2.0]
MVC at start 17.8% 9.1% 14.4% 16.7%
Diabetes duration (years) 3.9 [1.8 - 5.9] 4.7 [1.3 - 6.8] 4.0 [2.0 - 6.3] 4.0 [1.9 - 6.8]
Data are mean (standard deviation), median [interquartile range] and %. MVC=Macro vascular 
complication. 
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Table 1: Demographic and clinical characteristics of patients at baseline.
M+Glicazide (n=521) M+Glibenclamide (n=43) M+Glimepiride (n=964) M+Tolbutamide (n=1427)
Age Start (Years) 63.1 (11.7) 63.5 (12.3) 62.1 (11,3) 63.5 (11.5)








HbA1c % (mmol/mol) 7.1 [6.6 - 7.6] 
(54, [49 - 60])
(n=522)
7.0[6.6 - 7.7] 
(53 [54 - 61])
(n=44)
7.0 [6.6 - 7.5] 
(53 [49 – 58])
(n=965)
7.0 [6.6 - 7.5] 
(53, [49 – 58])
(n=1427)








BMI 30.9 (5.7) 31.4 (6.1) 30.7 (5.6) 30.2 (5.0)
Systolic Blood pressure (mmHg) 140 (17) 140 (14) 139 (17) 138 (16)
Diastolic Blood pressure (mmHg) 81(10) 83 (9) 82 (10) 80 (9)
Cholesterol-HDL ratio 3.7 [3.1 - 4.7] 3.9 [2.8 - 4.8] 3.7 [3.1 - 4.6] 3.7 [3.0 - 4.6]
Creatinine (µmol/L) 78 [66 - 90] 70 [57 - 83] 76 [65 - 88] 76 [64 - 88]
Albumin Creatinine Ratio 1.0 [0.5 - 2.9] 0.8 [0.5 - 1.0] 1.0 [0.4 - 2.1] 0.8 [0.5 - 2.0]
MVC at start 17.8% 9.1% 14.4% 16.7%
Diabetes duration (years) 3.9 [1.8 - 5.9] 4.7 [1.3 - 6.8] 4.0 [2.0 - 6.3] 4.0 [1.9 - 6.8]
Data are mean (standard deviation), median [interquartile range] and %. MVC=Macro vascular 
complication. 
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DISCUSSION
In this study, there was no evidence for a significant weight change within and between 
the four SU add-on groups in the years after starting a SU. When used as add-on therapy 
to metformin, increases in weight with comparable glycaemic efficacy have been reported 
in randomized studies (8, 10, 14, 25-27) investigating glibenclamide (7, 26, 28), gliclazide 
(29, 30), glimepiride (9), and glipizide (31). Most studies showed only modest increases 
in bodyweight (ranging from 0.5 to 3 kg) and most had a maximum follow-up time of 12 
months. One study with 10 years of follow-up, showed that weight was gained only in 
the first 3 years after initiation of a SU (26).
Our results are in contrast with results from RCT’s. The differences in weight change 
between this study and previous RCT’s could partly have resulted from differences in 
design and baseline factors. Compared to RCT’s, the patients included in this study 
differed with respect to glycaemic control; the average baseline HbA1c level in most 
RCT’s (ranging from 7.3% (56 mmol/mol) to 8.5% (69 mmol/mol)) was higher than the 
HbA1c 7.2% (55 mmol/mol) before treatment intensification in this cohort (9, 26-32). In 
addition, patients not only differed with respect to glycaemic control but probably also 
according to intensity of patient visits and patient counselling regarding life-style; factors 
possibly responsible for the lower average glycaemic control. 
These results indicate that it is possible to maintain strict glycaemic control in 
the majority of patients in a real life setting without relevant weight increases when 
starting an SU. Effects of SUs on weight appear to be different from effects found in 
observational studies. In these studies, significant or relevant weight increases have only 
been reported in studies with unfavourable glycaemic control at baseline and only when 
SUs were analysed as one group (32, 33). However, based on the confidence intervals the 
possibility of a small weight increase could not be excluded in our study. In contrast with 
previous observational studies, the glycaemic control of patients included in the ZODIAC 
cohort was excellent (34). Moreover, when interpreting weight changes in observational 
cohort studies, there are several other possible explanations for weight increase besides 
medication effects. In the general population aged between 55 and 65 an increase of 
several ounces per year is a phenomenon that is observed in several population studies 
performed in middle- and high-income countries and therefore is not necessarily related 
to diabetes medication (35, 36). 
In the Netherlands a form of protocol-based care is deployed, which probably could 
be an explanation for the on average small and seemingly non-relevant decrease in HbA1c. 
At the time the study was performed, patients treated in the Netherlands are checked 
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at least once a year by their general practitioner and 3 times a year by practise nurses. 
During these visits there is a strong focus on life-style advices as well as glycaemic control 
(20). When patients are above their HbA1c target treatment is immediately intensified, 
even when patients are slightly above their target. In the RCTs there were no structured 
life-style advices described in their methods section. Non-adherence to life-style advices 
has been associated with worsening glycaemic control and weight gain (37-39), with 
subsequent increases in HbA1c leading to treatment intensification (40).
This study sample has a high degree of generalizability, and represents the majority 
of primary care treated patients in the Netherlands. Large regions of the Netherlands are 
participating in projects similar to this study project, and all patients with type 2 diabetes 
have the opportunity for opting out. In the Netherlands all patients have a primary care 
physician and from all patients with type 2 diabetes, more than 80% of patients with (T2)
DM are treated exclusively in primary care(23). In contrast to the observational design in 
the current study, RCTs often have strict selection criteria, limiting the number of patients 
eligible for inclusion, possibly leading to sample selection bias and therefor complicating 
the generalizability to daily practise (41).
Strengths of this study were the number of patients, the daily care setting and the 
new-user design; thereby avoiding two potential types of bias; under ascertainment 
of weight changes that occur early after the start of add-on therapy and the inability 
to control for disease risk factors that may be altered by the study drugs themselves 
(24). Furthermore, over 97% of all observations on weight and 99% of all observations 
on HbA1c from any study visit was complete at baseline and during follow-up. The 
outcome measures weight and HbA1c were missing in a small percentage but this 
posed no problem when using linear mixed models, because all missing values 
are caused by random omissions in the registration and are consequently missing 
completely at random (MCAR). The decrease in number of patients can mostly be 
explained by the study design. Patients entered the ZODIAC cohort at different time 
points and also entered into the study at different time points. A patient who, for 
example, entered the study in 1998 can have the maximum follow-up of 6 years. 
However, a patient who entered in 2009 can only have 3 years of follow-up since 
the study cohort is censored at 31 December 2012. In addition, when a patient 
was included in the ZODIAC cohort the maximum length of the follow-up was also 
shortened when this patient has for example three years of metformin monotherapy 
before receiving an addon, because in the current study follow-up starts in the year 
before receiving the addon. Table S5 shows the number of people censored because 
of changes in medication during follow-up. 
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This study also had important limitations. Although there were no significant within-
class differences in weight change after starting SUs in the first 5 years after treatment 
intensification, the number of patients in the gliclazide and glibenclamide group were 
small and a potentially relevant increase in weight could not be excluded. Furthermore, 
the decrease in number of patients in the tolbutamide and glibenclamide groups was 
relatively high compared to the other groups. 
Secondly, baseline macrovascular complications (MVC) differed between the SU 
groups. Although the Dutch diabetes guideline did not base the choice of an oral glucose 
lowering agent on the presence of MVC, this theoretically could have influenced the 
choice of SU. However, the post-hoc sensitivity analysis (see table S3 and table S4) showed 
that the addition of MVC does not relevantly change the results. Third, the quality and 
reliability of our data were dependent on the accuracy of the data provided by practice 
nurses and GP’s as part of a yearly benchmark. Information on doses and adherence 
to medication were not recorded within the ZODIAC cohort. Since data on medication 
adherence was not available, patients could have stopped medications during the 
following year which possibly could have resulted in misclassification. In addition, since 
patients may have been prescribed a SU at different time points during the year, the time 
between the first prescription of a SU and the measurement of bodyweight varied and 
was not always one year. However, there was no reason to assume that adherence and 
time of initiation within the year would substantially differ between groups. Furthermore, 
it is possible that patients who started to gain weight while using an SU, wanted to try a 
different drug. However, we have no evidence that this is the case (see supplementary 
table S6). The rapid decrease in number of patients after year 2 could complicate the 
interpretation of the results. However, in our study the confidence intervals remain 
narrow. A common side-effect in SUs as a group are severe hypoglycaemic events, which 
are not recorded in our database. However, the hazard of severe hypoglycaemia is very 
limited in gliclazide users (16), the most prescribed SU in the Netherlands. Furthermore, 
since no significant differences in weight were found, a dose response analysis was not 
performed.
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CONCLUSION
There was no evidence for relevant within-class SU differences in weight during follow-up. 
The results of this study support the view that strict glycaemic control can be maintained 
in a substantial part of the primary care patients in the Netherlands with type 2 diabetes 
without clinically relevant weight change when adding SUs to metformin. In real life, 
when weight gain does occur, other factors than medication effects, for example life-style 
associated factors, are likely to be more important factors.
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Number of patient for weight analysis*:
Metformin/gliclazide = n. 520
Metformin/glibenclamide = n. 43
Metformin/glimepiride = n. 963
Metformin/Tolbutamide = n. 1415
Number of patient for HbA1c analysis*:
Metformin/gliclazide = n. 521
Metformin/glibenclamide = n. 43
Metformin/glimepiride = n. 964





Fig S1: Selection of patients. *The number of patients during follow-up differ due to missing data.
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Table S1: Parameter estimates of the fixed effects for the mixed model analysis of the 
change in weight.






Intercept 96.52 <0.001 95.36 97.67
Female -9.43 <0.001 -10.53 -8.33
Male 0b . . .
Age -0.49 <0.001 -0.54 -0.44
Diabetes duration -0.13 0.095 -0.28 0.02
Follow-up year 0.00 0.920 -0.11 0.12
[Metformine + gliclazide] 1.43 0.074 -0.14 2.99
[Metformine + glibenclamide] 2.14 0.364 -2.49 6.77
[Metformine + glimepiride] .74 0.259 -0.55 2.03
[Metformine + tolbutamide] 0b . . .
[Metformine + gliclazide] * Follow-up year -0.00 0.946 -0.23 0.21
[Metformine + glibenclamide] * Follow-up year -0.39 0.215 -1.01 0.23
[Metformine + glimepiride] * Follow-up year -0.03 0.785 -0.21 0.16
[Metformine + tolbutamide] * Follow-up year 0b . . .
b. This parameter is the reference category
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Table S2: Parameter estimates of the fixed effects for the mixed model analysis of the change 
in HbA1c.  






Intercept 7.45 <0.001 7.35 7.54
Female -0.02 0.337 -0.07 0.02
Male 0b . . .
Age -0.01 <0.001 -0.01 -0.01
Diabetes duration -0.01 0.010 -0.02 -0.00
Follow-up year -0.24 <0.001 -0.30 -0.17
Follow-up year * Follow-up year 0.03 <0.001 0.02 0.04
[Metformin + gliclazide] 0.12 0.157 -0.05 0.29
[Metformin + glibenclamide] -0.00 0.999 -0.49 0.49
[Metformin + glimepiride] 0.10 0.147 -0.04 0.24
[Metformin + tolbutamide] 0b . . .
[Metformin + gliclazide] * Follow-up year -0.09 0.173 -0.21 0.04
[Metformin + glibenclamide] * Follow-up year 0.02 0.914 -0.33 0.36
[Metformin + glimepiride] * Follow-up year -0.11 0.032 -0.21 -0.01
[Metformin + tolbutamide] * Follow-up year 0b . . .
[Metformin + gliclazide] * Follow-up year * 
Follow-up year
0.01 0.269 -0.01 0.03
[Metformin + glibenclamide] * Follow-up year * 
Follow-up year
0.01 0.840 -0.05 0.06
[Metformin + glimepiride] * Follow-up year * 
Follow-up year
0.02 0.021 0.00 0.04
[Metformin + tolbutamide] * Follow-up year * 
Follow-up year
0b . . .
b. This parameter is the reference category
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Intercept 96.05 <0.001 94.29 97.81
Female -9.48 <0.001 -10.59 -8.38
Male 0b . . .
Age -0.48 <0.001 -0.53 -0.44
Diabetes duration -0.12 0.108 -0.27 0.03
Macrovascular complications (No) 0.52 0.524 -1.08 2.13
Macrovascular complications (Yes) 0b . . .
Follow-up year 0.00 0.947 -0.11 0.12
[Metformin + Gliclazide] 1.40 0.080 -0.17 2.97
[Metformin + Glibenclamide] 2.11 0.371 -2.56 6.74
[Metformin + Glimepiride] 0.78 0.238 -0.51 2.06
[Metformin + Tolbutamide] 0b . . .
[Metformin + Gliclazide] * Follow-up year -0.01 0.914 -0.23 0.21
[Metformin + Glibenclamide] * Follow-up year -0.39 0.216 -1.00 0.23
[Metformin + Glimepiride] * Follow-up year -0.03 0.728 -0.21 0.15
[Metformin + Tolbutamide] * Follow-up year 0b . . .
b. This parameter is the reference category
4Addition of sulphonylurea and weight changes (ZODIAC-39)  |  95









Intercept 7.42 <0.001 7.30 7.53
Female -0.03 0.293 -0.08 0.02
Male 0b . . .
Age -0.01 <0.001 -0.01 -0.01
Diabetes Duration -0.01 0.011 -0.02 -0.00
Macrovascular complications (No) 0.03 0.385 -0.04 0.10
Macrovascular complications (Yes) 0b . . .
Follow-up year -0.23 <0.001 -0.30 -0.17
Follow-up year * Follow-up year 0.03 <0.001 0.02 0.04
[Metformin + Gliclazide] 0.13 0.138 -0.04 0.30
[Metformin + Glibenclamide] 0.00 0.993 -0.49 0.50
[Metformin + Glimepiride] 0.11 0.134 -0.03 0.25
[Metformin + Tolbutamide] 0b . . .
[Metformin + Gliclazide] * Follow-up year -0.09 0.150 -0.22 0.03
[Metformin + Glibenclamide] * Follow-up year 0.01 0.936 -0.33 0.36
[Metformin + Glimepiride] * Follow-up year -0.12 0.027 -0.21 -0.01
[Metformin + Tolbutamide] * Follow-up year 0b . . .
[Metformin + Gliclazide] * Follow-up year * 
Follow-up year
0.01 0.233 -0.01 0.03
[Metformin + Glibenclamide] * Follow-up year * 
Follow-up year
0.01 0.816 -0.05 0.06
[Metformin + Glimepiride] * Follow-up year * 
Follow-up year
0.02 0.017 0.00 0.04
[Metformin + Tolbutamide] * Follow-up year * 
Follow-up year
0b . . .
b. This parameter is the reference category
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Table S5. Reasons for censoring
Number of patients
Deceased 77
Switch to metformin monotherapy 191
Switch to other monotherapy 79
Switch to metformin + insulin 60
Switch to insulin 6
Other medication 429
Table S6. Weight and HbA1c in year prior to censoring1. Continued on next page. 
Addon Reason for censuring Weight HbA1c
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Table S6. Continued
Addon Reason for censuring Weight HbA1c


























































1) Mean (SD), 95% CI, N of patients.
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ABSTRACT
Objective: 
to investigate the relationship between BMI and obesity-related cancers in men and 






A total of 52.044 patients with type 2 diabetes who participated in the ZODIAC study 
between 1998 and 2012 was included (49% women). A dataset of these patients was 
linked to available information of the Netherlands Cancer Registry (NKR) to obtain data 
on cancer incidents.
Primary outcome measures: 
Analyses were performed for the total group of obesity-related cancers and for non sex-
specific and sex-specific obesity-related cancers (in men: advanced prostate cancer, in 
women: ovarian, endometrial and postmenopausal breast cancer).
Results: 
The median follow-up period in all analyses was 3.1 (1.7 – 5.0) years in men and 3.1 (1.7 
– 5.1) in women. During follow-up, 689 men and 914 women were diagnosed with an 
obesity-related cancer. In men, BMI was associated with a higher risk of the total group 
of obesity-related cancers and non sex-specific obesity-related cancers (HR (per 5 kg/
m2 increase) 1.12 (95%CI 1.02–1.23) and HR 1.18 (95%CI 1.06–1.31)). No association 
was found with prostate cancer. In women, an association between BMI and all obesity-
related cancers combined and sex-specific obesity-related cancers was present (HR 1.15 
(95%CI 1.08–1.22) and HR 1.22 (95%CI 1.14–1.32)). No association with non sex-specific 
cancers was found in women. 
Conclusions: 
BMI is associated with obesity-related cancers in men with type 2 diabetes, except with 
advanced prostate cancer. The results of this study provide reason to reconsider the 
classification of advanced prostate cancer as an obesity-related cancer, at least in type 
2 diabetes. In women, BMI is associated with the total group of obesity-related cancers 
and with sex-specific obesity-related cancers.
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INTRODUCTION
Type 2 diabetes is associated with an increased risk for cardiovascular morbidity and 
mortality (1,2). Furthermore, type 2 diabetes is also related to a higher cancer risk (3,4). 
This increased cancer risk appears to be site-specific; a higher risk for liver, pancreas, 
endometrial, colorectal, breast and bladder cancer has been reported in patients with 
type 2 diabetes (3). Whether this increased risk is directly related to type 2 diabetes, 
caused by longer periods of hyperglycaemia and/or elevated insulin levels, or indirectly, 
due to common risk factors like obesity, is not clear (3). 
According to the World Cancer Research Fund, being overweight or obese is related 
to an increased incidence of oesophageal, stomach (cardia), colorectal, liver, gallbladder, 
pancreatic and kidney cancer in both sexes in the general population. Furthermore, being 
overweight or obese is related to an increased incidence of ovarian, endometrial and 
postmenopausal breast cancer in women and to advanced prostate cancer in men (5). 
Whether there is an association between body mass index (BMI) and excess risk 
of developing obesity-related cancers in patients with type 2 diabetes is unclear. One 
previous study did not find an association between BMI and obesity-related cancers in 
type 2 diabetes (6). Another study investigated this association with colon cancer and 
found only a significant relationship in patients who suffered from obesity for a total 
duration of 4 years or more (7). 
Even more unclear is whether there is a sex difference in the association between 
BMI and obesity-related cancers in patients with type 2 diabetes. A large prospective 
study from Sweden reported an association between being overweight and obesity with 
all cancers and gastrointestinal cancers in men. However, in women only an association 
with obesity and both cancer groups were found (8). This could indicate that the threshold 
for BMI to act as a risk factor for obesity-related cancer is lower in men compared to 
women with type 2 diabetes. Therefore, the aim of the present study was to investigate 
the relationship between BMI and obesity-related cancers in men and women with type 
2 diabetes and specifically non sex-specific and sex-specific obesity-related cancers. 
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MATERIALS AND METHODS
Study group
The study population consisted of patients who were included in the Zwolle Outpatient 
Diabetes project Integrating Available Care (ZODIAC) study. This project started in 1998 
and was part of a study at that time that primarily investigated the effects of shared 
care in patients with type 2 diabetes treated in primary care in the Zwolle region of the 
Netherlands (9). This shared care initiative became the standard care for the Zwolle region 
in 2002 and expanded to other regions in the Netherlands in the years thereafter. In 
these regions, general practitioners (GPs) provide data on an annual basis to the Diabetes 
Centre for benchmark and research purposes. Only type 2 diabetes patients treated in 
primary care are included in the ZODIAC project. The diagnosis of type 2 diabetes was 
based on the guidelines of the Dutch College of General Practitioners (twice a fasting 
plasma glucose level ≥ 7 mmol/l or once a non-fasting plasma glucose level ≥ 11.1 mmol/l 
accompanied by symptoms of hyperglycemia). Patients with a very short life expectancy 
or insufficient cognitive capabilities are excluded from participation. At the start in 1998, 
53 GPs participated in this project, and this number increased to more than 700 GPs in 
2012. 
For the current study, available information on clinical variables from patients 
participating for at least one year in the ZODIAC project between 1998 and 2012 was 
linked to available information of the Netherlands Cancer Registry (NKR) to obtain data 
on cancer incidents in the years between 1989 and 2012. Information from the NKR 
in the period before 1998 was used to exclude patients who were diagnosed with an 
obesity-related cancer before entering the ZODIAC study. The NKR started in 1989 and 
records all malignancies based on notification by the National Pathology Archive (PALGA) 
and hospital discharge registries in the Netherlands. Basal cell carcinoma of the skin, 
carcinoma in situ of the cervix, myelodysplastic syndrome, myeloproliferative disorders 
are not registered in the NCR database. Data on patient characteristics, tumor type and 
grade, and treatment are collected by specially trained data-managers directly from the 
patients’ files in all hospitals in the Netherlands. The linking was performed by a trusted 
third party using postal code, full name, date of birth and sex. The NKR expects that the 
number of false-positive and the number false-negative for the ZODIAC-NKR linkage is 
both under 1%. The combined ZODIAC-NKR database contains 71.634 patients, of which 
10717 (15%) were diagnosed with cancer. 
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Data collection 
For the current study a database was constructed which consisted of both the variables of 
the ZODIAC project and the variables of the NKR. The demographic and clinical data which 
were used in the present study were collected as part of ZODIAC project and included: 
sex, age, diabetes duration, HbA1c, serum creatinine, BMI, smoking status and the use 
of metformin, sulfonylurea derivatives and insulin. Information on smoking was collected 
during the check-up of the patient by the general practitioner or practice nurse as part of 
the ZODIAC project whereby smoking was documented as yes or no. No data concerning 
previous smoking was available. Baseline was defined as the first year that a patient was 
included in the ZODIAC project. Cancer characteristics provided and collected by the NKR 
were: cancer origin, incidence date, TNM stage, morphology and type of therapy. 
Study procedure
The association between BMI and obesity-related cancer was investigated for three groups; 
total group of obesity-related cancers, non sex-specific obesity-related cancers and sex-
specific obesity-related cancers. The non sex-specific cancer group consisted of gastric-cardia 
(ICD C16.0), colorectal (ICD C18,19,20), liver (ICD C22), gall bladder (ICD C23), pancreas (ICD 
C25) and kidney cancer (ICD C64) and adenocarcinoma of the oesophagus (ICD C15.5 + 
morphological codes 8140 or 8560). In men, the sex-specific cancer group was formed by 
advanced prostate cancers only (ICD C61 + TNM 3 or 4 or GLEASON > 7) (further referred to 
as prostate cancer). In women, the sex-specific cancer group consisted of ovarian (ICD C56), 
endometrial (ICD C54.1) and postmenopausal breast cancer (ICD C50) (further referred 
to as ovarian, endometrial and breast cancer). The total group of obesity-related cancers 
consisted of non sex-specific cancers and prostate cancer in men and of non sex-specific 
cancers and ovarian, endometrial and breast cancer in women. Post-menopausal breast 
cancer was in the present study defined as breast cancer in women ≥ 55 years of age (10). 
All included cancer cases were histologically confirmed by a pathologist.
Patients with a BMI <18.5 kg/m2 were excluded in all analyses, as undiagnosed cancer 
may lead to becoming underweight (n= 130 (0.2%)). Furthermore, patients were excluded 
if they had only baseline data recorded (only one check-up by their care provider) (n= 
18.643 (26.0%)). For the analyses of the total group of obesity-related cancers, patients 
diagnosed with a non sex-specific or sex-specific obesity-related cancer before entering 
the ZODIAC study were excluded (n = 2061 (2.9%)). For the non sex-specific analysis, only 
patients with a non sex-specific cancer before entering the ZODIAC study were excluded (n 
= 817 (1.1%)). For the sex-specific cancer analysis, only patients with a sex-specific cancer 
before entering the ZODIAC study were excluded (n = 1278 (1.8%)) (Fig. 1). 
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Fig. 1. Flowchart of inclusion. * For the analyses of the total group of obesity-related cancers, 
patients diagnosed with a non sex-specific or sex-specific obesity-related cancer before entering 
the ZODIAC study were excluded. For the non sex-specific analysis, only patients with a non 
sex-specific cancer before entering the ZODIAC study were excluded. For the sex-specific cancer 
analysis, only patients with a sex-specific cancer before entering the ZODIAC study were excluded.
Clinical endpoint in all analyses was the first obesity-related cancer after baseline. 
Patients were not censored if they were diagnosed with a non-obesity-related cancer 
during follow-up. The end of follow up for patients who were not diagnosed with cancer 
was based on the last check up by their general practitioner. 
Statistical analyses 
Statistical analyses were performed using SPSS version 23 for Windows (SPSS Inc., 
Chicago, Illinois, USA) and Stata version 14.0 for Windows (StataCorp, College Station, 
Texas, USA). Multiple imputation analysis was performed for missing data on the 
independent variables, assuming that data was missing at random (MAR) or completely 
at random (MCAR). All variables of model 2 were included in the imputation model and 
the fully conditional specification model in SPSS was used to predict the missing data. 
Ten imputated datasets were created and the pooled results are presented. Baseline 
data are expressed as mean with standard deviation (SD) or median with interquartile 
range (IQR) for normally distributed and non-normally distributed data, respectively. 
Categorical variables are described in numbers and percentages. Normal distribution was 
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assessed on the basis of histograms and QQ-plots. A two-sided p<0.05 was considered 
significant. Cox proportional hazard analyses were used to investigate the association 
between BMI as a continuous and categorical variable and obesity-related cancers in 
men and women with type 2 diabetes, separately. Hazard ratios refer to a BMI increase 
of 5 m2/kg in the analyses for BMI as a continuous variable. For the analyses of BMI as a 
categorical variable, four BMI categories were used (≥ 18.5 - < 25.0 kg/m2, ≥ 25.0 - < 30.0 
kg/m2, ≥ 30.0 - < 35.0 kg/m2, ≥ 35.0 kg/m2). The lowest category was used as reference 
category. Age was used as the time-scale in all analyses, because the risk of cancer is not 
proportional with age. Patients entered the analysis at their baseline age and exited at 
their event/censoring age. Two models were used: an age-adjusted model (model 1) and 
a model additionally adjusted for diabetes duration, HbA1c, serum creatinine, smoking 
status and the use of metformin, SU-derivatives and/or insulin (model 2). Furthermore, 
the analyses for model 2 were stratified according to the year of inclusion in the ZODIAC 
cohort. The assumption of proportional hazards for baseline predictors was investigated 
by visual inspection of the Schoenfeld residuals. 
RESULTS
Total group of obesity-related cancers 
Baseline results for the men and women who are included in the analyses for the total 
group obesity-related cancers are described in table 1. In these analyses, 25.811 men 
and 24.989 women were included. Mean age was 64.0 (SD 11.2) years in men and 66.6 
(12.1) years in women. The median diabetes duration was higher in women. More men 
than women were current smokers and men had a lower BMI than women. A higher 
percentage of men used metformin whereas insulin use was more frequent in women. 
30.4% of the patients did not use metformin, SU-derivates or insulin. These patients were 
on dietary interventions or other diabetes medication. The median follow-up period for 
these patients was 3.1 (1.7 – 5.0) years in men and 3.1 (1.7 – 5.1) in women. During 
follow-up, 689 (2.7%) men and 914 women (3.7%) were diagnosed with an obesity-related 
cancer.
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Table 1. Baseline characteristics of men and women.
Variable Men Women P-value* 
N 25811 (49.2) 24989 (50.8)
Age (years) 64.0 (±11.2) 66.6 (±12.1) < 0.001
Diabetes duration (years) 2.5 (0.7 – 5.8) 2.8 (0.8 – 6.3) < 0.001
HbA1c (mmol/mol) 49 (43 – 55) 49 (43 – 54) 0.091
Creatinine (µmol/L) 83 (73 – 95) 68 (59 – 79) < 0.001
Smoking (yes) 8029 (31) 4857 (19) < 0.001
BMI (kg/m2) 29.2 (4.6) 30.4 (5.7) < 0.001
Use of metformin (yes) 14813 (57) 13539 (54) < 0.001
Use of SU-derivatives (yes) 7977 (31) 7638 (31) 0.408
Use of Insulin (yes) 2135 (8) 2512 (10) < 0.001
* P-value for the difference between men and women. Values are depicted as n (%), mean (± SD), 
or median (IQR). Continuous data were analysed using independent t-tests or the Mann-Whitney 
U test. Categorical variables were analysed using chi square tests.
The results of the association between BMI as a continuous variable and the total group 
of obesity-related cancers are described in table 2 for men and women separately. In both 
men and women, BMI was associated with a higher risk of obesity-related cancer in the 
age and fully adjusted analyses (in men: HR 1.11 (95% CI 1.01 – 1.22) and HR 1.12 (95% CI 
1.02 – 1.23), in women: HR 1.14 (95% CI 1.07 – 1.21) and HR 1.15 (95% CI 1.08 – 1.22)). 
Analysis of BMI as a categorical variable showed that in men a BMI of 30.0 - 35.0 kg/m2 was 
associated with a higher risk of obesity-related cancer compared to the reference group. In 
women, a BMI of 30.0 - 35.0 kg/m2 and a BMI ≥ 35.0 kg/m2 were both associated with a 
higher risk of obesity-related cancer compared to the reference group (table 3). 
Non sex-specific obesity related cancers 
In the analyses for non-sex specific obesity-related cancers, 25.945 men and 26.099 
women were included. Baseline results for these patients did not significantly differ 
from the baseline results described in table 1 (data not shown). The median follow-up 
period was 3.1 (1.7 – 5.0) years in men and 3.1 (1.7 – 5.1) in women. During follow-up, 
533 (2.1%) men and 385 (1.5%) women were diagnosed with a non-sex specific obesity-
related cancer.
In men, BMI was associated with a higher risk of non-sex specific obesity-related cancer in 
the age and fully adjusted analyses (HR 1.17 (95% CI 1.05 – 1.30) and HR 1.18 (95% CI 1.06 
– 1.31)) (table 4). In the categorical analyses, a BMI of 30.0 - 35.0 kg/m2 and a BMI ≥ 35.0 
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kg/m2 were also associated with a higher risk of non-sex specific obesity-related cancer 
in men (table 3). In women, no significant associations between BMI as a continuous or 
categorical variable and non-sex specific obesity-related cancers were found. 
Sex-specific obesity-related cancers 
In the analyses for sex-specific obesity-related cancers, 26.226 men and 25.357 women 
were included. Baseline results for these patients did not significantly differ from the 
baseline results described in table 1 (data not shown). The median follow-up period 
for these patients was 3.1 (1.7 – 5.0) years in men and 3.1 (1.7 – 5.1) in women. During 
follow-up, 170 (0.7%) men and 575 (2.3%) women were diagnosed with a sex-specific 
obesity-related cancer.
Table 2. Regression analyses for all obesity related cancers in men and women#. 
Men Women









































(0.86 – 1.22) 
1.11
(0.93 – 1.33) 
# gastric-cardia (ICD C16.0) (events in men: 18, events in women: 3), colorectal (ICD C18,19,20) 
(events in men: 330, events in women: 247), liver (ICD C22) (events in men: 15, events in women: 
8), gall bladder (ICD C23) (events in men: 2, events in women: 7), pancreas (ICD C25) (events in 
men: 59, events in women: 41), kidney cancer (ICD C64) (events in men: 60, events in women: 38) 
and adenocarcinoma of the oesophagus (ICD C15.5 + morphological codes 8140 or 8560) (events 
in men: 46, events in women: 7). In men supplemented with advanced prostate cancers (C61 + 
TNM 3 or 4 or GLEASON > 7) (events in men: 159). In women supplemented with ovarian (ICD 
C56) (events in women: 39), endometrial (ICD C54.1) (events in women: 117) and postmenopausal 
breast cancer (ICD C50 and age ≥ 55 years) (events in women: 407).
108  |  Chapter 5











































(0.90 – 1.33) 
1.33
(1.01 – 1.76) 
# gastric-cardia (ICD C16.0) (events in men: 19, events in women: 3), colorectal (ICD C18,19,20) 
(events in men: 330, events in women: 270), liver (ICD C22) (events in men: 15, events in women: 
8), gall bladder (ICD C23) (events in men: 2, events in women: 8), pancreas (ICD C25) (events in 
men: 59, events in women: 44), kidney cancer (ICD C64) (events in men: 62, events in women: 45) 
and adenocarcinoma of the esophagus (ICD C15.5 + morphological codes 8140 or 8560) (events 
in men: 46, events in women: 7).
Table 3. Regression analyses with BMI categories for all obesity related cancer groups in men 
and women.
Men Women
Variable All Non-sex specific Sex-specific All Non-sex specific Sex-specific
BMI (kg/m2) events HR (95% CI) events HR (95% CI) events HR (95% CI) events HR (95% CI) events HR (95% CI) events HR (95% CI)
≥ 18.5 - < 25.0 110 Reference 83 Reference 31 Reference 118 Reference 62 Reference 63 Reference












≥ 30.0 - < 35.0 194























Analyses were adjusted for age, diabetes duration, HbA1c, serum creatinine, smoking status and 
the use of metformin, SU-derivatives and/or insulin.* Only one event. 
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Table 3. Regression analyses with BMI categories for all obesity related cancer groups in men 
and women.
Men Women
Variable All Non-sex specific Sex-specific All Non-sex specific Sex-specific
BMI (kg/m2) events HR (95% CI) events HR (95% CI) events HR (95% CI) events HR (95% CI) events HR (95% CI) events HR (95% CI)
≥ 18.5 - < 25.0 110 Reference 83 Reference 31 Reference 118 Reference 62 Reference 63 Reference












≥ 30.0 - < 35.0 194























Analyses were adjusted for age, diabetes duration, HbA1c, serum creatinine, smoking status and 
the use of metformin, SU-derivatives and/or insulin.* Only one event. 











































(0.55 – 1.19) 
1.00
(0.79 – 1.27) 
# In men supplemented with advanced prostate cancers (C61 + TNM 3 or 4 or GLEASON > 7) (events 
in men: 170). In women supplemented with ovarian (ICD C56) (events in women: 39), endometrial 
(ICD C54.1) (events in women: 119) and postmenopausal breast cancer (ICD C50 and age ≥ 55 
years) (events in women: 417).
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In men, no significant associations between BMI as a continuous or categorical 
variable and prostate cancer was found (table 2 and table 5). In women, BMI was 
associated with a higher risk of ovarian, endometrial and breast cancer in the age and 
fully adjusted analyses (HR 1.22 (95% CI 1.13 – 1.31) and HR 1.22 (95% CI 1.14 – 1.32)). 
In the categorical analyses, a BMI of 25.0 - 30.0 kg/m2, a BMI of 30.0 - 35.0 kg/m2 and a 
BMI ≥ 35.0 kg/m2 were associated with a higher risk of ovarian, endometrial and breast 
cancer in women (table 2).
DISCUSSION
The results of the present study showed that BMI was associated with the total group 
of obesity-related cancers in both men and women with type 2 diabetes. Important 
differences between men and women were found; BMI was associated with non sex-
specific obesity-related cancers in men, but not in women. Results concerning the 
sex-specific cancers showed that BMI was associated with ovarian, endometrial and 
postmenopausal breast cancer in women. No association between BMI and advanced 
prostate cancer was found in men. 
This is the first study which describes the association between BMI and the total 
group of obesity-related cancers in a large cohort of men and women with type 2 diabetes. 
A study from Japan could not find an association between BMI and all obesity-related 
cancers (6). However, this was a study that included 2334 patients of whom only 35 
patients developed cancer during follow-up (6). 
The absence of a significant association between BMI and non sex-specific obesity-
related cancers in women may indicate that BMI (in contrast to men) is not a risk factor 
for this group of cancers. Only one study has previously described sex differences in the 
association between BMI and non-sex-specific obesity-related cancers in patients with 
type 2 diabetes (8). A study from Sweden found that being overweight or obese was 
associated with a higher risk of gastrointestinal cancers in men, whereas in women only 
obesity but not overweight was found to be associated with gastrointestinal cancers (8). 
The sex difference in the association between BMI and non-sex specific obesity-related 
cancers could partly be the result of a sex difference in distribution of fat. In general, obese 
men have more intra-abdominal fat compared to obese premenopausal women. Although 
the sex difference in intra-abdominal fat is less apparent in patients with type 2 diabetes, 
the amount of intra-abdominal fat is probably still higher in men (11). Especially this 
abdominal adiposity is associated with many metabolic abnormalities which may increases 
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cancer risk. It might be that BMI was not accurate enough to represent the amount of 
abdominal fat especially in women with type 2 diabetes. Using waist circumference as a 
marker of abdominal fat might have been more accurate. 
In the present study, obese women had a 51% higher risk for ovarian, endometrial 
and, post-menopausal breast cancer compared to lean women with type 2 diabetes during 
follow-up. Only one previous study has described an association between BMI and sex-
specific cancers in women with type 2 diabetes. Jonasson et al. described a 39% higher 
risk for postmenopausal breast cancer compared to lean women (8). The association of 
BMI with these types of cancer might be attributed to an increase in oestrogen production 
in adipose tissue in overweight and obese women with type 2 diabetes (12). Not only 
BMI but also type 2 diabetes itself has been found to be related to a higher risk of 
endometrial and breast cancer (3). Taken this together, this indicates that especially obese 
women with type 2 diabetes are at risk for the development of endometrial cancer and 
postmenopausal breast cancer. On the other hand, some researchers have questioned 
the relation between type 2 diabetes itself and breast cancer. They have suggested that 
the higher risk of postmenopausal breast cancer in women with type 2 diabetes could be 
completely explained by residual confounding by overweight and not by having a problem 
with metabolic disturbance related to glucose control (13). 
In line with the results of the present study, Jonasson et al. could not find an 
association between BMI and prostate cancer in men with type 2 diabetes (8). However, 
they included all prostate cancers, whereas only advanced prostate cancer is described 
by the World Cancer Research Fund to be related with BMI in the general population (5). 
Nevertheless, the International Agency for Research on Cancer (IARC) Working Group 
has recently described that evidence for a preventive effect of the absence of excess 
body fat for fatal prostate cancer is limited (14). The present study adds to the literature 
that a relation between BMI and advanced prostate cancer is not present, at least not in 
men with type 2 diabetes. Advanced prostate cancer should therefore be reconsidered 
as being obesity-related. 
The strengths of the present study were the prospective design and the use of a large 
cohort of type 2 diabetes patients of which data on BMI was available. Some limitations of 
the present study should also be mentioned. Firstly, the study population consisted only 
of patients with T2D who are treated in primary care. Patients in secondary care often 
have worse manifestations of T2D and might therefore have a higher cancer risk. Although 
this limitation implies that the generalisability of our results is limited to primary care, it is 
still representative for a large part of the T2D population due to the fact that the majority 
(>85%) of the patients with T2D are treated in primary care in the Netherlands (15).
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Secondly, the clinical data and the data on medication use of the ZODIAC cohort 
were collected annually by practice nurses and general practitioners. The reliability of 
the data is therefore dependent on their accuracy. Thirdly, data on BMI was missing 
for 9% of the patients. BMI values for these patients were estimated using multiple 
imputations. Fourthly, the grouping of obesity-related cancers could be discussed. All 
different cancers were taken together as the number of total events would be too small 
when investigating each of the obesity-related cancers separately. Nevertheless, separate 
analyses would have been better. Finally, the follow-up period was relatively short for 
cancer epidemiology and therefore the number of events is relatively small. 
CONCLUSIONS
In men with type 2 diabetes mellitus BMI is associated with the total group of obesity-
related cancers and with non sex-specific obesity-related cancers. However, BMI is not 
related to advanced prostate cancer. The present study provides an extra argument for 
questioning advanced prostate cancer being obesity-related, at least in men with type 
2 diabetes. In women, BMI is associated with the total group of obesity-related cancers 
and with ovarian, endometrial and postmenopausal breast cancer. BMI is not related to 
non sex-specific obesity-related cancers in women with type 2 diabetes.
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ABSTRACT
Background: 
Diabetes and obesity seem to be partly overlapping risk factors for the development of 
obesity-related cancer (mainly breast, prostate and colorectal cancer) in patients with type 
2 diabetes (T2DM). In the general population, women have a lower risk for obesity-related 
cancer compared to men. Previous studies involving cardiovascular disease have shown 
that T2DM eliminates a female advantage of lower CVD risk in the general population 
compared to men. It is unclear whether the same could be true for obesity-related cancer. 
This study aimed to this investigate obesity-related cancer incidence in women and men 
known with T2DM as compared to the Dutch general population.
Methods:
This study included 69,583 patients with T2DM selected from a prospective primary care 
cohort, which was linked to the Dutch National Cancer Registry to obtain cancer specific 
data. Obesity-related cancers included liver, kidney, colorectal, gallbladder, pancreas, 
ovarian, endometrial, advanced prostate cancer, post-menopausal breast cancer and 
oesophageal adenocarcinoma. Primary outcome was sex-stratified, age and year of cancer 
diagnosis adjusted standardized incidence ratios (SIRs) for three time periods: 5 years 
before, the year after diagnosis and the next 4 years after T2DM diagnosis. The Dutch 
general population was used as reference group.
Results: 
Women with T2DM were at an increased risk for obesity-related cancer compared to 
women in the general population already 5 years before diabetes diagnosis (SIR 1.77; 
95%CI: 1.63-1.91). In both men and women, there was a peak in obesity-related cancer 
incidence following diabetes diagnosis (SIR: 1.38; 95%CI 1.11-1.64 and SIR: 2.21; 95%CI 
1.94-2.30, respectively). From the second to the fifth year after diabetes diagnosis the 
obesity-related cancer incidence was higher in women compared to women in the general 
population (SIR: 2.12; 95%CI 1.94-2.30). 
Conclusions: 
Women with T2DM seem to have a substantially higher obesity-related cancer risk. 
As opposed to men, in women this risk was already increased years before diabetes 
diagnosis. These results could imply that a relative advantage of women in the general 
population with regard to cancer risk is lost in women with T2DM. 
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INTRODUCTION
Patients with type 2 diabetes (T2DM) have an increased risk of developing specific types 
of cancer compared to the general population(1). An increased risk has been reported 
for the development of cancers of the liver, pancreas, endometrium, colon, rectum, 
breast and bladder(1-4). The increased risk of these specific types of cancer in patients 
with T2DM largely overlap with the so called ‘obesity-related cancers’. The World Cancer 
Research Fund acknowledges liver, kidney, colorectal, gallbladder, pancreas, ovarian, 
endometrial, advanced prostate cancer, post-menopausal breast cancer and oesophageal 
adenocarcinoma as obesity-related cancer (4, 5). A large portion of patients with T2DM 
are overweight or obese (6, 7). So, diabetes and obesity appear to be partly overlapping 
risk factors for the development of cancer in patients with T2DM (8, 9). The development 
of diabetes is mostly a progressive process (10). It is well-known that being overweight 
is a very important factor in type 2 diabetes (11). Patients who are diagnosed with T2DM 
are already different with respect to i.e. body mass index, compared to persons in the 
general population also in the years prior to diabetes diagnosis (12, 13). Furthermore, 
these patients will for example have a more frequent impaired glucose tolerance and/or 
impaired fasting glucose, accompanied by higher glucose and insulin levels (14, 15). Both 
are growth factors important in tumour development (16, 17). In addition, it has been 
suggested that sex hormones increase cancer risk (18).
In the general population, risk for obesity-related cancer, like the risk for cardiovascular 
disease (CVD), is lower in women than in men (19). However, previous studies investigating 
risk of CVD have shown that T2DM eliminates this female advantage (20, 21). It is unclear 
if the same could be true for (obesity-related) cancer. Indeed, several small studies 
reported sex differences in cancer risk in patients with pre-diabetes or T2DM. Reports 
show that in the pre-diabetes phase, the risk to develop breast cancer is increased 
compared to women without pre-diabetes (22, 23). In addition, a significant increase 
in colon cancer incidence before T2DM diagnosis has been reported in men, where this 
was not observed in women (24, 25). The increased incidence of cancer among T2DM 
patients has only partly been observed in larger studies that investigated the distribution 
of overall incidence of cancer over the years before and after the diagnosis of diabetes 
(2, 26). However, those studies did not stratify the risk to develop cancer for males and 
females (2, 26). T2DM and adiposity have been associated with a significant additive effect 
of obesity-related cancer (27). This increased cancer incidence seems to be different in 
the periods before the diagnosis of diabetes, shortly after (1 year) and the period after 1 
year after the diagnosis of diabetes (28). Thus far, only few studies investigated the overall 
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and obesity-related cancer risk in T2DM stratified for males and females to answer the 
question whether there are sex differences in cancer risk. 
The primary aim of this study was to investigate the incidence of obesity-related 
cancers in women and men in relationship to the time of diabetes diagnosis. The obesity-
related cancer incidence was analysed in the periods 5 years before, the year after and 2 
to 5 years after the diagnosis of diabetes. A secondary aim was to investigate the incidence 
of all-cancer incidence in patients with a diagnosis of diabetes.
METHODS
This study is reported according to the STROBE (Strengthening the reporting of 
observational studies in epidemiology) recommendations (29).
Study design and data collection
For this study, two prospective cohorts were combined. A T2DM specific cohort, the 
observational ZODIAC (Zwolle Outpatient Diabetes project Integrating Available Care) 
cohort study, was merged with the Netherlands Cancer Registry (NCR). To obtain cancer 
specific data for patients included in the ZODIAC cohort, all cancer events that occurred 
between 1989 and 2012 were linked to the data of the ZODIAC cohort via a trusted 
third party using postal code, full name, date of birth and sex. The NCR expects that the 
number of false-positive and the number false-negative for the ZODIAC-NCR linkage is 
both under 1%.
ZODIAC is a prospective primary care cohort study, which was initiated in 1998 in the 
Zwolle region. The cohort has been expanded to different regions several times and now 
includes almost all patients in the north-eastern part of the Netherlands, part of Flevoland 
province and part of the province of North Holland. As such, the cohort represents the 
majority of primary care treated patients in the Netherlands and has a high degree of 
generalizability. In the ZODIAC study, clinical data were sent annually to the Diabetes 
Centre by general practitioners (GPs) for benchmarking and research purposes. Patients 
included in the ZODIAC study were diagnosed with T2DM and were at inclusion treated 
exclusively in primary care. There was no age restriction for participation. Patients were 
not eligible for participation if they had a short life expectancy, a cognitive impairment or 
were treated in secondary care. From all patients included in ZODIAC, diabetes specific 
data was electronically collected annually. Data includes date of birth, sex, date of 
diabetes diagnosis, HbA1c, height, weight, serum creatinine, albuminuria, cholesterol/
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HDL ratio, blood pressure, micro- and macrovascular complications, medication use 
(both diabetes specific and other medication), smoking status and alcohol use. Entire 
primary care practises participated in ZODIAC and the project has been expanded to 
new regions several times and therefore included newly diagnosed and previously 
diagnosed T2DM patients. All patients were followed prospectively. All T2DM patients 
within participating primary care practises who were treated in primary care for their 
diabetes could participate. 
The primary care provider in the Netherlands has a very important role in the health 
care system, for example as a mandatory gatekeeper to secondary care. All inhabitants 
of the Netherlands have a GP and health insurance. Since the late nineties the majority 
of patients (around 88%) with T2DM are treated exclusively in primary care (30) and 
benchmarking has become a mandatory part of receiving health care reimbursements. 
The quality of the Dutch diabetes primary care is regarded to be high and for example 
the average HbA1c is 6.7% (6).
The NCR is a population based mandatory national registry, founded in 1989, 
and records all malignancies based on notification by the National Pathology Archive 
(PALGA) and hospital discharge registries. Data is gathered by specially trained data-
managers directly from the patients’ files in hospitals in the Netherlands. Data 
recorded includes incidence date, TNM stage, morphology, location and primary 
cancer treatment. Basal cell carcinoma of the skin, carcinoma in situ of the cervix, 
myelodysplastic syndrome, myeloproliferative disorders were not registered in the 
NCR database. Benign and borderline tumours were excluded, with the following 
exceptions; benign brain tumours (included from 1999), carcinoids of the appendix 
(included from 2001), borderline tumours of the ovaries (included from 2001), 
thymoma (included from 2001), phyloides tumours (included from 2001) and T-cell 
leukaemia (included from 2004). Comorbidities, including diabetes, were also not 
registered in this database. 
Patient selection
The combined ZODIAC-NCR database contained 71,648 patients of which 10,717 were 
diagnosed with 12,617 cancer events between 1 January 1998 and 31 December 2012. 
Only the first obesity-related cancer event (for the obesity-related cancer analyses) or 
first cancer event (in the all-cancers combined analyses) were included in the analysis. 
From the 71,648, a total of 2,065 (2.9%) patients were excluded because a cancer event 
occurred before the study period of interest, i.e. more than 5 years before diabetes 
diagnosis.
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Baseline (time zero) was set at the date of diabetes diagnosis. The date of diabetes 
diagnosis was based on the electronically documented date of diabetes diagnosis derived 
from the medical history for patients with newly diagnosed diabetes. As previously 
mentioned, the date of diabetes diagnosis could very well be different to the time of 
entry into the ZODIAC study. 
OUTCOME MEASURES
The primary outcome was the sex-stratified, age and year of cancer diagnosis adjusted 
standardized incidence ratios (SIR) of obesity-related cancers in three time frames; the 
5 years before diabetes diagnosis, the first year following diabetes diagnosis and year 2 
to 5 after diabetes diagnosis. The comparator group was the Dutch general population 
(including patients with diabetes). The following cancers (ICD-10 codes) were defined as 
obesity-related cancer: liver (C22), kidney (C64), colorectal (C18, C19, C20), gallbladder 
(C23), pancreas (C25), ovarian (C56), endometrial (54.1) and advanced prostate cancer 
(C61 with TNM 3 or 4 or Gleason > 7), post-menopausal breast cancer (C50 and age > 54) 
and oesophageal adenocarcinoma (C15.5) (5). 
The secondary outcome was the same as the primary outcome but, instead of 
obesity-related cancer, combined all-cancers (non-melanoma skin cancer was excluded). 
Statistical analysis
Using the date of diabetes diagnosis and the date of the first cancer event, age and 
year of cancer diagnosis standardized obesity-related and overall cancer incidence were 
calculated for one-year intervals from 5 years prior to 5 years after the diagnosis of 
T2DM. Patients from whom only the year (and not the month) of diabetes diagnosis was 
available, the first of July was chosen as date of diabetes diagnosis. The cancer incidence 
rate in the ZODIAC cohort was calculated first. The NCR provided incidence rates of 
the general population from the same time points that were included in the ZODIAC 
cohort. The NCR is unable to identify diabetes status, and thus the comparator group 
also includes patients with diabetes. Standardized incidence ratios with 95% confidence 
intervals stratified for sex and adjusted for age and year of cancer (in 5-year intervals) 
were calculated to compare the cancer incidence in the ZODIAC cohort to the general 
population (31). The SIR is analogous to the commonly used standardized mortality ratios 
(32). Incidence ratios were calculated by dividing the total number of cancer events in 
one-year time periods by the amount of contributed time in this one-year time period. 
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Reference data for all-cancer and for obesity-related cancer incidence of the whole Dutch 
population were provided by the NCR. 
Both all-cancer and obesity-related SIR were stratified for sex. A separate analysis 
stratifying by BMI was performed. This analysis only includes patients who have a 
BMI recorded at diabetes diagnosis. Advanced prostate cancer and post-menopausal 
breast cancer were also examined separately. Furthermore, to make obesity-related 
cancers somewhat comparable in men and women T2DM an analysis excluding sex-
specific cancers was performed. Sex-specific obesity-related cancers were ovarian, 
endometrial and post-menopausal breast cancer in women and advanced prostate 
cancer in men. 
A sensitivity analysis excluding pancreas cancer was performed to investigate the 
effect of pancreatic cancer on T2DM diagnosis. Analyses were performed in STATA 
v14.
Ethics Statement
The medical ethics committee of Isala, Zwolle, the Netherlands approved the procedure of 
this study including the anonymous linking of the ZODIAC with the NCR (METC reference 
number 13.0765). No written informed consent was required. Patients consented with 
the anonymous use of their data for study purposes in the ZODIAC study. 
RESULTS
Baseline characteristics are shown in Table 1. Among the 69,583 patients included, 49% 
were female and 40,417 patients had a follow-up of at least 5 years. Women were older 
and had a higher BMI compared to men. 
Obesity-related cancers
Incidence ratios for obesity-related cancers are shown in Fig 1, S1 and S2 Table. Compared 
to the general population, in men and women combined the incidence of obesity-related 
cancer were elevated in the 5 years prior to, the first year after and year 2 to 5 after 
diabetes diagnosis, with the highest cancer incidence in the first year after diabetes 
diagnosis (SIR 1.80, 95%CI 1.59 – 2.01). 
In women, the 5 years prior to diabetes diagnosis, there was a significantly increased 
obesity-related cancer incidence in all years compared to women in the general 
population. The SIR gradually increased from 1.86 (95%CI 1.37 – 2.00) at 5 years prior to 
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diabetes diagnosis to 2.06 (95%CI 1.74 – 2.39) at 2 to 1 year prior to diabetes diagnosis 
but decreases in the year before diagnosis of diabetes (SIR 1.44, 95%CI 1.17-1.70). The 
first year after diabetes diagnosis the SIR was the highest (SIR 2.21, 95%CI 1.88-2.54) and 
remained increased in the 5 years after diabetes diagnosis. 




(n = 35,271, 50.5%)
P-value *
Age at diabetes diagnosis (SD), years 63.0 (12) 60.5 (11) < 0.001
Diabetes duration (IQR), years 2.5 (0.6 – 6.3) 2.1 (0.5 – 5.7)
HbA1c at diabetes diagnosis (IQR), 
mmol/mol
HbA1c at diabetes diagnosis (IQR), %
49 (43 – 55), 
6.6 (6.1 – 7.2)
49 (43 – 55),
6.6 (6.1 – 7.2)
0.32
BMI at diabetes diagnosis§ (IQR) 29.5 (26.3 – 33.7) 28.4 (26.0 – 31.5) < 0.001
Creatinine at diabetes diagnosis (IQR), 
µmol/L
68 (59 – 80) 87 (74 – 95) < 0.001
Cancer events
All-cancer (n, %) 2130 (6.2) 2139 (6.1)
Obesity-related cancer (n, %) 1344 (3.9) 709 (2.0)
Non sex-specific obesity-related 
cancer (n, %)
374 (1.1) 479 (1.4)
BMI categories§ < 0.001
18 to 25 (%) 16.5 16.8
25 to 30 (%) 36.6 47.1
>30 (%) 46.9 36.1
SD: Standard deviation, IQR: Inter-quartile range, BMI: Body mass index. § Includes only patients 
who had a BMI recorded at diabetes diagnosis. Continuous data were analysed using independent 
t-tests or the Mann-Whitney U test. Categorical variables were analysed using chi square tests. 
*P-value for the difference between men and women at baseline. 
In men, no significantly increased cancer risk was observed in 5 to 1 year prior to 
diagnosis of diabetes. In contrast, in the year prior and the year after diabetes diagnosis 
the SIR was significantly increased cancer risk compared to men in the general population, 
1.32 (95%CI 1.06 – 1.58) and 1.38 (95%CI 1.11 – 1.64), respectively. 
An analysis where patients were stratified by BMI below or above 30 at diabetes 
diagnosis were in line with the main analyses (S7 Table and S3 to S4 Figs). The SIR for 
obesity-related cancers was higher in women compared to men for all years, with non-
overlapping confidence intervals, except the one year before diagnosis of diabetes.

























Fig 1. Standardized Incidence Ratio with 95%CI bars of obesity-related cancer. The horizontal 
line is 1.00 and means that there was no difference between the ZODIAC population and the 
general population.
Sex-specific influences on obesity-related cancer incidence
Fig 2, S1 and S3 Table show the SIR for obesity-related cancer when the sex-specific 
obesity-related cancer types (breast, ovarian and endometrial cancer in women and 
advanced prostate cancer in men) were excluded. In women a significantly increased SIR 
for obesity-related non-sex specific cancer before diabetes diagnosis was only observed 
for year minus 2 to minus 1 year before diabetes diagnosis (SIR 1.64, 95%CI 1.14-2.14). 
In the year following diabetes diagnosis a significantly increased SIR was observed (SIR 
2.61, 95%CI 2.00-3.23) for all years after diabetes diagnosis. A separate analysis which 
included only breast cancer (S6 Table and S1 Fig) showed that the SIR was increased for 
all time points, and also showed an apparent decrease the year before diabetes diagnosis. 
In men, there was a significant difference in cancer incidence at minus 3 years (SIR 
1.50, 95%CI 1.06 – 1.94) and minus 1 year (SIR 1.96, 95%CI 1.49 – 2.42) prior to diabetes 
diagnosis compared to the general population. Cancer incidence was highest in the first 
year after diabetes diagnosis (SIR 2.04, 95%CI 1.56 – 2.51). A separate analysis investigating 
specifically advanced prostate cancer showed a decreased incidence in advance prostate 
cancer the 5 year prior to diabetes diagnosis and no significant difference compared to 
the general population in the years after diabetes diagnosis. 
The SIRs for non-sex-specific obesity-related cancers were, based on overlapping 
confidence intervals, not significantly different between sexes.






















Time (months to diabetes diagnosis)
Obesity related cancers (excluding sex-speciﬁc cancers)
Male
Female
Fig 2. Standardized Incidence Ratio with 95%CI bars of obesity-related cancer excluding sex-
specific cancers. The horizontal line is 1.00 and means that the was no differences between the 




















Time (months to diabetes diagnosis)
All Cancer (No non-melanoma skin cancer)
Male
Female
Fig 3. Standardized Incidence Ratio with 95%CI bars of all-cancer combined (excluding non-
melanoma skin cancer). The horizontal line is 1.00 and means that the was no differences 
between the ZODIAC population and the general population.
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Standardized incidence ratios - all-cancers combined
The SIR for all-cancers combined for men and for women are shown in Fig 3, and S1 and S4 
Table. Over the years, there was a gradual increase in SIR in men and women combined, 
becoming significantly from 3 to 2 years prior to diagnosis of diabetes (see S4 Table). A 
rise in cancer incidence was present for men and women combined the year prior to and 
around diabetes diagnosis, see S4 Table. There were increased cancer incidences in year 
2 to 5 after diabetes diagnosis.
In women, there was an increased cancer incidence that started to increase from 
5 years prior to diabetes diagnosis, see Fig 3 and S4 Table. In men, only the year prior 
to diabetes diagnosis and 5 years thereafter were increased, see Fig 3 and S4 Table. 
A sensitivity analysis excluding pancreas cancer did not change results significantly (S5 
Table). An analysis where patient were stratified by a BMI below or above 30 at diabetes 
diagnosis were in line with in line with the main analyses (S8 Table and S3 to S4 Fig). 
DISCUSSION
This study is the first to investigate standardized obesity-related cancer incidence ratios 
in three time periods (5 years before, the first year after and 2 to 5 years after diabetes 
diagnosis) and accounting for sex-differences. 
In women there was an increase in obesity-related cancer incidence already 5 years 
before T2DM diagnosis and this was also increased after diabetes diagnosis compared to 
women in the general population. This was not observed in men. Also, from year 2 to 5 
after diabetes diagnosis, women had a higher obesity-related cancer incidence compared 
to women in the general population. 
The observed increase in obesity-related cancer incidence in women with T2DM 
compared to women in general population was explained to a large part by the contribution 
of sex-specific cancers, for example breast cancer. The exclusion of sex-specific cancers 
in women mitigated the increased obesity-related cancer incidence before diabetes 
diagnosis, highlighting the importance of sex-specific cancers in women. Furthermore, 
the differential effects do not seem to be confounded by obesity. It seems to be that after 
diabetes diagnosis, irrespective of the presence of obesity or not, there was an increased 
cancer incidence compared to the general population. 
The analysis that included only breast cancer was in line with the obesity-related 
and all-cancer analyses and showed an increased breast cancer incidence in women with 
diabetes compared to the general population. This is in accordance with previous studies 
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that investigated breast cancer incidence also showed that breast cancer risk was already 
elevated in the pre-diabetes phase (23, 33). It could be that women put on relative more 
weight in the pre-diabetes phase. From all obesity-related cancers, breast cancer appears 
to show the strongest correlation with weight increases (10, 34). It has been suggested 
that the increased incidence could be due to increased aromatization of androgens to 
oestrogens locally in fat tissue (35). Eventually, this could lead to increased ERα signalling 
in breast cancer and possibly a greater risk of oestrogen-dependent breast cancer (35). 
Indeed, especially oestrogen receptor positive breast cancer risk has been reported to 
be increased in women with T2DM (36). 
There was a decrease in obesity-related SIR in women 1 year before diabetes diagnosis 
for which we have no obvious explanation. There is some evidence that especially breast 
cancer in strongly associated with obesity and weight gain as such (37, 38). There are 
reports suggesting that obese patients could also be less likely to respond to screening 
programs (38, 39). During the study period, there were no national screening programs 
involving men. Another possible explanation could be related to the care provided. It 
could be that there is some degree of clinical distraction or pre-occupation with metabolic 
parameters that results in fewer diagnosis of cancer (40). An incidental cancer diagnosis 
is perhaps delayed until the diagnosis of diabetes is made. It could also be that during the 
year prior to diagnosis of diabetes cancer screening tests are performed but the definitive 
cancer diagnostic test takes longer to complete, thus delaying the cancer diagnosis until 
after diabetes is diagnosed. However, most cancer diagnostic tests don’t take long to 
complete. A fourth possible explanation is that there is an issue with the registration of 
cancer events. However, this seemed unlikely since all cancer diagnoses in the Netherlands 
are automatically registered with the Cancer Registry. None of these factors seemed 
plausible. A final explanation could be that this finding is a coincidence for which we have 
no causal explanation. Cancer screening programmes in place in the Netherlands at the 
time of the study period are for breast cancer and cervical cancer. Nationwide, there was 
an attendance rate of 79% and 65%, respectively (41, 42). Previous studies have shown 
that women with comorbidity, for example obesity (39), and lower social economic status 
are less likely to attend screening (43-45). The incidence of diabetes is increased in people 
with lower socio-economic status (46-48). It would thus be more likely that there would 
be a decreased screening attendance instead of an increased screening attendance in 
the prediabetes phase. In addition, women with diabetes are also less likely to undergo 
a mammogram than women without diabetes (43). Some studies have shown more 
favourable survival rate in screen detected breast cancers and emphasized the importance 
of cancer screening in patients with diabetes (49). In the analyses excluding sex-specific 
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cancers this decline disappeared, which could point to breast cancer as a likely causative 
cancer. The decline was not present in men, which likely excludes a methodological error 
as an explanation. Overall, we have no causal explanation for this finding. 
There was a pronounced increase in cancer incidence around the time of diabetes 
diagnosis. This increased detection has been reported in previous studies (26, 50). However, 
it seems questionable that detection bias is an important plausible explanation before 
diabetes diagnosis and in the years after the first year following diabetes diagnosis (2, 26, 
28, 49). Another possible explanation for the differential effects observed is diagnostic 
bias. Patients diagnosed with diabetes are more likely to have additional diagnostic tests 
(50-52). The first year after diabetes diagnosis, obesity-related cancer incidence increased 
121% for women and 38% for men compared to the general population. No previous 
studies combining obesity-related cancer incidence were found. However, an Austrian 
cohort study (n=5709, T2DM patients) also reported elevated SIRs for cancers of the 
pancreas (1.78, 95%CI 1.02 – 2.89) and corpus uteri (1.79, 95%CI 1.15 – 2.66) in women 
and for cancers of the liver (2.71, 95%CI 1.65 – 4.18) and pancreas (1.87, 95%CI 1.11 – 
2.96) in men in the year after diagnosis of diabetes (53). 
The peak in cancer incidence around diabetes diagnosis could partly be directly 
explained by diabetes developing as a result of for example pancreas cancer (49, 51). A 
higher cancer mortality has been reported in female pancreatic cancer patients compared 
to men (54). However, exclusion of pancreas cancer in a sensitivity analyses did not 
relevantly change results (S5 Table). Increased detection of diabetes in a cancer work-
up or cancer in a diabetes work-up could also play a role in the rise in cancer incidence 
immediately after diagnosis of diabetes in both men and women (50-52). There is 
evidence from previous studies that detection bias is partly responsible for the increase 
in cancer incidence patients with T2DM, at least for the excessive peak that has been 
observed (2, 26). 
In the period from 2 to 5 years after diabetes diagnosis obesity-related and all-cancer 
incidence was substantially and significantly higher in women and remained increased 
throughout year 2 to 5 after diabetes diagnosis. In men, there was a less obvious increase 
in obesity-related and all-cancer incidence. 
In men, as opposed to women, exclusion of sex-specific obesity-related cancer (i.e. 
advanced prostate cancer) substantially increased obesity-related cancer incidence the 
years after diabetes diagnosis. This could point to a protective effect of T2DM to prostate 
cancer. Previous meta-analyses already showed a decreased risk of low stage prostate 
cancer in T2DM patients (49, 55, 56). The analysis which included only advanced prostate 
cancer showed a decreased cancer incidence in the 5 years prior to diabetes diagnosis, 
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and no difference in cancer risk after diabetes diagnosis. Our results could suggest that 
advanced prostate cancer might thus not be positively related to obesity. These results are 
in contrast to the definition used by the WCRF (5). A recent viewpoint of the International 
Agency for the Research of Cancer (IARC) also stated that there is limited evidence for 
fatal prostate cancer being related to obesity (57). 
Strengths and Limitations
This study sample represents the majority of primary care treated T2DM patients in the 
Netherlands and has a high degree of generalizability. Another strength of this study 
was the size of the ZODIAC cohort. Thirdly, the long follow-up periods made it possible 
to estimate incidence ratios as early as five years before diagnosis of diabetes and study 
cancer incidence before diabetes onset.
There were also limitations. Some patients were selected with a date of diabetes 
diagnosis occurring before 1994. In theory, taking into account the 5-year window before 
diabetes diagnosis used in this study, patients could already have had a cancer event 
while diagnosed with diabetes before the NCR commenced in 1989. This cancer event 
would not have been registered in the NCR. However, we expect this effect to be fairly 
negligible, since only 4.4% of patients in our data were diagnosed with diabetes before 
1994. A second limitation was that cancer incidence before diabetes diagnosis could be 
influenced by survival bias. Since the ZODIAC cohort only consists of patients diagnosed 
with T2DM, patients who died from, amongst others, cancer, could never have been 
included in this cohort since they did not have time to develop diabetes. Thirdly, the 
general population also included people diagnosed with diabetes; around 10 % of the 
general population in this age category in the Netherlands are diagnosed with diabetes 
(58, 59). It has been shown that with increasing age the proportion of people diagnosed 
with diabetes increases (59). Furthermore, as opposed to our cohort, the general 
population also included people with a history of cancer. If these two factors would be 
accounted for, they both would likely lead to an underestimation of the effect seen. The 
reported higher cancer incidence rates in patients with diabetes would in reality be more 
pronounced (58). In addition, we were unable to adjust for confounders other than age 
and sex. For example, BMI data in the general population were not available. Fourthly, the 
ZODIAC cohort expanded to different regions in the Netherlands at several time points 
and both patients with known diabetes and newly diagnosed diabetes were included. 
The date of diabetes diagnosis was based on an electronic health record and verified by 
a practice nurse. This could have been subject to recall bias. For example, some patients 
could not remember the month of diabetes diagnosis. In this case the first of July was 
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used as month of diabetes diagnosis in an attempt to minimize this bias. Unfortunately, 
we could not exclude a relevant effect of this recall bias, however, we have no reason to 
assume that this would be different in men or women. 
It is plausible that detection bias is also present in the current study, explaining the 
peak in cancer incidence at diabetes diagnosis. This could in turn also explain the slight 
decrease in cancer risk seen in the 2 to 3 years after diabetes diagnosis in the present 
study which would be almost absent if there would not have been a peak. Increased 
detection does not necessarily lead to bias nor is it always a negative effect, but it is a 
phenomenon that partly results from increased contact with health care professionals 
(26).
Although no specific indications exist which suggests that people in the ZODIAC regions 
have a different cancer risk compared to the general population in the Netherlands, we 
do not know that for sure. It would have been better if we could have used a comparator 
group from the ZODIAC regions, but unfortunately such a group was not available. Lastly, 
hormone receptor status of breast cancer was not available in the current study, making 
it impossible to investigate the influence of oestrogen-dependent breast cancer. This will 
be subject for further studies.
In summary, in men and women with T2DM, cancer incidence peaked the year after 
diabetes diagnosis. A clear difference in cancer risk was observed between men and 
women. Women, not men, with T2DM had an increased obesity-related standardised 
cancer incidence compared to women in the general population, as early as 5 years before 
diabetes diagnosis. After diabetes diagnosis, both men and women had an increased SIR 
but the effect was more pronounced in women. 
Exclusion of sex-specific obesity-related cancers resulted in a lower incidence in 
women and a higher incidence in men compared to the SIR in all obesity-related cancers. 
The latter might suggest that, in addition to low risk prostate cancer, advanced prostate 
cancer is not associated with obesity in patients diagnosed with T2DM.
Next to relative cancer risk, absolute obesity-related cancer risk in the general 
population show that women have a lower risk than men (19). It appears to be that 
the relative advantage in women disappears in the presence of diabetes and exemplify 
that the relative protective effect in women is lost when diabetes develops, which is 
comparable to CVD. The difference in women with T2DM compared to women in the 
general population and the difference of women compared to men with T2DM could 
mean that in the general population women have an advantage concerning cancer risk 
but when diabetes develops this advantage disappears. The impact of this should be 
subject of further investigations. 
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SUPPORTING INFORMATION (AVAILABLE ONLINE)
S1 Table. Pooled standardized incidence ratio
S2 Table. Standardized incidence ratio of obesity-related cancers. Cancers included: liver, 
kidney, colorectal, gallbladder, pancreas, ovarian, endometrial and advanced prostate 
cancer, post-menopausal breast cancer and esophageal adenocarcinoma.
S3 Table. Standardized incidence ratio of obesity-related cancer excluding sex-specific 
cancers. Cancers included: liver, kidney, colorectal, gallbladder, pancreas and esophageal 
adenocarcinoma
S4 Table. Standardized incidence ratio all cancers combined. 
S5 Table. Standardized incidence ratio all cancers combined (excluding pancreas)
S6 Table. Standardized incidence ratio breast cancer (women) and advanced prostate 
cancer (men). 
S7 Table. Standardized incidence ratio of obesity-related cancers in patients with a BMI 
below 30 and 30 and above. Cancers included: liver, kidney, colorectal, gallbladder, 
pancreas, ovarian, endometrial and advanced prostate cancer, post-menopausal breast 
cancer and esophageal adenocarcinoma.
S8 Table. Standardized incidence ratio all cancers combined in patients with a BMI below 
30 and 30 and above.
S1 Fig. Standardized Incidence Ratio of postmenopausal breast cancer in women.
S2 Fig. Standardized Incidence Ratio of advanced prostate cancer in men.
S3 Fig. Standardized Incidence Ratio of all and obesity-related cancer stratified to BMI 
<> 30 in men 
S4 Fig. Standardized Incidence Ratio of all and obesity-related cancer stratified to BMI 
<> 30 in women
S1 File. Cancer incidence rate general population.
S2 File. SIR Data.
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ABSTRACT
Background: 
Patients with type 2 diabetes (T2D) are at increased risk for developing cancer. As 
approximately 8% of the world’s population is living with T2D, even a slight increase in 
cancer risk could result in an enormous impact on the number of persons developing 
cancer. In addition, several glucose lowering drug classes for treating patients with 
T2D have been associated with a difference in risk of cancer overall, and especially for 
obesity related cancers. In what way and to what degree cancer risk is modified by the 
use of different sulfonylureas (SU) is unclear. The primary aim of this study will be to 
evaluate within-class SU differences in obesity related cancer risk. Secondary aims will 
be to investigate within-class SU differences in risk for all cancers combined and site-
specific cancers separately (i.e. breast, colorectal, prostate, bladder and lung cancer) and 
to account for duration-response relationships between individual SU use and cancer risk.
Methods: 
Patients will be selected from a Dutch primary care cohort of patients with T2D linked with 
the Dutch Cancer Registration (ZODIAC-NCR). Within this cohort study annually collected 
clinical data (e.g. blood pressure, weight, HbA1c) and nationwide data on cancer incidence 
are available. Time-dependent cox proportional hazard analyses will be performed to 
evaluate SU cancer risk, adjusted for potential confounders. 
Discussion: 
This study will be the first prospective cohort study investigating within-class SU 
differences in cancer risk and could contribute to improved decision making regarding 
the individual drugs within the class of SUs, and possibly improve quality of life and result 
in an increased cost-effectiveness of healthcare in patients with T2D. 
Trial Registration: 
Nederlands Trialregister (www.trialregister.nl), NTR6166, 6 Jan 2017.
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BACKGROUND
Patients diagnosed with type 2 diabetes (T2D) are at increased risk for developing cancer; 
especially the risk of obesity-related cancers (1-5). According to the most recent World 
Cancer Research Fund (WRCF) definitions obesity related cancers include oesophageal 
cancer, liver cancer, kidney cancer, stomach cardia cancer, colorectal cancer, advanced 
prostate cancer, post-menopausal breast cancer, gallbladder cancer, pancreatic cancer, 
ovarian cancer and endometrial cancer (6).
In addition to T2D and obesity, glucose-lowering agents used in the treatment of 
T2D have also been associated with cancer risk and some studies have reported 
that these relations can be drug specific. For example, the use of pioglitazone, not 
rosiglitazone, has been linked to the development of bladder cancer in some studies 
(7, 8), although the robustness of the evidence underlying this possible relationship 
remains unclear and was absent in recent reports (9, 10). Also, insulin glargine has 
been linked to higher breast cancer risk in some studies (11), although - again - several 
studies reported no or even an inverse association (11-13). Metformin has more 
consistently been associated with a decreased cancer risk (14), however concerns 
have been raised that this association might have been influenced by several types 
of bias (15, 16). 
The sulfonylureas (SUs) are one out of six classes of oral glucose-lowering agents 
advised by the EASD and ADA as a second step when the glycaemic treatment targets 
are not reached with metformin mono-therapy (17). Sulfonylureas have been available 
for many years and are highly efficacious at low costs. In the Dutch primary care 
treatment guideline for T2D, gliclazide is the preferred SU, as opposed to both the 
ADA and EASD which do not recommend a specific SU (17). Previous studies have 
shown that within the class of SUs differences exist with regard to hypoglycaemia 
risk (18), for example there have been no reports of severe hypoglycaemia events 
in gliclazide users (18). In addition, within-class differences in risk of cardiovascular 
events and safety when prescribed to patients with renal failure have been reported 
(19, 20). 
An association between the class of SUs and increased overall cancer risk has also 
been reported (21-24). Most previous studies are limited by methodological issues, for 
example many studies reported baseline SU use and did not account for duration of SU 
use (22-24). There is also evidence suggesting within-class SU differences in cancer risk, 
where gliclazide use has been associated with a lower cancer risk (21-24). There are 
several potential mechanistic explanations, one of which could be that gliclazide leads 
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to a more selective glucose dependent insulin response and lower insulin levels. In what 
way and to what degree cancer risk is modified by different SUs in unclear and requires 
further investigation and confirmation. 
Most evidence, however, is derived from small observational cohort studies and 
substantial knowledge gaps exist. This also holds true for the presumed favourable long-
term cancer safety profile of gliclazide in particular. The relations between use of glucose 
lowering agents and cancer are complex and there is overlap in risk factors; for example, 
several glucose lowering agents have been associated with weight gain, which in itself 
has also been related to an increased cancer risk.
The primary aim of this study is to evaluate within-class SU differences in risk for 
obesity-related cancer (excluding non-melanoma skin cancers) accounting for weight 
changes during follow-up and drug exposure (6). Secondary aims are to evaluate within-
class SU differences concerning all cancers combined and the cancer risks of the five 
largest groups of site-specific cancers (breast, colorectal, prostate, bladder and lung 
cancer) accounting for duration of drug use.
METHODS/DESIGN
Data source
This study will be conducted using a combined database of the ZODIAC (Zwolle Outpatient 
Diabetes project Integrating Available Care) study and NCR (Dutch National Cancer 
Registration). 
ZODIAC
The ZODIAC cohort is part of an ongoing primary care prospective study initiated in 
1998, in which annually collected data are used for care improvement, benchmarking 
and research (25). Patients consented with the anonymous use of their data for study 
purposes. Patients included are diagnosed with T2D and are exclusively treated in primary 
care in a shared care setting. Data on age, sex, date of T2D diagnosis, HbA1c, length, 
weight, estimated GFR, creatinine, albumin-creatinine ratio (ACR), cholesterol/HDL ratio, 
blood pressure, macrovascular complications (myocardial infarction, TIA, CVA) medication 
use (both diabetes-specific and other medication), smoking (yes/no) and alcohol use (yes/
no) are recorded. 
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NCR
The Netherlands Cancer Registration (NCR) was founded in 1989 and has since recorded 
almost every cancer event in the Netherlands, and includes incidence date, TNM (tumour, 
node, metastasis) stage, morphology, location and the therapy received (26). Basal cell 
carcinoma of the skin, carcinoma in situ of the cervix, myelodysplastic syndrome and 
myeloproliferative disorders are all excluded for the NCR database. Benign and borderline 
tumours are excluded with the following exceptions; benign brain tumours (included from 
1999), carcinoids of the appendix (included from 2001), borderline tumours of the ovaries 
(included from 2001), thymoma (included from 2001), phyllodes tumours (included from 
2001) and T-cell leukaemia (included from 2004).
Study population
Combined ZODIAC-NCR cohort
All cancer events that occurred between 1 January 1989 and 2012 were linked to the 
data of the ZODIAC study via a trusted third party using postal code, full name, date of 
birth and sex. The medical ethics committee of Isala, Zwolle, the Netherlands approved 
the linkage of ZODIAC and NCR (METC reference number 13.0765). The NCR expected 
that the number of false-positive and the number false-negative linkage is both under 
1%. By combining the two databases a cohort composed of patients diagnosed with T2D 
between 1 January 1998 and 31 December 2012 was assembled.
Patient selection
The study cohort entry date and baseline date will be the date the patients started 
participation in the ZODIAC cohort. 
Inclusion
All patients included will be participating in the ZODIAC-NCR cohort on or after January 
1998 and will be users of SUs.
Exclusion
Patients treated with long-acting or mixed insulin before oral glucose lowering agents 
and those receiving insulin on top of SU at study entry will be excluded. Patients who 
received a cancer diagnosis before receiving a SU will be excluded. For the main analyses 
patients who switch medication within the class of SUs will be excluded at the time the 
switch occurs. 
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Follow-up
All patients will be followed from the year of cohort entry until a diagnosis of cancer 
(3-5). Patients with no diagnosis of cancer will be censored at the time of death, end of 
registration within the ZODIAC cohort or end of the study period (31 December 2012), 
whichever occurred first.
Study endpoints
The primary outcome will be within-class SU difference in obesity-related cancer risk (see 
table 1 for included cancers). The secondary outcomes will be all cancer risk (table 2), 
site-specific cancer risk and the presence of a duration response relationship between 
SU use and cancer. Cancer sites of special interest will be specific cancers of the breast, 
colorectal, bladder, advanced prostate and lung cancer. Study endpoints will be evaluated 
for men and women separately. 
Table 1. Cancers included in primary endpoint obesity related cancer.
Men Women
Oesophageal (adenocarcinoma) Oesophageal (adenocarcinoma)






Prostate cancer Ovarian 
Breast 
Endometrial
Table 2. Cancer excluded from secondary endpoint all cancer risk
Men (cancers excluded) Women (cancers excluded)
Non-melanoma skin cancer Non-melanoma skin cancer
Breast Prostate 
Ovarian Male genital organs
Endometrial
Female genital organs
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Exposure
Patients will be considered unexposed to SUs until the time of the first SU prescription 
within ZODIAC. A one-year lag period will be accounted for. A lag period is necessary to 
take into account a latency time window and to minimise possible detection bias around 
the time of treatment initiation. Exposure to a SU will be classified according to one of 
the following, mutually exclusive, categories: gliclazide use, glimepiride use, tolbutamide 
use, glibenclamide use, non-SU use. 
We aim to determine whether there are duration-response relationships between 
the use of SUs and obesity-related cancer incidence. Duration-response will be 
assessed in terms of cumulative duration of use, defined as the total number of 
years of use calculated by summing the durations of yearly prescriptions received 
between cohort entry and the time of the event and will be used as a time-dependent 
covariate. 
Co-variates
Co-variates collected at cohort entry and annually thereafter are: age, sex, year of cohort 
entry, HbA1c (continuous), diabetes duration (time between diabetes diagnosis and 
cohort entry, continuous), BMI (continuous), serum creatinine (continuous), metformin 
use (yes, no), insulin use (yes/no), history of cancer (no non-melanoma skin cancer) (yes, 
no) and smoking (ever, never, unknown). 
Primary analysis
Descriptive statistics will be used to characterize the patients at cohort entry. Time 
dependent cox proportional hazard analyses will be used to estimate the adjusted hazard 
ratio of developing obesity-related cancer when using gliclazide compared to other SUs 
(both individual and grouped as non-gliclazide SU). Exposure to SUs will be included as 
the cumulative number of years exposed to a specific SUs. Exposure status for SU will be 
updated annually. The primary analyses will be corrected for the previously mentioned 
confounders measured at baseline. 
Secondary analyses
In a secondary analyses changes diabetes medication during follow-up will be accounted 
for. Time dependent cox proportional hazard analyses will be used to estimate the 
adjusted hazard ratio of developing all cancer when using gliclazide compared to other SUs 
(both individual and grouped as non-gliclazide SU). Exposure to confounders (including 
concurrent metformin and insulin use) will be handled as time varying variables where 
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follow-up is available. The updated mean method will be used for HbA1c, BMI and serum 
creatinine. These analyses will be repeated to investigate the adjusted hazard ratio of 
breast, colorectal, prostate, bladder and lung cancer.
Missing data
When appropriate, in case of missing data multiple imputation will be used. In case 
multiple imputation cannot be used (e.g. data are not missing at random or missing 
completely at random), the updated means method will be used. The updated mean 
method averages the baseline values with the mean annual values (27). The updated 
mean method is similar to the technique used in the UKPDS (28). When calculating the 
updated means, we will allow a maximum of 2 consecutive years to be missing, with a 
maximum of 3 years in the complete follow-up. 
Subgroup analyses
In subgroup analyses effects of exposure to BMI and HbA1c during follow-up and the 
relation between SUs and cancer will be investigated and interaction will be tested. A 
second subgroup analysis will investigate cancer risk in patients who do and do not use 
metformin in combination with an SU.
Sensitivity analyses
Six sensitivity analyses will be planned for supporting the main analyses. Firstly, because 
the latency window is uncertain, the primary analyses for within-class differences will 
be repeated with lag periods of zero and two years. Secondly, the primary analysis will 
be repeated but the adjusting confounders will be measured at the year before first SU 
prescription. Thirdly, the main analysis will be repeated but with the exclusion of cancer 
events 1 year after initiation of a SU. Fourthly, to investigate the accuracy of our results the 
analysis will be repeated in patients in whom all data on medication are complete. Fifthly, 
to investigate the accuracy of our results the analysis will be repeated in patients who 
have no missing data on HbA1c, BMI and serum creatinine. Sixthly, to quantify the effect 
of patients switching medication within the class of SUs, an intention-to-treat analysis 
for patients who switch SUs will be performed.
7SU treatment and differences in cancer risk - a study protocol  |  143
DISCUSSION
This study will be the first large observational cohort study investigating differences in 
cancer risk within the class of SUs. An estimated 8% of the global population is known 
with T2D (29) and this could translate into an increased risk of cancer for a substantial 
amount of people. The prevalence of T2DM is expected to rise evermore, at least for the 
next decades (30). A minimal change in cancer risk could result in a substantial change 
in the relative and even absolute number of patients diagnosed with cancer. If this study 
confirms the presence of within-class SU cancer risk differences, it could help patients and 
physicians in making a shared decision for a specific SU. This could contribute to quality of 
life of the patients as well as contribute to increasing effective care and cost-effectiveness 
of healthcare. If no differences are present, the safety, efficacy, and cost of SU will remain 
the only criteria for selecting the best SU. 
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SUMMARY OF MAIN FINDINGS
Type 2 diabetes (T2D) affects many people worldwide and its prevalence is expected to 
increase in the next decades 1–3. Cancer, also highly prevalent 4,5, occurs more frequently in 
patients with T2D (Standardized incidence ratio (SIR) men 1.08, 95%CI 1.07-1.09, women 
1.22 95%CI 1.20-1.23) 6. Insulin resistance is an important characteristic of T2D. Age, 
obesity and hyperinsulinemia are related to insulin resistance. Insulin resistance is one of 
the possible etiologic mechanisms in the relationship between T2D and (obesity-related) 
cancer. 
In recent years, an increasing amount of studies have been conducted investigating 
the effect of glucose-lowering medication on cancer risk. There is a possible positive 
relationship between the class of sulphonylureas (SU) as a whole and the risk of cancer 
7. Results from several small observational studies suggested that within-class differences 
in cancer risk could exist within the SU class 8–11. 
The general aim of this thesis was to investigate cancer risk in a Dutch primary care 
diabetes population, with special attention for possible within-class differences when 
using a SU derivate. For this purpose, a large prospective Dutch primary care treated 
diabetes population was studied. 
A systematic literature review on potential mechanisms behind the relationship 
between SU use and cancer was performed. In an observational cohort, potential factors 
that potentially can confound the relationship between SU and cancer were explored in 
patients diagnosed with T2D. 
In chapter 2, a systematic review was conducted reviewing clinical and preclinical 
literature regarding the relationship between the various SUs and cancer (risk). 
Results from preclinical studies showed potential anti-cancer effects of SUs on cancer 
cell growth, cell transporters and channels, growth factor pathways, DNA damage, blood 
vessel formation and metastases. When assessing the association between different SUs 
and cell growth in different cell lines, the results lead to unequivocal conclusions in the 
various preclinical studies. 
Out of 228 initially identified records of clinical studies, only six were eligible for 
further analysis and comparison. The clinical studies showed that T2D patients using 
gliclazide seemed to have a lower cancer risk compared to T2D patients using other 
SUs. In addition, patients using glibenclamide had an increased cancer risk compared 
to patients using tolbutamide and gliclazide. Unfortunately, no meta-analysis could be 
performed because the methodology of the studies varied too much to allow pooling of 
the data; different SUs were compared, different study designs were used, and different 
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statistical methods were applied. Pre-clinical evidence for gliclazide was limited, and 
most evidence was found for glibenclamide. The anti-cancer effects of glibenclamide 
reported in the preclinical studies was not confirmed in observational clinical and 
epidemiological studies. Results of three of the four studies investigating glibenclamide 
suggested that the use of glibenclamide was associated with an increased risk of cancer 
12. For other SUs, no conclusive data was available, thus precluding firm conclusions 
with regards to gliclazide, glimepiride, and tolbutamide. Part of this thesis addresses 
the effects of these molecules. 
In Chapter 3, the time between SU initiation and the need for treatment intensification 
with insulin was investigated. The moment that glycaemic control worsens and treatment 
intensification is needed, the addition of once-daily insulin could be regarded as an 
indicator of disease progression and increasing insulin resistance 13–15. This assessment 
was performed for a variety of reasons. First, even when starting SU treatment with the 
lowest effective dose, dose increases will be necessary, thus contributing to exposure to 
higher cumulative doses. Ultimately, after reaching the maximum allowed daily dose, 
insulin can be added. In this study, insulin initiation was partly considered to be the 
surrogate endpoint for use (at that point) of the maximum (tolerated) SU dose. This 
would translate into a lower cumulative SU exposure; the exact consequences of such 
a finding are unclear. Moreover, insulin treatment will (in general) lead to higher insulin 
concentrations compared to oral treatment. Higher insulin concentrations are associated 
with a higher cancer risk 16. In addition, when SU treatment failure occurs, the earlier the 
failure, the earlier there will be exposure to higher HbA1c levels. Higher HbA1cs have also 
been associated with increased cancer risk 17,18. 
In total, 3507 patients starting a SU in addition to metformin were included (gliclazide 
643, glimepiride 1178, tolbutamide 1686). Using metformin/gliclazide as a reference, 
there were neither differences in time to insulin in the metformin/glimepiride group 
(HR 1.10, 95%CI 0.78-1.54) nor in the metformin/tolbutamide group (HR 0.93, 95%CI 
0.67-1.30).
Therefore, and with some hesitation, it might be concluded that, since there were no 
differences in time to insulin initiation between SUs, factors like exposure to the effects 
of higher HbA1cs, and changes in insulin concentrations can be considered comparable 
between the different SUs. Of course, the total cumulative dose has not been assessed, 
and since equipotency of SU is related to glucose levels attained and not to total milligram 
dose of use, this point remains open. The results, as described in this study, suggest that 
at least the duration of SU exposure and insulin treatment-induced changes in insulin 
concentrations are comparable within SUs. 
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In chapter 4, the presence of within-class differences in body weight trajectories in 
new users of SUs in a Dutch T2D cohort was investigated. Being overweight and obese 
has been associated with the development of certain specific cancer types 19. Within-class 
SU differences in body weight trajectories after the start of SUs can therefore confound a 
possible relationship between SU and cancer. Cancers of the oesophagus, stomach (cardia), 
colorectal, liver, gallbladder, pancreas and kidney have been associated with obesity in men 
and women in the general population 19. Significant weight changes were observed neither 
within individual SUs (p = 0.24) nor between the different SUs (p = 0.26). Baseline weight 
(kilogram) was 91.8 (90.3-93.4) for the gliclazide group, 92.2 (86.2-98.2) for glibenclamide 
group, 91.3 (90.2-92.4) for the glimepiride group and 89.4 (88.5-90.3) for the tolbutamide 
group. The year after addition of a SU weights were 91.9 (90.3-93.5), 92.4 (85.7-99.1), 91.3 
(90.2-92.4) and 89.7 (88.8-90.6), respectively. None of these weight changes was significant. 
The average HbA1c decreased from 55 mmol/mol before intensification to 53 mmol/mol 
after intensification with a SU. It was thus possible to maintain good glycaemic control with 
SU as second-line therapy without the offset of relevant weight changes in this Dutch Cohort. 
Therefore, in this cohort, there was no indication that the relationship between 
different SUs and cancer is potentially confounded by differences in weight changes after 
SU initiation because new use of any SU was not associated with relevant weight changes.
In the study in chapter 5, the relationship between BMI and obesity-related cancer 
in men and women was investigated. In 25,811 men, 689 obesity-related cancers were 
identified. In this study, BMI was associated with obesity-related cancers in men with 
T2D (HR 1.12 95%CI 1.02 to 1.23), except for advanced prostate cancer (HR 0.93 95%CI 
0.75 to 1.16). In women, 24,989 patients were included and 914 were diagnosed with 
obesity-related cancer. BMI was associated with obesity-related cancers (HR (per 5 kg/
m2 increase) 1.15 95%CI 1.08 to 1.22) and with sex-specific obesity-related cancers in 
women with T2D (HR (per 5 kg/m2 increase) 1.22, 95%CI 1.14 to 1.32). 
In conclusion, this study further enhances earlier findings in other studies with 
regards to the relation of various cancers with BMI. As such, one has also to keep an 
open eye for the possibility, that the increased cancer occurrence in patients with T2D 
is to a large extent due to the higher BMIs in patients with T2D. Moreover, because of 
the findings in this study, there are reasons to reconsider the assumption that advanced 
prostate cancer is obesity-related. It also shows that individual cancers provide individual 
cancer risk and should also be analysed separately. 
The study confirms the association between BMI and obesity-related cancer and sex-
specific cancers (ovarian, endometrial, postmenopausal breast cancer) in women with 
T2D. However, in women, the group of non-sex specific obesity-related cancers was not 
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associated with BMI. This could imply that in women with T2D, BMI is not a risk factor 
for this group of cancers, in contrast to men with T2D. No proper explanation for this 
finding could be formulated.
Previous studies have suggested that the incidence of cancer around the diabetes 
diagnosis is increased compared to cancer incidence in the general public. In Chapter 6, 
the results show that in both men and women a peak in excess obesity-related cancer 
incidence exists at the time of diabetes diagnosis (SIR 1.38; 95%CI 1.11 to 1.64 and SIR 
2.21; 95%CI 1.94 to 2.30, respectively). Women, as opposed to men, already had an 
excess obesity-related cancer incidence five years before diabetes diagnosis (SIR 1.77; 
95%CI: 1.63 to 1.91). After the diabetes diagnosis, women continue to have an excess 
obesity-related cancer incidence. In men, obesity-related cancer incidence decreases 
after diabetes diagnosis to a non-significant elevated incidence compared to the general 
public. These results could imply that at least part of the relative advantage of women in 
the general population concerning cancer risk is lost in women with T2D; a comparable 
phenomenon has been observed for cardiovascular disease 20,21.
GENERAL DISCUSSION
The relationship between T2D, cancer and diabetes medication is complicated, and there 
are many different possible pathophysiological mechanisms, confounding factors and 
biases. 
The general aim of this thesis was to investigate cancer risk in a Dutch primary care 
diabetes population, with special attention for possible within-class differences when 
using a SU derivate. For this purpose, a large prospective Dutch primary care treated 
diabetes population was studied. 
Methodological reflection: confounders
Describing the relationship between SU, T2D and cancer risk in a primary care cohort with 
T2D patients can be complicated by confounding and bias. Cancer risk, as well as T2D, can 
be influenced by an unhealthy diet and insufficient physical activity, through food content, 
but also through insulin resistance. This can be independent of medication use but also 
mediated by medication. Only a few studies evaluating the relationships between SU 
use and cancer risk accounted for important confounding factors and bias 22–24. Especially 
time-dependent adjusting for confounding factors is lacking in most previous studies in 
this field 22–24. 
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Body weight
One of the most important confounders in the relationship between T2D and cancer 
is body weight, in particular obesity 16. It has been hypothesised that certain specific 
subtypes of cancer are responsive to the metabolic conditions found in T2D 16. A majority 
of patients diagnosed with T2D are either overweight or obese, and obesity is strongly 
related to insulin resistance syndrome. Furthermore, it has been shown that insulin 
resistance is associated with both low and high levels of IGF-1 in a U-shaped manner 25. 
IGF-1 is has been identified as a growth factor for cancer and high IGF-1 levels in insulin 
resistance could, therefore, contribute to cancer risk and growth 26. Especially visceral 
(abdominal) fat has been associated with increased insulin resistance 27–29. Previous 
studies reported that SU use is associated with weight gain 30,31. 
The results of chapter 4 show that - in a primary care Dutch group of patients with 
T2D - SU use (on top of metformin) was associated with neither a clinically important 
nor significant weight gain, and that at the same time adequate glycaemic control can 
be maintained in a primary care setting. This suggests that when weight gain does occur, 
other causes like lifestyle factors might be more important to explain weight gain than 
SU initiation 32.
This observation is in contrast with previous assumptions and observations in other 
studies 33,34. Up until now, it has been generally reported that SU use is associated with 
clinically significant weight gain 33,34. The fact that weight gain does not occur in this 
primary care cohort is important when investigating cancer risk. Visceral obesity has 
been associated with adipose tissue inflammation, production of cytokines and changes 
in adipokines 16. Both can contribute to insulin resistance in fat, liver and skeletal muscle. 
The World Cancer Research Fund (WCRF) recognises that oesophageal, stomach (cardia), 
colorectal, liver, gallbladder, pancreatic, and kidney cancer are related to being overweight 
or obese in both men and women 19. Additionally, in women, ovarian, endometrial and 
postmenopausal breast cancer, and advanced prostate cancer in men are also associated 
with an increased body weight 19. Obviously, when a specific SU causes weight gain, this 
could confound a possible relationship between cancer risk and SU use via alterations 
in body weight. 
Sex
Differences in fat distribution between men and women might explain the reported 
differences in cancer risks 35. In people without diabetes, fat distribution between men 
and women is different, with men generally having relatively more visceral fat, and women 
having more subcutaneous fat 35. Specifically, visceral fat is associated with metabolic 
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abnormalities that could increase cancer risk 16. It could be that in women with T2D, 
BMI does not accurately depict the amount of visceral obesity. In patients with T2D, the 
difference in visceral fat mass between men and women is reduced, but it is probably 
still higher in men 36. 
Furthermore, adiposity is also associated with increased levels of oestrogen. Insulin 
resistance has been shown to decrease the synthesis of sex hormone binding globulin 
37,38. Moreover, obesity has been associated with an increased aromatisation of androgens 
to oestrogen. The interaction of these two phenomena leads to higher bioavailability of 
oestrogen. This could partly contribute to the risk of hormone-dependent breast cancer 
and endometrial cancer 39,40. 
It has been shown that weight loss after bariatric surgery decreases obesity-related 
cancer risk by 38% 41. All cancer risk decreased by 27% in women. Intentional weight loss 
of more than 9kg has also been associated with a decreased obesity-related cancer risk 
in women (RR 0.79, 95%CI 0.65-0.97). 
In conclusion, abnormally increased body weight is a significant factor in modifying 
obesity-related cancer risk and differs between the sexes. 
Methodological reflection on the results reported in this thesis: Bias
In all studies, it is essential to search for and identify bias and try to avoid bias in the 
design of the study or to adjust for bias in the analysis of the data. Especially observational 
studies are prone to bias since the selection of patients and the treatments are not at 
random. 
Detection and diagnostic bias are two important types of bias and can influence the 
interpretation of results. This kind of bias might explain at least partly the findings in 
chapters 4 and 5. Different studies have shown that the epidemiological association 
between cancer and diabetes can – at least partly – be explained by detection bias around 
the time of diabetes diagnosis 6,42. At the time of diagnosis, there is more contact with 
health care professionals, e.g. to educate patients and evaluate the effects of medication 
23. By having more contact, there are more opportunities for patients to express complaints 
and for the health care professional to identify (signs of) other diseases. It could also be 
that patients on e.g. glibenclamide experience more hypoglycaemic events than patients 
on other SUs 43. This could lead to more encounters with healthcare professionals and 
possibly more routine diagnostic work-ups in patients using glibenclamide. 
Reverse causality can also play a role in falsely assuming a relation between increased 
cancer risk and individual sulphonylurea use 44. Reverse causality needs to be considered 
when it seems that factor A, for example hyperglycaemia, is associated with factor B, for 
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example pancreatic cancer. However, the real association is in reverse, i.e. pancreatic 
cancer is the cause of the hyperglycaemia by a dysfunction in insulin secretion caused by 
the effect of the tumour on the pancreatic endocrine function. Reverse causality might at 
least partly explain the findings in the study presented in chapter 6. For example, when 
pancreatic cancer develops, some of its symptoms might be related to hyperglycaemia. 
This might then be regarded as T2D, which in due course is accompanied by a diagnosis of 
pancreatic cancer, which in its turn is (to a large extent) responsible for the hyperglycaemia. 
It is not caused by the insulin resistance of beta cell deficiency caused by increasing age. 
In all analyses, we chose not to include prevalent users but instead applied a new 
user design. The ZODIAC cohort, however, does include not only new users but also 
prevalent users. Including prevalent users in a study can introduce two kinds of bias. The 
first is selection bias, as prevalent users can be seen as survivors of a previous period of 
pharmacotherapy. This can be problematic if, as is the case with cancer, the risk varies 
with time. Also, at study entry covariates of users of a specific drug could be affected by 
the drug. This might, for example, lead to a different treatment choice in patients with 
chronic kidney disease. The European Network of Centres for Pharmacoepidemiology 
and Pharmacovigilance (ENCePP) advises using new-user designs to avoid the biases 
introduced by using prevalent users 45. 
Immortal time bias, also known as survivor bias, is a type of selection bias. It occurs 
when, during a period of time, a certain outcome cannot occur. It has been shown that 
this type of bias often occurs in observational studies 46,47, and can lead to an illusion of 
treatment effectiveness. In a review investigating metformin and cancer risk showed that 
13 out of the 26 observational studies suffered from immortal time bias 48. 
The ZODIAC cohort also included patients with previously diagnosed diabetes. In 
other words, patients could have been diagnosed with diabetes years before they entered 
the cohort. In Chapter 6, a retrospective analysis into cancer risk is performed prior to 
diabetes diagnosis. Patients who previously died before the diagnosis could, are not 
included in the analysis and could lead to an underestimation of cancer-risk. Diabetes-
related data was only collected from the moment patients were included in the cohort. 
Any SU use before inclusion in the cohort can have an effect on cancer risk. However, the 
date of diabetes diagnosis was reported at inclusion. 
Strengths and limitations
A major strength of the studies as presented in this thesis is the inclusion of a large 
population of patients with T2D treated for their diabetes in primary care. 90% of the 
patients diagnosed with T2D in the Netherlands are treated in primary care 50. Diabetes-
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related data was gathered in one prospective database (ZODIAC database: Zwolle 
Outpatient Diabetes project Integrating Available Care). The diagnosis of T2D was made 
according to well-defined criteria 51,52, and care is well organised 53. All patients treated 
in primary care diagnosed with T2D except those with a very short life expectancy 
were included at baseline (baseline data of specific patients could be in different 
years, depending on the year of inclusion in the cohort) 53. Data collection on T2D was 
standardized according to the Dutch Primary Care guideline on T2D 52, and the vast 
majority of data considered to be relevant was rather complete; of those items on which 
data were collected, data were complete in the majority of items for over 95%; exceptions 
were information on foot control and eye control, with information available on 89% of 
the participants) . Date of diabetes diagnosis was reported at baseline. BMI was collected 
over several years and the date of diagnosis of diabetes was recorded by practice nurses 
at inclusion. 
Data on cancer history, incidence and prevalence were obtained through the 
national cancer database, the IKNL (Integraal Kankercentrum Nederland) registry; this 
database contains a plethora of relevant information concerning cancer with regard to 
type, severity, duration, treatment, and outcomes (both morbidity and mortality) of the 
included patients. However, this database also has limitations. For example, pancreas 
carcinoma is likely underreported as it is also recorded by the Dutch Pancreatic Cancer 
Group. 
Matching these databases and blinding of individual patients in the new database 
was performed by an independent organization, resulting in a database with information 
over a long time-span (IKNL data from 1989, ZODIAC data from 1997, merging of data 
of both databases until 2014), partly also with information on individuals with regard to 
cancer events both before and after the diagnosis of T2D. 
Strengths can also be limitations at the same time. Including in a study a large, 
mainly unselected population of patients with T2D with a reasonable life expectation 
treated in primary care means, that patients with a short life expectancy and patients 
with T2D who need very intensive counselling or have a difficult to treat T2D could 
have been treated in secondary care and therefore were excluded from analysis. The 
results probably are only generalizable to about 90% of the population and patients 
with a reasonable to well-regulated glycaemic control. Furthermore, the average 
HbA1c of this population was below 53 mmol/mol 54. Even though about 90% of the 
patients diagnosed with T2D in the Netherlands are treated in primary care 50, this could 
obviously have some impact. The effect could be an imprecise estimate with regards 
to actual cancer incidence and prevalence within the total population of patients 
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with T2D. In general, patients with T2D treated in secondary care will have a more 
complex disease and multimorbidity, often necessitating a treatment approach different 
from the standard treatment. This also may be reflected in a different incidence or 
prevalence of cancer compared to patients with T2D treated in primary care. However, 
when assessing within-class differences, this impact probably will be limited, unless 
other – up to now unknown - factors play a role. Part of such a bias can be alleviated 
by including a well-matched control group in the analyses; this was not possible within 
the scope of this thesis. Although the ZODIAC dataset is quite comprehensive, no data 
about socio-economic status (SES) was recorded. It is conceivable that this could play 
a role in developing T2D, obesity and cancer 55–57. 
Another possible limitation is the lack of complete and extensive information with 
regards to medication, which was collected annually, better would have been monthly, 
weekly or even daily. The dose of diabetes medication was not available in the ZODIAC 
dataset. This might hamper a proper evaluation of the effects of specific medication on 
cancer incidence since cumulative dose might be one of the factors which need to be 
taken into account. 
Another factor which is important for evaluating the relationship between drugs 
and cancer is exposure time irrespective of dose 58,59. Data on medication were extracted 
from the primary care electronic records once yearly only, thus leading to exposure times 
within that specific year theoretically varying from 1 to 364 days. A switch in medication 
is not noticed until the next annual check-up. A last factor concerning medication to be 
taken into account is exposure and dosing of other (chronic) medication used for other 
conditions throughout the years. 
In recent years, attention has grown with regards to the effects of lifestyle on the 
occurrence of both diabetes and cancer. Although BMI and smoking habits were part of 
the dataset (also longitudinally), no further information on exercise, alcohol and eating 
habits (for example red meat consumption) was available. In recent analyses, such lifestyle 
factors were found to have an impact on cardiovascular disease and especially T2D and 
possibly also cancer occurrence 32,60. In conclusion, data on exercise, alcohol consumption 
and eating habits could help improve analyses in cancer risk. 
Implications for care and possible further research
The results of the various studies presented in this thesis, and specifically the confounding 
factors described in this thesis, should be taken into account when designing future 
research investigating the relationship between different treatment modalities and (the 
development of) cancer. The inclusion of BMI and BMI changes as a confounder in these 
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relationships is important. Moreover, confounding factors should be adjusted for in a 
time-dependent manner. To avoid immortal time bias, a Cox proportional hazard model 
with time-dependent covariates could be used. 
The points as described under limitations could be further addressed. Extending 
research to a secondary line population might add knowledge. Combining data of ZODIAC 
and IKNL with data derived from a cause-specific mortality registry (CBS) or national 
reimbursement data information (Vektis) would further enhance the detailing of the 
available information. Implementing some of the linkages is impossible at the moment 
in light of the interpretation of the existing privacy law. Taking the existing privacy law 
into account, in Chapter 7, a detailed research proposal is suggested for a possible first 
follow-up step.
Still, the results again emphasise, that with overweight and obesity combined 
with diabetes, attention should not only focus on preventing or delaying the risk of 
microvascular and macrovascular diabetes complications, but there should also be 
awareness of the relationship between weight and cancer in patients with diabetes. The 
latter fact might also be incorporated into patient education by physicians and patient 
associations. 
Furthermore, the finding that in a large primary care T2D cohort, weight gain does 
not occur when starting a SU as an add-on to metformin, is also important to incorporate 
in both patient and physician education. 
In most larger databases, no systematic information is available on lifestyle factors like 
eating habits and exercise activity. Adding such information in already existing databases 
is a challenge but should be considered imperative in order to gain more insight. 
As a final point at this stage, when (re)evaluating data, another important factor 
which should be taken into account is socio-economic status (SES). In the lowest SES 
range, the chance of developing diabetes is higher and life expectancy lower. Such 
information should elicit the use of SES when assessing data and matching populations. 
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INTRODUCTIE
Type 2 diabetes (T2D) is een aandoening die wereldwijd veel mensen treft. In Nederland 
hebben zijn meer dan 1 miljoen mensen bekend met T2D. Het is de verwachting dat het 
aantal patiënten bekend met T2D de komende jaren verder toe zal nemen. Dit heeft voor 
een groot deel te maken met toename in obesitas en verminderde lichamelijke activiteit. 
Het risico op het ontwikkelen van T2D neemt daarnaast ook toe met de leeftijd. Het is 
bekend dat T2D kan leiden tot problemen aan kleine en grote bloedvaten (zogeheten mi-
cro- en macrovasculaire problemen). Microvasculaire problemen kunnen leiden tot zenu-
wschade, oogschade en nierfunctiestoornissen. Macrovasculaire problemen kunnen leiden 
tot onder andere hart- en herseninfarcten en amputaties van de onderste extremiteiten. 
Naast diabetes komt kanker ook in Nederland in toenemende mate voor, o.a. in samen-
hang met de veroudering. In de afgelopen jaren zijn er steeds meer aanwijzingen dat 
bepaalde vormen van kanker vaker gezien worden bij patiënten met obesitas en ook bij 
patiënten met T2D. 
Overgewicht is een factor die zowel bij T2D als bij een aantal typen kanker een rol 
speelt bij het ontwikkelen van de ziekte. Daarnaast wordt er gesuggereerd dat er ook nog 
een relatie zou kunnen zijn met de medicatie die gebruikt wordt bij het behandelen van 
T2D. In recente studies wordt daarom ook gesuggereerd dat een deel van de verhoogde 
kans op kanker mogelijk gerelateerd is aan verstorende factoren, waarmee tot nu toe 
onvoldoende rekening is gehouden. Dit wordt “bias” genoemd. Hierbij kan bijvoorbeeld 
worden gedacht aan lichaamsgewicht en blootstelling aan bepaalde medicatie. Maar ook 
bijvoorbeeld dat een patiënt bekend met diabetes vaker contact heeft met een dokter en 
er dus mogelijk ook een hogere kans is dat een bepaalde ziekte eerder opgemerkt wordt. 
Daarnaast speelt mogelijk het chronisch gebruik van sommige vormen van medi-
catie een rol. Sulfonylureumderivaten (SU-derivaten) (een bepaalde groep van glucose 
verlagende medicatie waar glibenclamide, tolbutamide, glimepiride en gliclazide onder 
vallen) worden vaak als 2de stap na metformine ingezet in de behandeling van T2D. Er 
wordt gesuggereerd dat gebruik van deze medicatie mogelijk gepaard gaat met een hoger 
risico op kanker. Echter, de studies waarin dit onderzocht en geconcludeerd is, lijken 
onvoldoende van kwaliteit. 
Daarnaast komt als resultaat uit deze studies ook dat de middelen binnen deze groep 
mogelijk een verschillend risico op kanker hebben met een mogelijk lager kankerrisico bij 
patiënten die gliclazide gebruiken. Gliclazide is op dit moment in Nederland het medicijn 
van voorkeur wanneer er een SU-derivaat wordt voorgeschreven.
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Het doel van dit proefschrift was het onderzoeken van kankerrisico in een grote groep pa-
tiënten met T2D, die bij de huisarts behandeld werden, waarbij met name werd onderzocht of 
het gebruik van de verschillende SU-derivaten gepaard ging met een verschil in kanker risico. 
De studies in dit proefschrift zijn onder andere gebaseerd op data verzameld binnen 
de ZODIAC-studie. Dit is een groot cohort onderzoek met patiënten die voor hun T2D 
in de eerstelijn worden behandeld. Dit cohort is in 1998 opgezet in de regio Zwolle, en 
daarna in 2006, 2009 en 2012 uitgebreid naar andere regio’s. Jaarlijks wordt er door de 
aangesloten huisartsen data met betrekking tot patiënten met T2D verzonden naar het 
diabetes kenniscentrum in Zwolle. In deze data zit onder andere patiënt specifieke data 
als leeftijd, geslacht en gewicht en diabetes specifieke data als datum van diagnose, 
HbA1c en medicatiegebruik. HbA1c is een maat voor de ernst van de T2D. Met name 
het jaarlijks verzamelen van gewicht en HbA1c is uniek in dit type cohort. Dit cohort is 
gekoppeld met gegevens over diezelfde patiënten, als die aanwezig waren binnen de Ned-
erlandse Kankerregistratie om zo het gecombineerde ZODIAC-NKR cohort te verkrijgen. 
In het ZODIAC-NKR cohort daardoor is naast data over de behandeling van T2D ook data 
beschikbaar over het optreden verschillende vormen van kanker, wanneer de kanker is 
ontstaan en hoe deze is behandeld. 
RESULTATEN
In hoofdstuk 2 is er middels een systematische review onderzocht wat er in de klinische 
en preklinische literatuur al bekend is over of de verschillende soorten SU-derivaten 
onderling verschillen qua kankerrisico. Klinische studies worden verricht met patiënten. 
Preklinische studies bestaan over het algemeen uit onderzoeken op cellen in petrischalen. 
Uit de preklinische studies komen een heel aantal potentiële mechanismen naar voren 
hoe SU-derivaten van invloed zouden kunnen zijn op (de snelheid van) kankercelgroei, 
DNA-schade, bloedvatontwikkeling en metastasen (uitzaaiingen). De meeste studies 
onderzochten de effecten van één specifieke SU-derivaat, glibenclamide, en laten in prek-
linische studies een lager kankerrisico zien. Er waren maar weinig preklinische studies 
met onderzoek naar gliclazide.
De resultaten van de klinische studies laten zien dat gebruikers van gliclazide een 
lagere kans op kanker lijken te hebben in vergelijking met gebruikers van de andere 
SU-derivaten. Daarnaast laten de resultaten zien dat gebruikers van glibenclamide een 
hoger risico op kanker lijken te hebben ten opzichte van gebruikers van tolbutamide en 
gliclazide. Omdat de methodologie van de verschillende studies onderling te veel ver-
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schilde konden de resultaten niet goed worden vergeleken. De anti-kankereffecten van 
glibenclamide gevonden in de preklinische studies konden dus niet worden bevestigd 
in de klinische studies. Het merendeel van de klinische studies lieten juist een hogere 
risico op kanker zien, daar waar in de preklinische studies juist een beschermend effect 
zichtbaar lijkt te zijn. Voor de overige SU-derivaten is er op dit moment onvoldoende 
bewijs dat het kanker risico door het gebruik van die middelen wordt beïnvloed. Con-
cluderend kan er gesteld worden dat er op basis van de preklinische studies mogelijk 
interessante en plausibele anti-kankereffecten zijn gevonden. Echter, de klinische stud-
ies met patiënten zijn van een dermate matige kwaliteit dat er een grote kans is dat 
verstorende factoren de gevonden relatie verklaren, en er geen concreet advies voor 
patiënten op kan worden gebaseerd.
In hoofdstuk 3 werd de tijd tussen start van SU-derivaat en de behoefte aan 
intensivering van de behandeling met insuline onderzocht. T2D is vaak een pro-
gressief verlopende ziekte. Op het moment dat de glucose controle verslechtert en 
de behandeling moet worden geïntensiveerd, kan de toevoeging van eenmaal daags 
insuline worden beschouwd als een aanwijzing voor ziekteprogressie. Uiteindelijk 
kan insuline worden toegevoegd nadat de maximaal toegestane dagelijkse dosis van 
metformine en het SU-derivaat is bereikt. In deze studie werd de initiatie van insuline 
gedeeltelijk beschouwd als het surrogaat-eindpunt voor gebruik (op dat moment) 
van de maximale (getolereerde) SU-dosis. Dit zou zich kunnen vertalen in een lagere 
cumulatieve blootstelling aan een SU-derivaat; de exacte gevolgen van een dergelijke 
bevinding zijn onduidelijk. Bovendien zal een insulinebehandeling (in het algemeen) 
leiden tot hogere insulineconcentraties in vergelijking met een orale behandeling. 
Hogere insulineconcentraties worden geassocieerd met een hoger risico op kanker. 
Daarnaast zal, zodra een SU-derivaat niet meer voldoende werkzaam is, ook er eerder 
blootstelling aan hogere HbA1c-niveaus zijn. Hogere HbA1cs zijn ook geassocieerd 
met een verhoogd risico op kanker. 
De resultaten suggereren dat de duur van blootstelling aan SU-derivaat tot het mo-
ment dat insuline moet worden gestart niet significant verschilt tussen de verschillende 
SU-derivaten. Dat betekent dus, dat de duur van de blootstelling niet verschilt tussen de 
verschillende SU-derivaten, wat dan weer een aanwijzing is, dat de duur van blootstelling 
geen rol lijkt te spelen als het gaat om risico in een mogelijk verschil in kankerrisico tussen 
de verschillende SU-derivaten
In hoofdstuk 4 werd onderzocht of na starten van verschillende SU-derivaten er 
daadwerkelijk gewichtstoename optreedt en of dit voor de verschillende medicamenten 
verschillend is. 
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Een van de doelen van dit proefschrift was om verstorende effecten op de relatie tus-
sen medicatie en kanker te onderzoeken. Aangezien overgewicht in verband is gebracht 
met de ontwikkeling van bepaalde specifieke kankertypen en er wordt aangenomen dat 
het gebruik van SU-derivaten leidt tot gewichtstoename, is het belangrijk om te weten 
of er een verschil in gewichtsstijging is tussen de verschillende SU-derivaten. Verschillen 
tussen de individuele SU-derivaten in gewichtsverandering na het starten van een SU-
derivaat kunnen dan immers een mogelijke relatie tussen gebruikt van SU-derivaat en 
kanker vertekenen. 
Kankers van de slokdarm, maag, darm, lever, galblaas, alvleesklier en nier zijn in 
verband gebracht met obesitas bij mannen en vrouwen in de algemene bevolking. De 
resultaten lieten zien dat er geen verschil is tussen de verschillende SU-derivaten maar 
ook dat de mensen die starten met een SU-derviaat überhaupt geen significante gewicht-
stoename hebben. Hiermee wordt veel gehoorde stelling in de spreekkamer ontkracht.
In de studie in hoofdstuk 5 werd de relatie tussen BMI en obesitas-gerelateerde 
kanker bij mannen en vrouwen onderzocht. In deze studie werd BMI geassocieerd 
met obesitas-gerelateerde kankers bij mannen met T2D, met uitzondering van gevor-
derde prostaatkanker. Bij vrouwen met T2D werd weliswaar een associatie gevonden 
tussen BMI en obesitas-gerelateerde kankers, maar bij uitsplitsen tussen algemene 
en geslacht specifieke obesitas gerelateerd kankers werd uiteindelijk alleen een 
duidelijke relatie gevonden met geslacht specifieke obesitas-gerelateerde kankers 
(ovarium-, endometrium- en postmenopauzale borstkanker). Bij vrouwen werd de 
groep niet-geslachtsgebonden obesitas gerelateerde kankers (maag, colon, lever, gal-
blaas, alvleesklier en nierkanker en adenocarcinoom van de slokdarm) echter niet ge-
associeerd met BMI. Dit zou kunnen betekenen dat bij vrouwen met T2D, BMI geen 
risicofactor is voor deze groep kankers, in tegenstelling tot bij mannen met T2D. 
Deze studie bevestigd eerdere bevindingen in andere studies met betrekking tot de relat-
ie van verschillende kankers met BMI. Daarom moet er dan ook rekening mee worden 
gehouden dat het verhoogde voorkomen van kanker bij patiënten met T2D in hoge mate 
te wijten kan zijn aan de hogere BMI’s bij patiënten met T2D. Verder laten de resultaten 
zien dat de aanname in de literatuur dat gevorderde prostaatkanker gerelateerd is aan 
obesitas niet in ons cohort werd gevonden en mogelijk heroverwogen moet worden. Het 
laat ook zien dat afzonderlijke kankersoorten gepaard gaan met verschillende risico’s voor 
kanker en ook afzonderlijk moeten worden geanalyseerd.
Eerdere studies hebben gesuggereerd dat de incidentie van kanker rond de diagnose 
van diabetes hoger is in vergelijking met de incidentie van kanker bij de rest van de pop-
ulatie. In hoofdstuk 6 laten de resultaten zien dat zowel bij mannen als bij vrouwen een 
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piek bestaat in de incidentie van obesitas-gerelateerde kankers in de jaren rondom het 
stellen van de diabetes diagnose. Vrouwen, in tegenstelling tot mannen, hadden al vijf jaar 
vóór de diabetes diagnose een toegenomen incidentie van obesitas-gerelateerde kanker. 
Na de diabetes diagnose blijven vrouwen een verhoogde incidentie van obesitas-gerela-
teerde kanker behouden. Bij mannen daalt de incidentie van obesitas-gerelateerde kanker 
na diagnose van diabetes tot een niet-significante verhoogde incidentie in vergelijking 
met de algemene populatie. Deze resultaten kunnen impliceren dat ten minste een deel 
van het relatieve voordeel van vrouwen in de algemene bevolking met betrekking tot het 
risico op kanker blijvend verloren gaat bij vrouwen met T2D; een vergelijkbaar fenomeen 
is waargenomen voor hart- en vaatziekten.
CONCLUSIE EN AANBEVELINGEN VOOR DAGELIJKSE PRAKTIJK. 
De resultaten van dit proefschrift laten zien dat in patiënten met overgewicht en obesi-
tas, gecombineerd met diabetes, de aandacht niet alleen uit moet gaan naar het voor-
komen van micro- en macrovasculaire complicaties, maar ook naar de relatie tussen 
overgewicht en kanker. Dit zou ook moeten worden besproken met patiënten door hun 
hulpverleners. Een ander belangrijk resultaat is dat in een goed ingestelde populatie, 
het toevoegen van een SU-derivaat aan metformine niet leidt tot gewichtstoename. 
Voor toekomstig onderzoek is het belangrijk BMI dan wel BMI verandering als een ver-
storende factor te zien. Deze verstorende factoren zouden ook tijdsafhankelijk meege-
nomen moeten worden in het statistische model. Hoewel het op dit moment gezien de 
huidige privacywetgeving extreem lastig is, zou het verder koppelen van verschillende 
databases meer details aan de informatie kunnen toevoegen, waardoor het ook mogelijk 
zou zijn tot meer relevante bevindingen en conclusies te komen. Hierbij valt te denken 
aan het daadwerkelijk medicatiegebruik en de dosis. Hierdoor zouden betere analyses 
gemaakt kunnen worden. Om beter inzicht in de leefstijl van patiënten te krijgen zou 
het op de hoogte zijn van dieetgewoonten en de hoeveelheid beweging goed zijn. Dit 
zijn echter gegevens die nu vaak niet in andere grote cohorten beschikbaar zijn. Eerder 
onderzoek heeft laten zien dat patiënten met een lage socio-economische status (SES) 
hebben een hogere kans op het ontwikkelen van diabetes en ook een lagere levensver-
wachting. Informatie over socio-economische status (SES) van patiënten zou daarom een 
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